Novartis Research and Development
[SEG101/C rizanlizumab]
Clinical Trial Protocol CSEG101AUS05 / [STUDY_ID_REMOVED]
A Prospectiv e Phase II, Open -Label, Single -arm, 
Multicenter, Study to Assess Efficacy and Safety 
of 
SEG101 (crizanlizumab), in Sickle Cell Disease Patients 
with Priapism (SPA RTAN)
Document type: Amended Protocol Version
Version number: 03 Clean (Amended Protocol)
Clinical Trial Phase: II
Release date: 16-Dec-2022
Property of Novartis
Confidential
May not be used, divulged, published, or otherwise disclosed
without the consent of Novartis
Clinical Trial Protocol Template Version 2.0 (01 -Aug-2018)

Novartis Confidential Page 2
Amended Protocol Version 03 (clean ) Protocol No. CSEG101AUS05
Table of contents
Table of contents ................................................................................................................. 2
List of tables ........................................................................................................................ 5
List of figures ...................................................................................................................... 6
List of abbreviations ............................................................................................................ 7
Glossary  of terms ................................................................................................................. 9
Protocol summary .............................................................................................................. 27
1Introduction ....................................................................................................................... 31
1.1 Background ............................................................................................................ 31
1.1.1 Overview of Sickle Cell Disease pathogenesis, epidemiology  and 
current tr eatment ................................................................................... 31
1.1.2
Overview of SCD- related priapism, epidemiology  and current 
treatment ................................................................................................ 32
1.1.3 Role of P -Selectin in VOC .................................................................... 33
1.1.4 Role of P -Selectin in SCD -related priapism ......................................... 33
1.2
Introduction to investigational treatment(s) and other study  treatment(s) ............. 34
1.2.1 Overview of crizanlizumab (SEG101).................................................. 34
1.2.2 Clinical experience ................................................................................ 35
1.3 Purpose .................................................................................................................. 36
2Objectives and endpoints ................................................................................................... 37
2.1 Primary  estimands ................................................................................................. 37
3Study  design ................................ ................................ ................................ ...................... 38
4Rationale ............................................................................................................................ 40
4.1 Rationale for stud y design ................................ ................................ ..................... 40
4.2 Rationale for dose/regimen and duration of treatment .......................................... 40
4.3 Rationale for choice of control drugs .................................................................... 41
4.4 Purpose and timing of interim anal yses................................................................. 41
4.5 Risks and benefits .................................................................................................. 41
5Population .......................................................................................................................... 44
5.1 Inclusion criteria .................................................................................................... 44
5.2 Exclusion criteria ................................................................................................... 45
6Treatment ........................................................................................................................... 46
6.1 Study  treatment ...................................................................................................... 46
6.1.1 Investigational and control drugs .......................................................... 46
6.1.2 Additional study  treatments .................................................................. 47
6.1.3 Treatment arm/group ............................................................................. 47
6.1.4 Treatment duration ................................................................................ 47

Novartis Confidential Page 3
Amended Protocol Version 03 (clean ) Protocol No. CSEG101AUS05
6.2 Other treatments ................................ ................................ ................................ .....47
6.2.1 Concomitant therap y ............................................................................. 47
6.2.2
Prohibited medication ........................................................................... 49
6.2.3
Rescue medication ................................................................................ 49
6.3 Subject numbering, treatment assignment, randomization .................................... 50
6.3.1 Subject numbering ................................................................................ 50
6.3.2 Treatment assignment, randomization .................................................. 50
6.4 Treatment blinding ................................................................................................. 50
6.5 Dose modification .................................................................................................. 50
6.5.1 Follow -up for toxicities ......................................................................... 56
6.6 Additional treatment guidance ............................................................................... 57
6.6.1 Treatment compliance ........................................................................... 57
6.6.2 Recommended treatment of adverse events .......................................... 57
6.7 Handling of study  treatment and additional treatment .......................................... 57
6.7.1 Handling of study  treatment .................................................................. 57
6.7.2 Instruction for prescribing and taking stud y treatment ......................... 58
7Informed consent procedures
............................................................................................ 58
8
Visit schedule and assessments ......................................................................................... 59
8.1 Screening ............................................................................................................... 64
8.1.1 Eligibility  screening .............................................................................. 64
8.1.2 Information to be collected on screening failures ................................. 64
8.1.3
Subject demographics/other baseline characteristics............................ 65
8.2 Efficacy .................................................................................................................. 65
8.2.1 Primary  efficacy  endpoint ..................................................................... 65
8.2.2 Secondary  efficacy  endpoi
nts............................................................... 66
68
8.2.4 Collection of priapic event information ................................................ 68
8.2.5 Appropriateness of efficacy  assessments .............................................. 69
8.3 Safety  assessments ................................................................................................. 69
8.3.1 Physical assessments ............................................................................. 69
8.3.2 Laboratory  evaluations .......................................................................... 70
8.3.3 Urinaly sis.............................................................................................. 72
8.3.4 Coagulation ........................................................................................... 73
8.3.5 Cardiac assessments .............................................................................. 73
8.3.6 Hepatitis markers .................................................................................. 73
8.3.7
Urine protein/creatinine ratio ................................................................ 74
8.3.8 Additional test ....................................................................................... 74

Novartis Confidential Page 4
Amended Protocol Version 03 (clean ) Protocol No. CSEG101AUS05
8.3.9 Appropriateness of safety  measurements .............................................. 74
8.4
Additional assessments.......................................................................................... 74
74
75
8.5
Optional use of biological samples........................................................................ 75
9Study  discontinuation and completion .............................................................................. 76
9.1 Discontinuation ...................................................................................................... 76
9.1.1 Discontinuation of study  treatment ....................................................... 76
9.1.2 Withdrawal of i
nformed consent ........................................................... 77
9.1.3 Lost to follow -
up................................................................................... 77
9.1.4 Early study termi nation by  the sponsor ................................................. 77
9.2 Study  completion and post -study  treatment .......................................................... 78
10Safety  monitoring and reporting ................................ ................................ ........................ 78
10.1 Definition of adverse events and reporting requirements ...................................... 78
10.1.1 Adverse events ...................................................................................... 78
10.1.2
Protocol exempt AEs & SAEs .............................................................. 80
10.1.3 Serious adverse events .......................................................................... 80
10.1.4 SAE reporting
........................................................................................ 81
10.1.5 Pregnancy  reporting .............................................................................. 82
10.1.6 Reporting of stud y treatment errors including misuse/abuse ................ 82
10.2 Additional safet y monito ring................................................................................. 83
10.2.1
Steering committee................................................................................ 83
11Data Collection and Database M
anagement ...................................................................... 83
11.1
Data collection....................................................................................................... 83
11.2 Database management and quality  control ............................................................ 84
11.3 Site monitoring ...................................................................................................... 84
12Data analy sis and stat istical methods ................................................................................ 85
12.1 Analy sis sets .......................................................................................................... 85
12.2 Subject demographics a nd other baseline characteristics ...................................... 85
12.3 Treatments ............................................................................................................. 85
12.4 Analy sisof the primary  endpoint .......................................................................... 86
12.4.1 Definition of primary  endpoint ............................................................. 86
12.4.2 Statistical model, hy pothesis, and method of anal ysis.......................... 86
12.4.3 Handling of missing values/censoring/discontinuations ....................... 87
12.4.4 Sensitivity  and supportive anal yses...................................................... 88
12.5 Analy sis of secondary  endpoints ........................................................................... 89
12.5.1 Efficacy  endpoints
................................................................................. 89

Novartis Confidential Page 5
Amended Protocol Version 03 (clean ) Protocol No. CSEG101AUS05
12.5.2 Methods of anal yses.............................................................................. 89
12.6 Safety  endpoints ..................................................................................................... 90
12.6.1 Clinical laboratory  evaluations ............................................................. 90
12.6.2 Other safety
 evaluations ........................................................................ 91
91
91
91
92
92
92
12.8 Interim anal yses..................................................................................................... 92
12.9
Sample size calculation.......................................................................................... 92
13Ethical considerations and administrative procedures ...................................................... 93
13.1 Regulatory
 and ethical compliance ........................................................................ 93
13.2 Responsibilities of the investigator and IRB ......................................................... 93
13.3
Publicat ion of study  protocol and results ............................................................... 93
13.4 Quality  control and quality  assurance .................................................................... 93
14Protocol adherence ............................................................................................................ 94
14.1 Protocol amendments ............................................................................................. 94
15References ......................................................................................................................... 95
16Appendices ........................................................................................................................ 99
List of tables
Table 2
-1 Objectives and related endpoints .......................................................... 37
Table 6
-1 Dose and treatment schedule................................................................. 47
Table 6-2 Criteria for dose in terruption and re -initiation of crizanlizumab 
treatment for adverse drug reactions. .................................................... 52
Table 8-1 Assessment Schedule ................................ ................................ ............ 60
Table 8-2 Vaso -Occlusive Crisis Assessment Collection Plan ............................. 68
Table 8-3 Physical assessments ............................................................................. 70
Table 8
-4 Laboratory  Assessments ........................................................................ 72
Table 10
-1 List of Events Not Requiring AE/SAE Reporting ................................ 80
Table 10-2 Guidance for capturing the study  treatment errors including 
misuse/abuse ......................................................................................... 83
Table 16
-1 List of non- antipsy chotic and non- antidepressant drugs that may  
Induce Priapism ................................................................................... 112

Novartis Confidential Page 6
Amended Protocol Version 03 (clean ) Protocol No. CSEG101AUS05
Table 16-2 List of Antidepressants and Antipsy chotics that may  induce 
priapism ............................................................................................... 113
List of figures
Figure 1 -
1 P-selectin expression in penis of wild- type (WT) and sickle cell 
transgenic (βS) mice .............................................................................. 34
Figure 3 -
1 Study  Design ......................................................................................... 40

Novartis Confidential Page 7
Amended Protocol Version 03 (clean ) Protocol No. CSEG101AUS05
List of abbreviations
ADA
ADR
AEAnti-Drug Antibody
Adverse Drug Reaction
Adverse Event
ALP Alkaline Phosphatase
ALT Alanine Aminotransferase
ANC Absolute Neutrophil Count
APTT Activa ted partial thromboplastin time
AST Aspartate Aminotransferase
CI Confidence interval 
CK Creatinine Kinase
CMO&PS Chief Medical Office and Patient Safety
CMV Cytomegalovirus
CRA
CRFClinical Research Associate
Case Report/Record Form (paper or electronic)
CRO Contract Research Organization
CTCAE Common Terminol ogy Criteria for Adverse events
CV coefficient of variation
DDE Direct Data Entry
DILI Drug Induced Liver Injury
EBV Epstein -Barr Virus
ECG Electrocardiogram
ECHO Echocardiogram
EDC Electronic Data Capture
EDTA Ethylenediaminetetraacetic acid
ELISA Enzy me-linked immunosorbent assay
EOI End of Infusion
EOT End of treatment
eSource Electronic Source
FDA Food and Drug Administration
GCP Good Clinical Practice
GGT Gamma -glutam yl transferase
HbsAg Hepatitis B surface antigen
HBV Hepatitis B virus
HCV Hepatitis C virus
HIV Human immunodeficiency virus
HSV Herpes simplex virus
HU/HC Hydroxyurea/hydroxycarbamide
ICF Informed Consent Form
ICH International Conference on Harmonization of Technical Requirements 
for Registration of Pharmaceuticals for Human Use
INR International Normalized Ratio
IRB Institutional Review Board
IRR Infusion -related Reaction
IRT
IVInteractive Response Technology
Intravenous
LFT Liver function test 
LPT Low Platelet Count
LLN Lower Limit of Normal
LVEF Left ventricular ejection fraction

Novartis Confidential Page 8
Amended Protocol Version 03 (clean ) Protocol No. CSEG101AUS05
MedDRA Medical dictionary for regulatory activities 
mg milligram (s)
ml milliliter(s)
NOAEL No observed adverse effect level
PAP Pulm onary Arterial Pressure
PD Pharmacodynamic(s)
PLT Platelet
PK Pharmacokinetic(s)
PSGL -1 P-selectin gly coprotein ligand 1
PT Prothrombin time
QTcF QT interval corrected by Fridericia’s formula
RAP/SAP The Report and Analy sis Plan (RAP) is a regulatory document which 
documents preplanned statistical analy ses
RBC Red blood cell(s)
RVSP Right ventricular s ystolic pressure
SAE Serious Adverse Event
SCD Sickle cell disease
SD Standard deviation
SUSAR Suspected Unexpected Serious Adverse Reactions
TBIL Total bilirubin
TEAEs Treatm ent emergent adverse events
TRV Tricuspid Regurgitant Jet Velocity
ULN
USANUpper limit of normal
United States Adopted Name
VOC Vaso- occlusive crisis 
WBC White blood cell(s)
WHO World Health Organization 

Novartis Confidential Page 9
Amended Protocol Version 03 (clean ) Protocol No. CSEG101AUS05
Glossary  of terms
Additional treatment Medicinal products that may be used during the clinical trial as described 
in the protocol, but not as an investigational medicinal product ( e.g.any 
background therapy )
Assessment A procedure used to generate data required by the study
Biologic Samples A biological specimen including, for example, blood (plasma, serum), 
saliva, tissue, urine, stool, etc. taken from a study subject 
Dosage Dose of the study treatment given to the subject in a time unit ( e.g.
100mg once a day, 75 mg twice a day)
Electronic Data Capture 
(EDC)Electronic data capture (EDC) is the electronic acquisition of clinical 
study data using data collection s ystems, such as Web-based 
applications, interactive voice response s ystems and clinical laboratory 
interfaces. EDC includes the use of Electronic Case Report Forms 
(eCRFs) which are used to capture data transcribed from paper source 
forms used at the point of care.
End of the clinical trial The end of the clinical trial is defined as the last visit of the last subject or 
at a later point in time as defined by the protocol. 
Enrollment Point/time of subject entry into the study at which informed consent must 
be obtained 
eSource (DDE) eSource Direct Data Entry (DDE) refers to the capture of clinical study  
data electronically, at the point of care. eSource Platform/Applications 
reduce the use of paper capture source data during clinical visits. 
eSource combines source documents and case report forms (eCRFs) 
into one application, allowing for the real t ime collection of clinical trial 
information to sponsors and other oversight authorities, as appropriate.
Estimand As defined in the ICH E9(R1) addendum, estimand is a precise description 
of the treatment effect reflecting the clinical question posed by the trial 
objective. It summarizes at a population -level what the outcomes would be 
in the same participants under different treatment conditions being 
compared. Attributes of an estimand include the population, variable (or 
endpoint) and treatment of interest, as well as the specification of how the 
remaining intercurrent events are addressed and a population -level 
summary  for the variable
Intercurrent events Events occurring after treatment initiation that affect either the 
interpretation or the existence of the measurements associated with the 
clinical question of interest
Investigational 
drug/treatmentThe drug whose properties are being tested in the study
Medication number A unique identifier on the label of medication kits
Other treatment Treatment that may be needed/allowed during the conduct of the study 
(concomitant or rescue therapy)
Patient An individual with the condition of interest for the study
Period The subdivisions of the trial design (e.g. screening, treatment, follow -up) 
which are described in the Protocol. Periods define the study phases and 
will be used in clinical trial database setup an d eventually in analysis
Perpetrator drug A drug which affects the pharmacokinetics of the other drug
Premature subject 
withdrawalPoint/time when the subject exits from the study prior to the planned 
completion of all study drug administration and/or assessments; at this 
time all study drug administration is discontinued and no further 
assessments are planned

Novartis Confidential Page 10
Amended Protocol Version 03 (clean ) Protocol No. CSEG101AUS05
Run-in Failure A subject who is screened but not randomized/treated after the run -in 
period (where run -in period requires adjustment to subject’s intervention 
or treatment)
Screen Failure A subject who did not meet one or more criteria that were required for 
participation in the study
Source Data/Document Source data refers to the initial record, document, or primary  location 
from where data comes. The data source can be a database, a dataset, a 
spreadsheet or even hard -coded data, such as paper or eSource.
Start of the clinical trial The start of the clinical trial is defined as the signature of the informed 
consent by the first subject.
Study treatment Any single drug or combination of drugs or intervention administered to 
the subject as part of the required study proc edures .
Study treatment 
discontinuationWhen the subject permanently stops taking any of the study drug(s) prior 
to the defined study treatment completion date (if any) for any reason; 
may or m ay not also be the point/time of study discontinuation 
Subje ct A trial participant 
Subject number A unique number assigned to each subject upon signing the informed 
consent. This number is the definitive, unique identifier for the subject 
and should be used to identify the subject throughout the study for all 
data collected, sample labels, etc.
Treatment arm/group A treatment arm/group defines the dose and regimen or the combination 
andmay consist of 1 or more cohorts.
Variable A measured value or assessed response that is determined from specific 
assessments and used in data analysis to evaluate the drug being tested 
in the study
Withdrawal of study 
consent Withdrawal of consent from the study occurs only when a subject does 
not want to participate in the study any longer, and does not want any 
further visit s or assessments, and does not want any further study related 
contact
Amendment 3 (16- Dec-2022)
At the time of this amendment, the required number of 36 patients for the study  has been reached. 
The study  is closed to further enrollment .
The primary  purpo se of this amendment is to clarify  some statistical elements used to evaluate 
the study . In particular, the following points were addressed in the current protocol:
1.Section 2.1 was added to describe the primary  estimand by  the following attributes:
a.Population: Sickle Cell Disease patients with priapism.
b.Endpoint: Percent reduction from baseline period in priapic events (priapism 
defined as unwanted, or painful erection lasting at least 60 min self -reported) by 
26 weeks.
c.Treatment of interest: investigational drug will be a crizanlizumab solution 
provided every  4 weeks with an additional loading dose 2 weeks after the first 
dosing.

Novartis Confidential Page 11
Amended Protocol Version 03 (clean ) Protocol No. CSEG101AUS05
d.List of intercurrent events:
i.Treatment discontinuation 
ii.Initiation or discontinuation of HU/HC or l-glutamine (or other therapies 
to treat SCD and or to prevent/reduce VOCs such as voxelotor and 
erythropoietin) or of prophy lactic treatment
iii.Intake of analgesic (including opioids) or ad hoc transfusions 
administered temporarily.
e.The summary  measure: Median percent agechange from baseline period in 
priapic events (priapism defined as unwanted, or painful erection lasting at least 
60 min self -reported) b y 26 weeks .
2.It was clarified that aformal interim analy sis for this study  is not planned , shall not be 
performed and that for publication purposes, only descriptive data will be reported, as 
needed. 
3.It was clarified that the FAS include all enrolled subjects to whom the study  treatment 
has been assigned regardless of whether or not they have received at least 1 dose of 
study treatment or have at least 1 post -baseline assessment . 
4. L ower quartile (Q1) and upper quartile ( Q3)were included in the summary statistics 
5.The handling of missing values was described. It will be imputed using Poisson 
distribution, assuming the same effect as observed data. Imputed datasets will be created, 
and each dataset will be analyzed using the method described for primary  endpoint. The 
results will be combined using Rubin’s rule (Barnard J and Rubin DB 1999) 
6.Sensitivity  analy ses were modified to include the following:
a.To explore the robustness of analysis,  sensitivity  analysis as a 'tipping point 
approach will be performed for the primary endpoint to evaluate the impact of a 
deviation from the missing at random ( MAR ).
b.As part of the sensitivit y analysis, treatment policy  strategy  (that is, data after 
the intercurrent events will be included) will also be applied for the intercurrent 
events 4a and 4b, described in Section 12.4.2.
c.As part of the sensitivity analy sis, the primary  analysis will be analyzed on all 
subjects in FAS without missing data.
7.It was clarified that the assumption thatthe relative risk reduction of 25% (approved for 
VOC events) observed with L-glutamine (Endari™) would be similar for priapism was 
used for the purpose of study sample size calculation.
Other minor corrections are also applied throughout the protocol .
Changes to the Protocol
Throughout: t ypographical and grammatical errors addressed .

Novartis Confidential Page 12
Amended Protocol Version 03 (clean ) Protocol No. CSEG101AUS05
List of abbreviations: AUC, AUCinf, AUC t, Cmax, t1/2are not required and were
removed. IV was added.
Glossary of terms: The definitions of estimand and Intercurrent events were added.
“Randomization number” is not required as this is a single -arm stud y and was removed.
Section 2.1:
oSection added to define what an estimand is. Language was added to describe 
the attributes of the primary  estimand for this study : population, endpoint, 
treatment of interest, list of intercurrent events and the summary  measure. 
Correspondingl y similar cha nges were made in Section 12.4.2 .
Section 4.4 :
oLanguage was added to clarify  that for publication purposes, descriptive data 
will be reported and that any decision on study  continuation will not be based on 
the reports. Correspondingl
y similar changes were made in Section 12.8.
oChanged the word patient to subject when the term refers to a participant of this
study . Correspondingly  similar changes were made throughout the protocol as 
appropriate.
Section 6.3.2:
oLanguage was added to clarify  that the trial is a single arm study .
Section 9.2:
oLanguage was added to specify  that the recommendation applies to  “subjects 
who will receive commercially  approved crizanlizumab”.
Section 12:
oIncluded lower quartile (Q1) and upper quartile (
Q3) in the summary  statistics. 
Correspondingl y similar changes were made in Sections 12.2, 12.3, 12.4.2 and 
12.5.2.
oDefinition of the baseline 
period was clarified by removing the minus sign 
before 12 weeks and correcting “from” with “prior to”.
Section 12.1:
oThe  definition of the FAS was corrected to: The FAS include all enrolled 
subjects to whom the study  treatment has been assigned regardless of whether 
or not they have received at least 1 dose of study  treatment or have at least 1 
post-baseline assessment .
Section 12.3:
oDuration  of exposure will be assessed in weeks rather than days to align with 
other Novartis SEG101 studies.
Section 12.4.1:

Novartis Confidential Page 13
Amended Protocol Version 03 (clean ) Protocol No. CSEG101AUS05
oThe sentence “The primary  time point is week 26” was deleted as it was 
redundant given the previous sentence.
Section 12.4.2:
oThe <7 category  was included as a new number of priapic events category  in a 
subgroup anal ysis of the primary  endpoint.
oThe approach of accounting 
for the intercurrent events 4a, 4b and 4c was defined.
Section 12.4.3:
oThis section was modifi
ed to specify  that missing values will be imputed using 
Poisson distribution and imputed datasets will be created with each dataset 
analyzed using the method described for primary endpoint. The results will be 
combined using Rubin’s rule.
Section 12.4.4:
oThis section was re-written 
to outline a new sensitivity  analysis as a'tipping 
point approach will be performed for the primary  endpoint to evaluate the impact 
of a deviation from the MAR assumption.
oThe titles of the two subsections were removed. The paragraph related to the 
Annualized Priapic Event Rate was kept under “Supportive Analy ses” and the 
paragraphs on the COVID -19 sensitivity  anal yses were moved in the upper part 
ofSection 12.4.4.
Sections 12.5.1 and 12.5.2:
oThe words “(i.e. evaluation at Week 27, Day  1)”and  
“(i.e. evaluation at Week 
53, Day  1)” were deleted after “b y week 26” and “by week 52” respectivel y.
Section 12.6.1:
oThe words “or not” were removed.
Section 12.8:
oSentence was added to specify  that no decision on study  continuation will be 
based on these descriptive reports, and as such, no alpha adjustment will be 
nee
ded.
oThe paragraph on the primary  analysis was removed for clarit y. Similar 
information was alread y  detailed in Section 12.4.
Section 12.9 :

Novartis Confidential Page 14
Amended Protocol Version 03 (clean ) Protocol No. CSEG101AUS05
oThe paragraph related to the basis of the calculations was moved earlier on in 
the section.
oTwo sentences , referring the risk reduction of Endari™ were added
Section 15:
oReferences from Barnard and co; Edmond andco, Ratich and co as well as the 
ICH E9(R1) guideline were added.
Amendment 2 (
16-Dec-2021)
At the time of this amendment, 25patients have been enrolled in the stud y.
The primary  purpose of this amendment is described below:
1.Modify  selected Exclusion Criteria including:
Exclusion Criteria #8: Use of therapeutic anticoagulants or antiplatelet therapy  (other 
than aspirin or NSAIDs) within 10 days prior to Week 1 Day 1. Prophy lactic 
anticoagulant dose is now permitted, as per local guidelines .
Exclusion Criteria 
#10: Patients who have received crizanlizumab and/or other selectin 
inhibitor or plan to receive it during the duration of the study  will be excluded.
Exclusion Criteria #22: It was changed timing of “malignancies that were treated 
curativ
ely and have not recurred within... ” from 2 years to 3 years, to align with program 
guidelines.
2.The study  design was changed to lower the age of inclusion to 12 years old. A large 
review of published literature cases reported that approximately  half 
of all reporte d 
events of priapism in patients with sickle cell disease had their first episode before 18 
years of age (Rogers et al 2005; Hamre et al 1991).  An interview survey  of male patients 
with s
ickle cell disease reported that there was a prevalence of priapism of 27.5% b y 15 
years of age and reported literature calculated actuarial probability  of 50.5% of 
experiencing priapism by the age of 15 years. (Mantadakis et al 1999; Rogers et al 2005 ).  
The safety  and the PK analysis of crizanlizumab was evaluated as part of the 
CSEG101B2201 trial in 50 participants aged 12 to <18 years of age.  The dose of 5 
mg/kg was confirmed in this group based on the results of the first dose PK analysis and 
the CSEG101B2201 data monitoring committee did not raise any particular safet y 
concerns with this dose in this age group.  
3.Due to challenges identify ing and recr uiting adequate population at sites, the statistical 
power of the study  will be changed from 90% to 80% inSection 12.9, which reduces 
the number of evaluable patients from 44 to 34. The anticipated drop-out rate for the 
study  is also revised from 20% to 5% based on the current status of the trial, which 
reduces the targeted number of enrolled patients from 56 to 3
6 (Section 12.9 ).
4.The baseline for the primary  anal ysis will be changed from a combination of the 14-
weeks pre -screening period plus the 12- weeks screening period to onl y the 12 weeks 
of the screening period. The change is prompted by  the observed difficult iesfor 
patients and site to accuratel y recall and collect all the required information on the 

Novartis Confidential Page 15
Amended Protocol Version 03 (clean ) Protocol No. CSEG101AUS05
priapic events during the pre -screening period resulting in inconsistent data quality  
between patients and sites. The number of pre- screening priapic events to qualify  for 
the study  (4) will remain t he same. The change will also ensure consistency  between 
the priapic event reporting methods for the baseline period and the treatment period
(Section 12).
5.Specify  that the subjects who will receive comm ercially  approved 
crizanlizumab 
approximately  4 weeks after their last dose of study  treatment, do not need to complete 
the 105- day follow -up.
6.The recommendations for handling of study  treatment in case of active or suspected 
COVID -19 infection were added in Section 6.5.
7.In the laboratory  assessments, the word “albumin” was deleted from Table 8.4to clarify 
the panel.
Other minor corrections are also applied throughout the protocol .
Changes to the Protocol
Throughout: t ypographical and grammatical errors addressed .
Protocol Summary : updated in alignment to the protocol sections updated .
Section 1.1.1:
oUpdated list of treatments to include voxelotor .
Section 1.2.1:
oUpdated approval information language and deleted “non -clinical experience” 
to reflect the fact that the information can be found in the IB
.
Section 1.2.2:
oDeleted the “clinical experience” related to CSEG101A2101, CSEG101A2102 
and CSEG101A2202 and CSEGB2201 to reflect the fact that the most updated 
information can be found in the IB.
Section 1.3:
oUpdated baseline duration from 26 weeks to 12 weeks. Correspondingl y, similar 
language was added in Section 3 and Section 12.
Section 3:
oThe total number of patients to be eligible for the study  was updated from 56 to 
36 patients. Correspondingl y this number was also changed in Figure 3 - 1Study  
Design , Section 5 , and 12.9 Sample size calculation.
oStudy  duration language changed from ‘will be 79 weeks’ to ‘will be up to 79 
weeks’ -in parentheses, ‘15 weeks of follow -up period’ was changed to ‘15 
weeks of follow -up period if applicable’: Correspondingl y, the study  duration 
was changed in F ollow - up phase and Figure 3 -1Study  Design.

Novartis Confidential Page 16
Amended Protocol Version 03 (clean ) Protocol No. CSEG101AUS05
oRemoved the phrase ‘Mandatory  safety follow -up period’ and replaced with 
‘followed for safet y for up to...’ .
oAdded a paragraph to clarify  the follow-up period for subjects who receive 
commerciall y approved crizanlizumab after study  treatment. Correspondingly , a 
footnote was added in Table 8.1 to clarify  “as applicable”.
oPre-screening: T he date, number, and duration of the priapic events in a 14-week 
period required prior to consenting was added to clarif y the purpose of the form. 
Correspondingl y, a footnote was added in the 
visit evaluation schedule (Table 
8.1).
Section 4.2:
oAdded reference to stud y CSEG101B2201 to support dosage of 5 mg/kg.
Section 4.5:
oUpdated section on infusion -related reactio ns (IRRs) according to IBv11: 
percentages of certain events changed, events ‘hypertension’ and ‘dizziness’ 
were added.
oInfections percentages updated based on IBv11 .
oEffect on hemostasis updated: ‘decreased hemoglobin, and epistaxis’ added; 
reference to eligibility  criteria and permitted/prohibited concomitant 
medications removed.
oLaboratory  test interference with automated platelet counts: deleted language 
on 
mitigation of the laboratory  test interference.
oChanged the world participant to subject for langu age harmonization. 
Correspondingl y similar changes were made inSection 6.2.1.3, Table 6.2, 
Section
12.4.4 and Section 14.
oStatement added on how Novartis finds risk -
benefit ratio favorable.
oSmall paragraph on risk for patients due to COVID-19 vaccine added.
Section 5.1:
oInclusion criteria #2: Age of inclusion language changed from 16 to 12 years old. 
Correspondingl y, the minimum age was changed to 12 in Section 
3,Figure 3.1
andSection 5.
Section 5.2 :
oExclusion Criteria # 3 – added ‘(Lupron) or any other gonadotropin -releasing 
hormone receptor (GnRHR) agonist agents’ .
oExclusion Criteria # 8 original 
–deleted use of therapeutic anticoagulants .
oNew Exclusion Criteria #8is ‘received crizanlizumab’ to reflect alread y existing 
language in Section 6.2.2 .

Novartis Confidential Page 17
Amended Protocol Version 03 (clean ) Protocol No. CSEG101AUS05
oExclusion Criteria #10 – deleted original criteria and changed to ‘received other 
selectin inhibitor or plans to receive it during the duration of study .To reflect 
the fact that another experimental selectin inhibitor isbeing developed.
oExclusion Criteria #22 – revision in timeline for exception to malignant disease: 
‘malignancies that were treated curativel y and have not recurred within 2 years’ 
changed to ‘malignancies that were treated curatively  and have not recurred
within 3 y earsto align with other SEG101 clinical trial protocols .
Section 6.2.1.1:
oChange in timeline for notifying investigational site about any new medications 
taken with 30 days prior to initial dosing from ‘until the completion of (EOS)’ 
to ‘until the safet y follow -up or EOT -visit as applicable’ throughout the section. 
Corresponding ly,similar changes were alsomade in Section 
6.5.1, Section 9.1.1 , 
Section 9.2, Section 10.1.1, Section 10.1.4 and Section 12.6 .
oLanguage on 105 -day follow -up timeline removed.
oSentence starting with ‘Aspirin, NSAIDs and prophy lactic doses...’ changed: 
‘should be used with caution (refer to Section 6.2.1.3)’ added at the endto reflect 
the fact that anticoagulants at doses targeting therapeutic levels are no longer 
prohibited. Correspondingl y, a new sentence was added in Section 6.2.1.3.
Section 6.2.1.3:
oClarification that the decision to administer or withhold a vaccine should be done 
on case -by-case basis .
Section 6.2.2:
oCorrected that patients who have received a monoclonal antibody  or an 
immunomodulatory  agent within 1 year of screening or
have documented 
immunogenicit y to a prior biologic are not allowed to participate as per 
Exclusion criteria #9.
Section 6.5:
oThe discontinuation rules forpatient smissing 2 consecutive doses were 
clarified
: initially  said patient should be discontinued; changed to ‘if a subject 
misses two consecutive doses of crizanlizumab due to ADR (i.e., an AE 
attributable to study  drug), the subject should be discontinued from 
crizanlizumab. In addition, the criteria for subjects experiencing IRR alread y 
present in Table 6-2was inserted in the text: A subject with Grade 3 or 4 IRR 
will be permanentl y discontinued from crizanlizumab.’
oAdded crizanlizumab program language on course of treatment for patients with 
confirmed active COVID -19 or presenting s ymptoms of COVID -19.
Table 6-
2:
oInfusion-related reactions: clarified first recommendation in grade 2 AE from 
“interrupt infusion and increase monitoring …" to “temporaril yinterrupt 
infusion and increase monitoring...”
.

Novartis Confidential Page 18
Amended Protocol Version 03 (clean ) Protocol No. CSEG101AUS05
Section 6.7.1:
oClarified themonitoring visits related to drug accountabi lity 
–will be performed 
by field monitors during onsite / remote visits and at completion of trial.
oClarified the language on end of study  drug disposition -“at the conclusion of 
the study ... the investigator or delegate will destroy  all unused crizanliz umab, 
packaging, drug labels, as appropriate in compliance with site processes, 
monitoring processes, and as per local regulations/guidelines.”
Section 8 :
oIn allowed visit windows specified, ‘a + 7-day visit window for end of post-
treatment phase’ changed to ‘a + 7-day visit window for the end of the safet y 
follow -up phase.’
Table 8
-1:
oRemoved the Category  column .
oLast column, ‘follow up phase’ changed to ‘follow up phase (as applicable)’ .
oFor Priapism History , added an explicative footnote   stating that:The date, 
number, and duration of the priapic events in the 14-week period prior to 
consenting will be captured in a separate CRF .
oFor laboratory  assessments, a row is added for ‘platelets (local)’ with an 
explicative footnote reference also inserted 
at the end of the table.
oIn safet y assessments, a row wasadded for ‘IRR ’with an explicative footnote 
reference also inserted at the end of the table.
Section 8.2.3:
oThe word ‘ph ysician’ was changed 
to ‘health care professional.’
Section 8.3.2:
oParagraph starting with ‘for assessment of subject’s eligibility  to the study ...’, 
parentheses section revised to correct grammatical errors.
oFollowing sentence added after bullet points on criteria for lab results being 
recorded in the eCRF: ‘laboratory  assessments can be repeated during the 
screening period as deemed appropriate b y the investigator.’
oParagraph added before Table 8
-4on platelet counts and local sampling .
Table 8-4:
oIn the chemistry  assessment, the word ‘albumin’ was removed (subsequently 
removed from urinal ysis as well); transferase typo corrected; ‘glucose (fasting)’ 
changed to ‘glucose (non -fasting)’ .
Section 9.2:

Novartis Confidential Page 19
Amended Protocol Version 03 (clean ) Protocol No. CSEG101AUS05
oStudy  Completion visit definition was defined as last patient last visit .
Section 10.1.2:
o“In regard sto” was corrected to “in regard to”
.
Section 10.2.1 :
oRevised language on composition of steering committee: “investigators 
participating in the clinical trial...” changed to “SCD and priapism medical 
experts...”
Section 12.4.2:
oAdded language 
on the uniformity  in the occurrence of priapic events before 
exposure to crizanlizumab treatment .
oAdded text to specify  that the baseline will be adjusted for 26 weeks for analysis 
purpose.
Section 12.4.4:
oAdded language to specify that the n umber of priapic events will be 
summarized in the screening period (12 weeks baseline), in first 12 weeks on 
treatment (0 -12 weeks), and in the last 12 weeks on treatment (15 -26 weeks) 
and percent reduction from baseline will also be summarized
in supportive 
analyses.
oParagraph related to the methods of anal yzes using a mixed regression model 
was removed and will be instead included separately  in the statistical analysis 
plan.
Section 12.6:
oThe on -
treatment and post- treatment period segments of the overall observation 
period were edited to reflect that some patients might receive commercial 
crizanlizumab after their study  EOT.
Section 12.6.2:
oClarification that an ECG will also be conducted at end of treatment: “... at 
screening and end of treatment visit.”
Section 12.8:
oIt was clarified that the primary  anal ysis of the study  will be performed after 
the last subject has completed Week 26 visit or discontinued earlier . Also, it 
was clarified that the analy sis will be carried out on all visit -based safet y 
assessments.
Section 12.9:
oSample size calculation: The power of the study  was changed from 90% to 80%. 
The drop-out rate was reduced to fr
om 20 to 5% to reflect the higher -than-
expected retention rate observed for the study .  Based on the modification of 
these two parameters, the sample size calculation was revised to 34 evaluable 
subjects and approximately  36 subjects enrolled in the study .

Novartis Confidential Page 20
Amended Protocol Version 03 (clean ) Protocol No. CSEG101AUS05
Section 15:
oTwo new references ( Rogers et al 2005
;Hamre et al 1991) were added.
IRBs/IECs
A copy of this amended protocol will be sent to the Institutional Review Board 
(IRBs)/Independent Ethics Committee (I ECs) and Health Authorities.
The changes described in this amended protocol require IRB/IEC approval prior to 
implementation. 
The changes herein affect the Informed Consent. Sites are required to update and submit for 
approval a revised Informed Consent that takes into account the changes described in this 
protocol amendmen t.
Amendment 1 (31- July-2020)
At the time of this amendment, 7 patients hav e been enrolled in the study .
The primary  purpose of this amendment is described below:
1. M odify selected Inclusion/Exclusion Criteria including:
Inclusion criteria 6: Oxbry taTM(hereafter referred to as voxelotor )to be allowed on 
stable dose. The therap y was approved by the US FDA on 25- Nov- 2019 for SCD 
treatment in adults and pediatric patients 12 years of age and older .  Voxelotor has 
no reported beneficial effect on priapism.
Exclusion criteria 1: The timeframe for penile shunts was clarified. Instances of 
SCD patients suffering from priapism after having undergone penile shunt surgeries 
were reported to the team indicating that such procedures may not always prevent 
future occurrence of the complication.
Exclusion criteria 14: The d rug o r alcohol tests were replaced with a criterion based 
on a history  of drug or alcohol abuse .
3.Thevisit windows were clarified throughout the protocol to remove any discrepancies 
and align with the other Novartis crizanlizumab clinical studies.
4.Following a literature review of antidepressants and antipsy chotic drugsreported to 
cause priapism, the l ist of prohibited drugs was revised. Theseclassesof drugs are now
separately  listed in Table 16-2 in Appendix 5. Ten drugs were added . Lithium was 
removed from the list as no literature reference was uncovered.
5.The guidelines for the management of infusion- related reactions (IRR s) were clarif ied 
with regards to the rules for interrupt ing and restarting infusions. It was also added that 
steroids should be used with caution unless clinically  indicated (e.g. management of 
hypersensitivity /anaph ylaxis) .Sections related to IRRs were modified accordingl y 

Novartis Confidential Page 21
Amended Protocol Version 03 (clean ) Protocol No. CSEG101AUS05
throughout the protocol for consistency with other Novartis crizanlizumab clinical 
studies .
Other minor corrections are also applied throughout the protocol .
Changes to the Protocol
Changes to specific sections of the protocol are shown in track changes version of the protocol 
using strike through red font for deletions and red underline for insertions
Throughout: t ypographical and grammatical err ors addressed .
List of abbreviations : Anti- Drug Antibody  (ADA), Adverse -Drug Reaction (ADR), Clinical 
Research Associate (CRA) and United States Adopted Name (USAN) were added. 
Ultrasonograph y (USG) was re moved.
Protocol Summary : updated in alignment to the protocol sections updated
.
Section 1.1:
oIncluding Oxbryta ™
(voxelotor) as approved by US FDA on 25-Nov-2019 for SCD 
treatment in adults and pediatric patients 12 years of age and older .
Section 1.2.1:
oIncluding first global approval for crizanlizumab obtained from the US FDA on 15 -
Nov-
2019.
Section 1.3 andTable 2
-1:
oReplaced “greater than” and “more than” b y “at least” for clarit y.
Table 2-1:
oAdded the word “or” to align the definition of acute priapic events to that of priapism 
as defined in Section 8.2.1 . Correspondingly  the Protocol Summary andSection 
8.2.2.2 were updated.
o  
 Correspondingl y, Table 8-1was updated and the relevant sub-section 
in Section 8.2. was deleted .
Section 3 :
oPre-screening: Corrected that information to determine key eligibility  criteria may 
be collected using an optional pre- screening form .
oScreening Phase: Deleted the words “electronic” and “from Day 84 to Day 1” and 
referred to Section for schedule.
Section 4.5 :
oExpanded risk and benefit section to align with IB v10and included additional 
information on I RRs. 
oAdded language to risk and benefit section regarding the important potential risks 
of hemorrhages, infections, infusion related reactions and immunogenicit y in line 
with phase III crizanlizumab clinical trial.

Novartis Confidential Page 22
Amended Protocol Version 03 (clean ) Protocol No. CSEG101AUS05
oAdded language to risk and benefit section regarding lack of evidence on mAb 
transmission in seminal fluid.
Section 5.1:
oInclusion Criteria #6: Included voxelotor as a permitted concomitant therap y. 
Correspondingl y, voxelotor was added in the Protocol Summary  and four times in 
Section 6.2.1.1.
oInclusion Criteria #8: Clarified that the renal and hepatic function should be assessed 
prior to Week 1 Day  1.
oInclusion Criteria #9: Clari fied that laboratory  values should be assessed prior to 
Week 1 Day  1.
Section 5.2:
oExclusion Criteria #1: Clarified that only patients who had a shunt surgical 
procedure on the penis performed within 12 month s prior to consenting are not 
allowed. Correspondingly , the clarification was added in the Protocol Summary .
oExclusion Criteria #12 was modified to exclude patients on the basis of their famil y 
history  of long QT syndrome or Torsades rather than a QTcF equal or superior to 
470 msec.
oExclusion Criteria #13 was modified to remove History  of myocardial infarction, 
angina pectoris, coronary  artery  bypass graft, or uncontrolled congestive heart 
failure within 6 months 
prior to starting study  treatment asan exclusion factor. 
Specified the criteria indicating a significant risk of safet y as “Concomitant 
clinically  significant cardiac arrhy thmias (e.g ventricular tachycardia), and clinically  
significant second -or third -degree AV block without a pacemaker” .
oExclusion Criterion #14: current drug or alcohol abuse was replaced with a criterion 
to exclude patients with current drug or alcohol abuse as per investigator discretion. 
Correspondingl y, drug and alcohol screens were deleted or changed to drug and/or 
alcohol history  in Table 8-1(row and Footnote b), Section 8.1.3 , Section 8.3.2 and 
Table 8
-4.
oExclusion Criterion #15: Language edited for clarity .
Section 6.1.1:
oRemoved some irrelevant instruction related to the tear -off label on the medication 
package .
oDeleted the composition of the formulation for the infusion solution. All allowed 
formulation are listed in the Pharmacy  Manual.
Section 6.2.1.1:
oAdded information on pre-medication in case of 
Infus ion Related Reactions and a 
recommendation to use steroids with caution to treat I RR. Correspondingly , similar 
language was added in Section 6.2.1.3.
Section 6.2.1.3.

Novartis Confidential Page 23
Amended Protocol Version 03 (clean ) Protocol No. CSEG101AUS05
oText related to PK/PD was deleted because such procedures are not implemented in 
the protocol .
oClarif iedthe text by  adding “as outlined above” .
oClarified the data collection method if other forms of L -Glutamine are used .
oClarified the restrictions for administration of vaccines.
oAdded text related to the use of pre-medication in case of infusion- related reactions. 
Clarified that there is no clinical data on the concomitant use of crizanlizumab and 
corticosteroids. Added a reference to Table 6-2forfurther information on the 
management of infusion -
related reactions.
oAdded a recommendation to hold drug administration 4 weeks prior to a major 
surgery .
Section 6.2.2:
oClarified that subjects that prior use of crizanlizumab, other selectin targeting agents 
or new treatment to treat SCD and/or to prevent/reduce VOCs are not permitted .
Section 6.5:
oDeleted that dose changes must recorded in the CRF.
Table 6
-2:
oClarified that version 5 of the CTCAE dictionary  is used a reference.
oUpdated the units for Neutropenia and Thrombocy topenia to Internat ional System 
units.
oCriteria for body  temperature in febrile neutropenia changed from ≥38.5 °Cto ≥ 
38.3 °C.
oRange for Grade 1 to Grade 4 isolated direct bilirubin has been clarified.
oClarified the recommendations for dose interruptions for Grades 1 -4.
oRange for Grade 1 to G rade 4 Infusion-related reactions has been clarified.
oUpdated recommendation to continue study  treatment for Grade 1 infusion related 
reactions .
oFor Grade 2 infusion- related reaction, recommendation is updated to clarify  the 
conditions t o interrupt, administer pre -medication and res -start infusion .
oUpdated recommendation to discontinue stud y treatment for Grade 3 and 4 infusion 
related reactions.
oFoot note has been deleted regarding recommendation to continue study  treatment 
at Investigator’s discretion if total bilirubin > 3.0 × ULN is only due to indirect 
component .
Section 6.5.1.1:

Novartis Confidential Page 24
Amended Protocol Version 03 (clean ) Protocol No. CSEG101AUS05
oModified definition of potential DILI to include normal ALP along with elevation 
of transamina ses and increase in TBIL .
oDeleted the mention that AST will not be considered .
oCriteria for subjects with normal ALT and Direct BIL value at baseline modified to 
include that the subjects should be without evidence of cholestasis.
oText modified to reflect that LFTs will be repeated for certain defined criteria 
preferabl y within 48 -72 hours .
Section 6.7.1:
oReference to the Pharmacy  Manual has been added .
oThe language related to the management of I RRs was d eleted as it was not relevant 
to this section. Management of I RRs is described in 
Table 6-2
Section 8: Updating and clarify ing the permitted visit wind ows:
oScreening assessments must occur within 84 days (12 weeks) ± 7 days prior to the 
enrollment .
oFor all screening visits a general ± 7 day  visit window is allowed.
oA ± 7 day visit window is allowed at Week 1 Day 1 (calculated from day of consent) .
oA ± 3 day  visit window is permitted on assessments at Week 3 Day  1.
oFor all other dosing visits a general ± 7 day visit window is permitted on assessments .
oDeleted “to take into account scheduling over public holiday s”.
oCorresponding text was updated in Section 8.3.2.
Table 8
-1:
oDeleted “microscopic or macroscopic” as a microscopic panel is not alway s done. 
The conditions for urinalysis with a microscop ic panel are detailed in Section 8.3.3.
oPrior/concomitant medications
-“Hydroxyurea ”row was reformatted to highlight the 
continuous need to be recorded. The rows for “Transfusion,  Adverse 
Event/Serious Adverse Event and Prior/concomitant medications” were similarly  
modified.
oECG assessment was moved from Screening Visit 1 to Screening V isit 3 as it needs 
to be done closer to start of dosing. Corresponding language was clarified in Section 
12.6.2.
oFootnote “
a”was updated to clarify that if the dose is delayed for more than 7 days, 
every  effort should be made to bring the subject's infusions back onto the protocol -
defined schedule ( Section 6.5 ).
oFootnote “c ” became Footnote “b”.
Section 8.1:
oText modified in line with the modification of the screening wi
ndows in Section 8 .

Novartis Confidential Page 25
Amended Protocol Version 03 (clean ) Protocol No. CSEG101AUS05
oDeleted “use the electronic device(s) require” and added “as described in Section 
8.2.4” to reflect the possibility  of using a paper diary to record the priapic episodes. 
Correspondingl y, text was deleted in Section 8.2.1 and modified in Section 8.2.4.
oAdded text to clarify  the conditions for local testing when the resul ts from the central 
laboratory  are partial unavailable. Corresponding text was modified in Section 8.3.2.
oAdded text to clarify  that re-screening of subjects is allowed under certain conditions 
and the steps that need to be undergone.
Section 8.2.1:
oAdded text to clarify  that In order to be treated as independent priapic events, two 
events will have to be separated by at least 2 hours, and the event would have to 
return to baseline during those 2 hours.  
Section 8.2.2.1:
oAdded “efficacy ” to clarify  that priapism was the primary  efficacy  endpoint as 
specified in 
Section 8.2.1 .
Section 8.3.2:
oDeleted Flowchart as no central laboratory  document other than the laboratory 
manual has been developed .
Section 8.3.3:
oAdded text to clarify  that a microscopic panel will be performed centrall y if dipstick 
is positive.
Section 8.3.5.1:
oRemoved two portions of text related ECG evalua tion with a central laboratory. 
ECG are onl y done and interpreted locally .
Section 8.3.5.2:
oParameters to be assessed by Echocardiogram are re-defined: PAP replaced with 
mPAP .
Section 8.3.7:
oTimeframe for the repeat assessment was removed at EOT to align with EOT being 
conducted with 2 weeks of the last infusion.
Section 8.4.1 :
oText modified as PROs will not administered electronicall y but via paper.
Section 9.1.1:
oClarification that an EOT visit should be performed within 14 day s of the last dose 
of the discontinued study treatment.
Section 10.1.1:

Novartis Confidential Page 26
Amended Protocol Version 03 (clean ) Protocol No. CSEG101AUS05
oUpdated the list of outcomes to be recorded in the eCRF to include 
recovering/resolving AEs.
Section 10.1.5:
oDeleted the redundant word “Pregnancies ”
.
Section 11.1:
oText of the Section was simplified by removing unnecessary or redundant language 
related to data capture in CRF, data storage and transfer, methods of monitoring and 
data verification .
Section 11.3:
oClarified that 
continuous remote monitoring of each site’s data may be performed 
by a centralized Novartis -affiliated Clinical Research Associate (CRA) organization.
Section 12.4.2:
oAdded that additional analyses will also be performed for the subgroups of subjects 
who have experienced priapic episodes lasting less than one hour and not for 
stuttering priapism. Corrected that these anal yses are not for the primary  endpoi nt.
Section 12.4.3 and Section 12.4.4:
oAdded additional anal yses to assess the impact of the COVID- 19 crisis. 
Section 15:
oAdded the following additional references: Banholzer et al., Brandow 
et al. , Scialli 
et al. and and Vichinsky et al. . The same changes were made wherever applicable in 
the protocol summary .
Appendix 5 :
oTable 16-1 was modified to exclude the antipsy chotics and anti-depressant drugs. 
The title was revised accordingl y.
oTable 16-2 was created to emphasize the list of anti-depressants and Antipsy chotics 
that may induce priapism form other substances. 
Additional drugs uncovered from 
a systemic literature search were added. Tradenames were added for easier 
identification by  the investigator. References were also included.
IRBs/IECs
A copy of this amended protocol will be sent to the Institutional Review Board 
(IRBs)/Independent Ethics Committee (I ECs) and Health Authorities.
The changes described in this amended protocol require IRB/IEC approval prior to 
implementation. 
The 
changes herein affect the Informed Consent. Sites are required to update and submit for 
approval a revised Informed Consent that takes into account the changes described in this 
protocol amendment

Novartis Confidential Page 27
Amended Protocol Version 03 (clean ) Protocol No. CSEG101AUS05
Protocol summary
Protocol number CSEG101AUS05
Full TitleA Prospective Phase II, Open -Label, Single -arm, Multicenter, Study  to 
Assess Efficacy  and Safety of SEG101 (crizanlizumab), in Sickle Cell 
Disease Patients with Priapism (SPARTAN)
Brief titleStudy of efficacy  and safety SEG101 (crizanlizumab) in Sickle Cell Disease
(SCD) Patients with Priapism (SPARTAN)
Sponsor and Clinical 
PhaseNovartis
Phase of the trial: II
Investigation type Drug
Study type Interventional
Purpose and 
rationaleThe purpose of this study is to evaluate the effect of crizanlizumab on 
priapic events in sickle cell disease patients with a history of priapism. 
During screening, we will be collecting data for 12 weeks prior to the
treatment phase to create a baseline for priapic events (defined as an
event of an unwanted painful erection lasting at least 60minutes), acute 
priapic events (which is defined as an event of an unwanted or painful 
erection lasting at least 4hours), uncomplicated and complicated vaso -
occlusive crisis (VOC). Our hypothesis is that crizanlizumab treatment will 
reduce priapic events by at least 25% in SCD patients with priapism.
Primary Objective To evaluate the clinical efficacy (percent reduction from baseline) of 
crizanlizumab in SCD -related priapism
Secondary 
ObjectivesTo evaluate the clinical efficacy (r ate of priapic events )of 
crizanlizumab in SCD --related priapism
To evaluate the clinical efficacy of crizanlizumab in SCD- related 
acute priapism
To evaluate the clinical efficacy of crizanlizumab for 
uncomplicated VOC (defined as an acute event of pain with no 
known cause for pain other than a vaso -occlusive event; and 
requiring treatment with a parenteral or oral opioids or other 
parenteral analgesic; but is NOT classified as an acute chest 
syndrome, hepatic sequestration, splenic sequestration or 
priapism and these events will not be adjudicated)
To evaluate the clinical efficacy of crizanlizumab incomplicated 
VOCs (acute chest s yndrome, hepatic sequestration, splenic 
sequestration, and acute priapism) 
To assess the safety  and tolerability of crizanlizumab
Study designThis is a multicenter, prospective, phase II, single -arm, open -label study to 
assess the efficacy  and safety  ofcrizanlizumab in SCD patients with 
priapism. A total of approximately 36male subjects aged ≥12 years, who 
meet all of the inclusion criteria and none of the exclusion criteria will be 
eligible for the study. 
The baseline period is defined as the 12weeks screening period . Eligible 
subjects will be treated with crizanlizum ab at a dose of 5.0 mg/kg. From the 
first screening visit until the end of follow -up, the total study duration will be 
up to 79weeks (including 12weeks of screening, 52weeks of treatm ent 
and 15 weeks of follow -up period if applicable ). The primary  analysis of the 
study will be conducted by 26 weeks to assess efficacy of crizanlizumab in 

Novartis Confidential Page 28
Amended Protocol Version 03 (clean ) Protocol No. CSEG101AUS05
this patient population. The secondary  endpoints will be 
assessed by 26weeks and/or 52weeks. Subjects will be followed in the 
safety follow -up period until 105days (15weeks) after the last dosing .
Subjects who will receive commercially approved crizanlizumab 
approximately 4 weeks after their last dose of study treatment, do not need 
to complete the 105 -day follow -up.
PopulationA total of approximately 36male patients with SCD -related priapism aged
≥ 12years will be recruited across the United States. To be considered for 
this study , patients must have had≥ 4priapic events during the 14weeks 
prior to screening and having at least 3priapic events during the 12week 
screening period with at least 1event occurring within 4weeks prior to the 
first treatment.
Key Inclusion criteriaSubjects eligible for inclusion in this study  must meet all of the following 
criteria:
1. Signed informed consent and applicable adolescent assent 
and/or parental consent for adolescent subjects, must be 
obtained prior to participation in the study
2. Male patients aged 12years and above
3. Confirmed diagnosis of SCD by hemoglobin electrophoresis or 
high performance liquid chromatography. All SCD genotypes are 
eligible (HbSS, HbSβ0, HbSC, HbSβ+, and others) 
4. Patients who have experienced ≥ 4 priapic events (unwanted 
erection lasting at least 60 minutes) over 14 week pre -screening 
5. Patients who have experienced at least 3 priapic events 
(unwanted erection lasting at least 60 minutes) during the 
12week screening period with at least 1event occurring within 
4weeks prior to the first treatment.
6. If receiving hy droxy urea/hydroxy carbamide , L-glutamine , 
erythropoietin stimulating agent or voxelotor , must have been 
receiving the drug for at least 14 weeks prior to screening and 
plan to continue taking the drug at the same dose and schedule 
during the trial
7. If receiving prophylactic treatment for priapism, must have been 
receiving the drug for at least 14 weeks prior to screening and 
plan to continue taking the drug at the same dose and schedule 
during the trial
Key Exclusion 
criteriaFollowing are the key exclusion criteria:
1. Patients who have penile prosthetic implants . Shunts or any 
other surgical procedure on the penis performed within 12 
months prior to consenting are not allowed.
2. Patients who have taken drugs/medications that may  induce 
priapism ( as per Appendix 5 ) over the 14 weeks pre -screening 
period
3. Patients who have received leuprolide acetate ( Lupron) or any 
other gonadotropin -releasing hormone receptor (GnRHR) 
agonist agents within 3 months before pre -screening.
4. Patients who had an erection lasting more than 12 hours over 
the 14 week pre -screening period
5. Patients who had an erection lasting more than 12 hours during 
the 12 weeks of the sc reening period
Study treatment Crizanlizumab (SEG101) at 5.0 mg/kg

Novartis Confidential Page 29
Amended Protocol Version 03 (clean) Protocol No. CSEG101AUS05
Efficacy assessmentsFollowing are the key primary and secondary planned efficacy 
assessments:
!Percent reduction in priapic events by 26 weeks of treatment
!The rate of priapic events by 26 and 52 weeks of treatment
!Percent reduction in acute priapic events by 26 and 52 weeks of 
treatment
!The rate of complicated/uncomplicated VOCs by 26 and 
52 weeks of treatment
Key safety assessmentsFollowing are the key safety assessment planned for this study:
!Monitoring of AEs/SAEs
!Vital signs, Physical assessments
!Hematology, chemistry, coagulation, urinalysis, Hepatitis markers
!Presence of HIV Antibody (at screening only)
!Cardiac assessments: ECGs and echocardiogram
Other assessments 
Data analysisThe primary endpoint of the study is the percent reduction from baseline in 
priapic events by 26 weeks (i.e. up to pre-infusion Week 27, Day 1). Efficacy endpoints will be analyzed us ing all FAS subj ects who have 
completed treatment. It is hypothesiz ed that crizanlizumab treatment will 
reduce the priapic events by at least 25% in SCD subjects with priapism. 
Assuming uniformity of the events occurrence before exposure tocrizanlizumab treatment, baseline will be adjusted for 26 weeks for primary analysis purpose. Percent reduction from baseline in priapic events will be tested using a nonparametric test (i.e. Wilcoxon’s Sign Rank test) along withHodges-Lehmann estimate of median percent reduction Number of priapic 
events and percent reduction from baseline by Week 26 will be summarized 
descriptively.
As part of the supportive  analysis the primary analysis will be repeated on 
all subjects in FAS. In addition the annualized rate of priapic events will be summarized for all subjects in FAS that have completed treatment. Three additional supportive analyses will also be performed, the total number of 
priapic episodes in the screening period (12 weeks baseline) will be 
compared to the total number of priapic episodes occurring in the first 12 weeks on treatment (0-12 weeks) using a nonparametric test (i.e. Wilcoxon’s Sign Rank test). A similar analysis will be performed to compare to the total number of priapic episodes occurring in the last 12 weeks on treatment (15-26 weeks). Finally an  analysis using a mixed effects 
regression model will be performed using median event counts within pre-
specified time windows. 
Similar analyses on percent reduction in acute priapic events for subjects 
will be conducted, as was completed for primary endpoint. Descriptive summary statistics will be presented for the rate of events and number of 
priapic events at Baseline, by Week 26 and by Week 52. In addition, the 
rate of uncomplicated VOC events and VOC events will be summarized. Safety analyses will be based on the sa fety analysis set. Adverse events PI
Novartis Confidential Page 30
Amended Protocol Version 03 (clean ) Protocol No. CSEG101AUS05
will be summarized by system organ class and or preferred term, 
seriousness, CTCAE grade based severity, type of adverse event, relation 
to study treatment . Other safety assessments (e.g.ECG , vital signs) will be
summarized by treatment group .
Key wordsPriapism, sickle cell disease, crizanlizumab, P-selectin, vaso -occlusive 
crisis

Novartis Confidential Page 31
Amended Protocol Version 03 (clean ) Protocol No. CSEG101AUS05
1 Introduction
1.1 Background
1.1.1 Overview  of Sickle Cell D isease pathogenesis, epidemiology and 
current treatment 
Sickle cell disease (SCD) is a genetic blood disorder, caused by a single missense mutation 
(Glu6Val) in the β-globin gene, which early on progresses into a systemic disease. 
Vaso -occlusion is the hallmark of SCD and can lead to serious acute and chronic complications. 
Vascular dysfunction, inflammation, and P-selectin mediated cell -to-cell and 
cell -to-endothelium adhesion play an important role in the pathophy siology  of SCD. 
Uncomplicated vaso-occlusive crisis (VOC) is the most common clinical manifestation of SCD. 
Complicated VOCs include acute chest syndrome, hepatic and splenic sequestration ,and 
priapism. E very VOC increases morbidit y and can result in organ damage/failure and/or death 
(Ballas et al 2010, Brousseau et al2010, Powars et al2005 ). Additionally , VOCs lead to 
significant health care utilization and are the most common cause of emergency  room visits and 
hospital admissions in SCD patients, w ith total medical costs exceeding 1.1 billion USD 
annually  (Kauf et
al2009 ).
Sickle cell disease is the most common single gene disorder in African Americans, affecting 
approximately  1  i n 375-600 people of African ancestry  (Nietert et al 2002). Sickle cell 
conditions are also common among people of Mediterranean countries, Africa, Middle East, 
India, Caribbean, and parts of South and Central America (Clinical Practice Guideline No. 6. 
1993, Nietert et al2002 ). The most frequent and typicall ymost severe 
form ishomozy gous HbSS (sickle cell anemia) (α2βs2, HbS). Other forms of SCD
include compound heterozy gous conditions, such as hemoglobin C (HbC) with HbS (HbSC), 
HbS 
with β-thalassemia (HbS/β0-thalassemia or HbS/β+-thalassemia), and HbS with other 
variants (Ware et al 2017 ).Clinical signs appear within the first 6 months of life, but there is 
consi derable variability  in severity  (Gillet al 1995 )resulting from genetic and environmental 
factors. Patients describe acute pain crises and chronic pain clearly as the most debilitating 
effects on their lives, affecting them physically  and emotionally . Fatigue and cognitive 
effects also emerge as other debilitating effects. In addition, organ -damage and long-term 
complications have also a severe effect on 
them. As a result of these complications, patients 
often have reduced quality  of life, significant anxiety , depres
sion, and short life expectanc y 
(Pielet al 2017, Kanter and Kruse -Jarres 2013 ) .
Stem cellbone transplantation remains the only curative modality  for SCD patients. However, a 
limited number of patients are eligible, and substantial concerns remain about transplant -related 
mortality  and long -term toxicities, including infertility  (Ware et al 2017 ).
Blood transfusions are commonly  used as a single transfusion to ameliorate acute, even -life-
threatening complications, and/or as chronic transfusions to prevent long-term complicat ions 
most frequently related to stroke prevention.
Vaso -occlusive crises are typicall y treated symptomatically  with pain management and with 
other supportive care (Bender 2003, Rees et al 2010 ). Severe pain is often treated with opioids,
but their use is controversial due to the risk of opioid -related adverse events (AEs) .

Novartis Confidential Page 32
Amended Protocol Version 03 (clean ) Protocol No. CSEG101AUS05
Preventive treatments to reduce the number of VOCs are limited. 
Hydroxyurea/hydrox ycarbamide ( HU/HC )is approved to reduce the frequency  of painful crises 
and the need for transfusions in SCD patients aged 2 yearsand older with a history  of recurrent, 
moderate -to-severe painful crises. Treatment with HU/HC presents several limitations, 
including signif icant toxicities and need for blood monitoring leading to poor patient 
compliance. Itis cytotoxic, myelosuppressive and teratogenic, potentiall y carcinogenic, impacts 
fertility and has a number of contraindications orspecial warnings and precautions for use
(Charache et al 1995, Pászty et al 1997 , Hydrea-USPI 2016,Droxia -USPI 2017 ).
L-glutamine (Endari™), is approved in the United States to reduce the acute complications of 
SCD in adult and pediatric patients 5 years and older (Niihara et al 2018) and voxelotor
(Oxbry ta™) has been approved by FDA since 25 Nov 2019 for the treatment of SCD in adult 
and pediatric patients 12 years of age and older (Vichinski et al 2019
).
Despite the use of HU/HC, transfusions, L -glutamine and/or voxelotor ,patients with SC D may 
still experience VOC s.In particular, complicated VOCs such as priapism represent a major 
unmet medical need.
1.1.2 Overview  of SCD -related priapism , epidemiology  and current 
treatment
Priapism is an involuntary , painful, and persistent erection, in the ab sence of sexual activity  or 
desire (Furtado et al 2012 ). It was found that 29% of male children and adolescents with SCD 
reported priapism, and projected that up to 89% of men with SCD would experience priapism 
bythe age of 20 
(Mantadakis et al 1999). The vast majority  of cases are ischemic, in which 
increased pressure ,compromises the vascular circulation (i.e.a type of compartment syndrome). 
Its ischemic form, presenting as a single, major event , or recurrence , isassociated with penile 
pain, erectile tissue destruction and loss, and permanent erectile inability (Montague et al 2003 ,
El-Bahnasawy  et al 2002). The sickled erythrocy tes predispose to venous stasis, which therefore 
perpetu ates the priapism. Cavernosogra phy shows that this stasis results in obstruction of the 
deep dorsal penile vein 
(Adey oju et al 2002). The stagnation of blood within the sinusoids of 
the 
corpora cavernosa during a physiological erection increases erythrocy te rigidity  and impairs 
the venous outflow from the corporeal bodies. Prolongation of the erection and pain induced by 
ischemia of the corporeal tissues are potential consequences of these events. (Fowler Jr et al 
1991). Most of the affected patients had repeated events that l asted for less than 3 hours and a 
majority  of the attacks occurred during sleep, which could be due to the physiological 
dehy dration and metabolic acidosis that accompany sleep and that increase the rigidity  of 
erythrocy tes in patients with sickle cell anemia(FowlerJret 
al 1991) . Priapism may be one 
reflection of the vasculopathy  of SCD . (Kato et al 2017 ) .
Apart from anecdotal experiences, there is no clear evidence -based guidelines in management 
or medical prevention strategies. The goal of priapism treatment is to achieve detumescence 
and preserve erective dysfunction ( Montague et al 2003). Treatment for SCD - related priapism
are lacking due to the clinical misunderstanding and the ideal medical interventions have not 
been developed. In recent years, major scientific progress has advanced the understanding of 
pathophy siology  especially  in molecular effector pathway s mediating penile erection. The 
medical management of recurrent or stuttering SCD -related priapism is difficult and frustrating, 

Novartis Confidential Page 33
Amended Protocol Version 03 (clean ) Protocol No. CSEG101AUS05
often involving sequential attempts with several different drugs, and clearly , more rigorous 
clinical research is need ed in this area.
1.1.3 Role of P -Selectin in VOC
Extensive data have been published over the last decade that suggests a pivotal role for 
P-selectin in the pathophy siology  of SCD. Adhesion of leukocy tes to the endothelium during 
inflammation can involve multiple molecules and the process is initiated by P-selectin
(Lawrence and Springer 1991). P -selectin expression increases the specificity  of endothelial 
cell interactions with platelets and leucocy tes during inflammation, coagulation and 
atherosclerosis . P-selectin expressed on endothelial cells also increases sickle erythrocy te 
adhesion, although the precise ligand interaction involved is not known
. P-selectin is found in 
storage granules of resting endothelial cells and platelets and is rapidl y transferred to the cell 
membrane on activation of the cell during processes such as inflammation. Itis expressed on 
the surface of endothelium that mediates abnormal rolling and static adhesion of sickle 
erythrocy testo the vessel surface in vitro ( Matsui et al 2001, Matsui et al 2002 ). Translocation 
of endothelial P-selectin to the cell surface results in the prompt adhesion of sickle erythrocy tes 
to vessels and the development of vascular occlusion in transgenic mice with SCD (Embury  et 
al 2004).
The role of P -selectin in SCD is further substantiated by the fact that t ransgenic mice with SCD
that are deficient in P -selectin and E -selectin have defective leukocyte recruitment to the vessel 
wall and are protected from vaso-occlusion (Turhan et al 2012 )
. The adherence of sickle 
erythrocy tes and leukocy tes to the endothelium is substantially  reduced when P-selectin is 
blocked in transgenic mice expressing human HbS (Embury  et al 2004, Gutsaeva et al 2011).
These data support the concept that blockade of P
-selectin could reduce the risk of 
vaso-occlusion, inflammation, and sickle cell–related pain crises ( Ataga et al 2017 ) .
In addition to the studies done in animal s, human sickle red cells frequently  interacted and 
adhered directl y to the vascular endothelium ( Matsui et al2001). Platelets also respond to 
inflammation with the upregulation of P
-selectin and are known to bind to leukocy tes and 
endothelium, thereb y contributing to vaso-occlusion in SCD (Wood et al 2004, Inwald et al 
2000, Lee et al 2007 ). The adhesion of sickled human ery throcy tes to activated endothelium in 
SCD is also an important contributor to vaso-occlusion and pain crisis (Wagner et al2006,
Hebbel et 
al 1980, Stuart and Johnson 1987 ).
1.1.4 Role of P -Selectin in SCD -related priapism
Preclinical studies in transgenic mice have shown that SCD promotes an increased P-selectin 
expression in several vascular beds of various organs (e.g.lung, heart, small bowel, large bowel, 
penis etc.).The penis is the only organ where the vascular bed exhibited an increased expression 
of both P
-and E-selectin, which may be relevant to a SCD -related priapism .Although, priapism 
has been attributed to both ischemic and non-ischemic causes, vaso-occlusion -induced ischemia 
is generall y thought to account for the priapism associated with SCD. This raise sthe possibility  
of an inflammatory
 process in priapism ( Wood et al 2004 ).

Novartis Confidential Page 34
Amended Protocol Version 03 (clean ) Protocol No. CSEG101AUS05
Figure 1-1 P- selectin expression in penis of wild -type (WT) and sickle cell 
transgenic (βS) mice
Constitutive expression of P -selectin in the penis of wild -type (W T) and sickle cell (βS) mice. While 
significant P -selectin expression is detected in the penis of βS mice, it was not be detected in the W T 
penis ( P< .0005).
As P-selectin expression is increased in the penis and vaso-occlusion induced ischemia is 
thought to account for the priapic events, a study  evaluating the effects of P-
selectin inhibition 
on priapism associated with SCD is warranted.
1.2 Introduction to investigational treatment(s) and other study  
treatment(s)
1.2.1 Overview  of crizanlizumab (SEG101)
Crizanlizumab is a selective IgG2 kappa humanized monoclonal antibody  that binds to 
P-selectin with high affinity byblocking its interaction with its ligands, including P-selectin 
glycoprotein ligand 1 (PSGL -1). Extensive pre-clinical data have established P
-selectin as a key 
mediator of VOC in SCD (Matsui et al 2001 )and suggest that blockade of P-selectin could 
eliminate or reduce VOC. 
The compound , crizanlizumab was initially developed by Reprix ys Pharmaceuticals 
Corporation under the investigational drug code, SelG1. Novartis acquired the company  on 
18
-Nov- 2016, and is now the drug developer and sponsor for crizanlizumab, under the 
investigational drug code, SEG101. On 15 -November- 2019, the US FDA approved 

Novartis Confidential Page 35
Amended Protocol Version 03 (clean) Protocol No. CSEG101AUS05
ADAKVEO® (crizanlizumab-tmca), for the reduction ofthe frequency of VOCs in adults and
pediatric patients aged 16 years and older with sickle cell disease.
The approval was based on safety and efficacy data from the Phase II SUSTAIN study (Ataga 
et al 2017; see Section 1.2.2)below. 
The crizanlizumab IB provides detailed information related to toxicology, nonclinical 
pharmacology, drug properties, clinical and preclinical data.
1.2.2 Clinical experience 
Phase II Clinical Study (SUSTAIN – CSEG101A2201) 
Throughout this description of SUSTAIN,the study drug is denoted as crizanlizumab and refers 
to SelG1. The objective of this pivotal, randomized, placebo-controlled SUSTAIN study (Reprixys study code: [Se1G1-00005]; Novartis study code: [CSEG101A2201]) was to assess the safety and efficacy of crizanlizumab with or without HU/HC therapy in SCD patients with a history of VOC leading to a healthcare visit. A total of 198 SCD patients aged 16-65 years (inclusive), with any SCD genotype, a history of crisis within the previous 12 months, and either 
with a steady dose of HU/HC or not taking HU/HC, were randomized 1:1:1 to crizanlizumab 5.0 mg/kg, crizanlizumab 2.5 mg/kg or placebo. 
The median annual rate of VOC leading to a healthcare visit was 45.3% lower with 5 mg/kg 
crizanlizumab than with placebo(Hodges-Lehmann, median absolute difference of -1.01 versus placebo, 95% confidence interval (CI) [-2.00, 0.00]). The difference between the 5 mg/kg arm and placebo arm was statistically significant (Wilcoxon rank sum test, p=0.010). The median annual rate of uncomplicated crises and median number of days hospitalized were 62.9% and 41.8% lower in the 5.0 mg/kg than in the placebo group, respectively. Crizanlizumab also delayed the time to onset of first and second VOC, and consistent benefit was further observed in a number of clinically relevant subgroups for the primary endpoint. 
Crizanlizumab was generally well tolerated with similar incidence of treatment emergent 
adverse events (TEAEs) across the 3groups, and overall there were low incidence of discontinuations due to TEAEs (<5%). The proportion of subjects experiencingserious adverse events (SAEs)was 25.8% at 5.0 mg/kg, 32.8% at 2.5mg/kg and 27.4% in the placebo group. There were 5 deaths during the study (2 at 5.0 mg/kg, 1 at 2.5mg/kg and 2 inthe placebo group), and none was deemed to be treatment related. Please refer to Investigator’s Brochurefor further information. 
Overall, treatment of SCD patients with crizanlizumab at 5.0 mg/kg showed positive clinical 
activity as demonstrated by a statistically significant and clinically relevant decrease in the annual VOC rate compared with placebo and it was also found to be well tolerated.
All completed clinical studies described above were performed by Reprixys Pharmaceuticals 
Corporation. Thesestudies were conducted using monoclonal antibodies produced in Invitrogen CHO-S cells (SelG1). To ensure supply of future clinical studies as well as commercial demand, 
Novartis has optimized the production of crizanlizumab. SEG101 will be used in future clinical/toxicological studies and as a commercial product.
Novartis Confidential Page 36
Amended Protocol Version 03 (clean ) Protocol No. CSEG101AUS05
1.3 Purpose
The purpose of this study  is to evaluate the effect of crizanlizumab on priapic events in sickle 
cell patients with a history  of priapism. We will be collecting data for 12 weeks prior tothe 
treatment phase to create a baseline for priapic events (defined asan event of anunwanted 
painful erection lasting at least 60minutes) ,acute priapic events (which is defined as an event 
of an unwanted or painful erection lasting at least 4hours), uncomplicated and complicated 
VOCs. Our hypothesis is that crizanlizumab treatment will reduce priapic events by at least 
25% in SCD patients with priapism.
 

Novartis Confidential Page 37
Amended Protocol Version 03 (clean ) Protocol No. CSEG101AUS05
2 Objectives and endpoints
Table 2-1 Objectives and related endpoints
Primary  Objective Endpoint for primary objective
To evaluate the clinical efficacy of crizanlizumab 
in SCD -related priapismPercent reduction f rom baseline period in priapic 
events (priapism defined as unwanted, or painful 
erection lasting at least 60 min self -reported) by 2 6
weeks
Secondary Objective s Endpoints for secondary objectives
To evaluate the clinical efficacy of crizanlizumab 
in SCD -related priapismRate of priapic events by 26and 52 weeks
To evaluate the clinical efficacy of crizanlizumab
in SCD -related acute priapismPercent reduction from baseline in acute priapic 
events (defined as an unwanted orpainful erection 
lasting at least 4hours and mandates a visit to ER) 
by 26weeks and 52 weeks
To evaluate the clinical efficacy of crizanlizumab 
for uncomplicated vaso -occlusive crisis (VOC) 
(defined as an acute event of pain with no 
known cause for pain other than a 
vaso -occlusive event; and requiring treatment 
with a parenteral or oral opioids or other 
parenteral analgesic; but is NOT classified as an 
acute chest syndrome, hepatic sequestration, 
splenic sequestration or priapism and these 
events will not be adjudicated)Rate of uncomplicated VOC events (including both 
healthcare visit and self -reported) by 2 6and 
52weeks
To evaluate the clinical efficacy of crizanlizumab
in complicated VOCs (acute chest syndrome, 
hepatic sequestration, splenic sequestration, 
and acute priapism) Rate of complicated crisis (recorded by healthcare 
visit) by 26 and 52 weeks
To assess the safety an d tolerability of 
crizanlizumabNumber, seriousness, severity, and causality 
assessments of treatment emergent adverse events 
and other safety data as con sidered appropriate by 
52weeks (Safety assessments will consist of 
monitoring and recording all adverse events, based 
on Common Terminology Criteria for Adverse events 
(CTCAE ) V5.0. 
It will also include regular monitoring of laboratory 
testing of hematology, serum chemistry, and 
urinalysis, measurement of vital signs, and physical 
examinatio n.)
2.1 Primary  estimands

Novartis Confidential Page 38
Amended Protocol Version 03 (clean ) Protocol No. CSEG101AUS05
The estimand is the precise description of the treatment eff ect and reflects strategies to address 
events occurring during trial conduct which could impact the interpretation of the trial results 
(e.g. premature discontinuation of treatment).
The primary  clinical question of interest is: What is the effect of crizanlizumab on reduction 
from baseline period in priapic events , by week 26?
The primary  estimand is described by  the following attributes:
1.Population: Sickle Cell Disease patients with priapism. Further details about the population 
are provided in Section
5.
2.Endpoint: Percent reduction from baseline period in priapic events (priapism defined as 
unwanted, or painful erection lasting at least 60 min self- reported) b y 26 weeks .
3.Treatment of interest: investigational drug w ill be a crizanlizumab solution provided every 
4 weeks with an additional loading dose 2 weeks after the first dosing. Further details about 
the investigational treatment are provided in Section 6 .  
4. List of intercurrent events:
a)Treatment discontinuation 
b)Initiation or discontinuation of HU/HC or l-glutamine (or other therapies to treat 
SCD and or to prevent/reduce VOCs such as voxelotor and ery thropoietin) or of 
prophy lactic treatment for priapism as described in the 
Sections 6.2.1, 6.2.2, 6.2.3
c)Intake of analgesic (including opioids) or ad hoc transfusions administered 
temporaril yas described in the Section 6.5.
5.The summary  measure: Median percent agechange from baseline 
period in priapic events 
(priapism defined as unwanted, or painful erection lasting at least 60 min self -repor ted) by 
26 weeks
Handling of intercurrent events is discussed in Section 12.4.2.
3 Study  design
This is a multicenter, prospective , phase II, single -arm, open -label study  to assess the efficacy 
and safet y of crizanlizumab in SCD patients with priapism.
A total of approximately  
36male subject s aged ≥12years, who meet all of theinclusion criteria 
and none of the exclusion criteria will be eligible for the study. Subject s with ≥ 4priapic events 
during the 14 week pre-screening period and having at least 3priapic events during the 12week 
screening period with at least 1 event occurring within 4 weeks prior to the first treatment ,will 
be included in the study .
The baseline period is defined as the12 weeks screening period .Eligible subjects will be treate d 
with crizanlizumab at a dose of 5.0 mg/kg. From the first screening visit until the end of follow -
up, the total study  duration will be up to 79week s (including 12weeks of screening , 52 weeks 
of treatment and 15 weeks offollow - up as applicable ). The primary  analysis of the study  will 
be conducted b y 26weeks to assess efficacy  of crizanlizumab in those patient population, who
have completed 26 weeks oftreatment . The secondary   endpoints will be 
assessed by  26weeks and /or52weeks . Subject s will be followed for safety  for up to 105 day s
(15 weeks) after the last dosing if applicable .Subjects who will receive commerciall y approved 

Novartis Confidential Page 39
Amended Protocol Version 03 (clean ) Protocol No. CSEG101AUS05
crizanlizumab approximately 4 weeks after their last dose of study  treatment, do not need to 
complete the 105-day follow - up. The safet y follow -up of these subjects will be at the End of 
Treatment (EOT) visit . All other subjects are required to complete the 105 -day follow -upvisit.
Pre-screening
Before participating in the study , information to determine key eligibility  criteria may be 
collected as a part of a pre-screening form. In particular, the date, number and duration of the 
priapic events in a 14-week period required prior to consenting may be captured on this form.
The use of this form is optional .
S
creening phase
Eight y-four days (12 weeks) before start of treatment, written informed consent, according to 
local guidelines, will be signed by the subjects and prior to any study related screening 
procedures are performed. 
During this period, subject s will have 3visits and be monitored for priapic events to determine 
their eligibility  to the trial using areporting system. All screening evaluations must be 
performed during the screening period (see Section 8 for schedule) .
Treatment phase
Once eligibility  criteria have 
been confirmed by Novartis via the eligibility  checklist, the subject 
will receive investigational treatment. 
Subjects will receive investigational treatment by IV infusion over 30 min on Week 1 Day 1, 
Week 3 Day  1, and then on Day  1 of every  4-week cy cle. 
Safety  will be monitored as outlined in Section 
8. Subjects will receive investigational treatment 
for a maximum of 1year(52weeks) or until unacceptable toxicity , death, lost to follow -
up or 
discontinued from the study  treatment for any  other reasons prior to 52 weeks.
Following the treatment discontinuation, subjects will perform an e
nd of treatment (EOT) visit.
Follow -up phase
After the end of treatment visit, all subjects will be followed up for safety  up to 105days 
(15weeks) after the last infusion of study  treatment ifapplicable (see Section 9.2 ).

Novartis Confidential Page 40
Amended Protocol Version 03 (clean ) Protocol No. CSEG101AUS05
Figure 3-1 Study  Design
4 Rationale
4.1 Rationale for study  design
The efficacy  of crizanlizumab in SCD for the treatment of VOCs was established in the 
SUSTAI N study  but was not fully  investigated in priapism due to the limited number of cases 
observed during the study . The primary  aim of this study is to demonstrate the clinical benefit 
of crizanlizumab in SCD -related priapism . A d uration of 26weeks was setto evaluate the
primary efficacy  of crizanlizumab on SCD
-related priapism .This was based on studies
conducted by Burnett and Olujohungbe ,where recurrent ischemic priapi cpatients were 
evaluated over 16 and 26weeks , respectivel y (Burnett et al2014, Olujohungbe et al2011). In 
addition, steady  state concentration sfor crizanlizumab were considere d achieved by 15weeks 
in the SEG101A2202 study.
The total duration of 52 weeks of treatment will enable evaluation of additional secondary  
 
 endpoints for the study .
4.2 Rationale for dose/regimen and duration of treatment
In this study , subject s will receive crizanlizumab 5.0mg/kg every  4weeks by IV infusion. A 
loading dose of 5.0mg/kg will be administered 2weeks after the first dose to rapidly  achieve 
the stead y-state serum concentration. This will be followed by dosing of 5.0 mg/kg every 
4weeks to ensure that stead y-state serum conce ntration of crizanlizumab are maintained to 
provide a consistent blockade of P -selectin throughout the study .
In the SUSTAIN trial(SEG101A2201) , both 5.0mg/kg and 2.5 mg/kg of crizanlizumab on this 
same dosing schedule was tested and showed a statistical ly significant reduction in median 
annual rate of SCPC in the 5.0 mg/kg dose group versus placebo, while the 2.5mg/kg group 
did 
not have a statistically  significant reduction. The overall safet y was well-balanced across 
treatment and placebo groups (5.0 m g/kg: 86% AE and 26% SAE; 2.5 mg/kg: 88% AE and 
33% SAE; placebo: 89% AE and 27% SAE) (Ataga et al 2017). In addition, further PK 
modeling of 5.0 mg/kg and 2.5 mg/kg every 4weeks demonstrates that the 5.0mg/kg dose will 
provide trough PK levels of crizanlizumab above that necessary to achieve consistent blockade 
of P-selectin during the 12- month Phase II stud y.

Novartis Confidential Page 41
Amended Protocol Version 03 (clean ) Protocol No. CSEG101AUS05
Crizanlizumab 5mg/kg dose is further supported by the data from healthy  subjects in the 
Phase I Study  CESG101A2102, and by data from SCD patients in the Phase II Study 
CSEG101A2202 and the 1stcohort of CSEG101B2201.
4.3 Rationale for choice of control drugs
This is a single arm study. Therefore, no control group will be assigned.
4.4 Purpose and timing of interim analy ses
A formal interim analysis for this study  is not planned and shall not be performed. For 
publication purposes, only  descriptive data will be reported, as needed. Any  decision on study 
continuation will not be based on these reports, as such no alpha adjustment will be needed.
4.5 Risks and benefits
Please refer also to the latest version of the Investigator Brochure for the most recent 
information on the efficacy  and safet y of crizanlizumab. 
Results from the randomized, placebo -controlled SUSTAI N study  in SCD patients (aged 16 
years and older, any  genoty pe) established the efficacy  of crizanlizumab 5 mg/kg compared to 
placebo b y showing a statistically significant and clinically meaningful reduction of the annual 
rate of VOC leading to healthcare visit. In addition, a more than a two-fold increase in the 
number of patients who remained completel y free of VOC 
leading to healthcare visit during the 
study , and a three -fold increase in the median time to first VOC leading to healthcare was 
observed. 
Pooled safet y data from the SUSTAIN and CSEG101A2202 studies in patients treated with 
crizanlizumab 5 mg/kg (n=111 patients, Mar Oct 2019 cutoff) showed that crizanlizumab is 
generall y associated with a favorable safet y profile. Adverse drug reactions (ADRs) were 
nausea (16.2%), back pain (15.3%), arthralgia (14.4%), pyrexia (14.4%), abdominal pain 
(9.0%), diarrhea (8.1%), pruritus (7.2%), vomiting (5.4%), myalgia (4.5%), musculoskeletal 
chest pain (4.5%), orophary ngeal pain (3.6%), infusion site reaction (2.7%), and infusion-
related reaction (1.8%).  
In addition, in the randomized SUSTAI N study  the overall frequency  of AEs, SAEs and AEs 
leading to treatment discontinuation was similar among patients treated with crizanlizumab 5 
mg/k g and placebo. Use of crizanlizumab in combination with HU/HC did not result in any 
meaningful differences in the safet y profile. 
Based on class effects, pre-/clinical findings, the mechanism of action of crizanlizumab, 
identified and potential risks incl ude the following: 
Infusion -related reactions (IRRs) 
Administration of monoclonal antibodies (mAbs) can be associated with IRRs. A focused 
search for potentially  “severe” IRRs (i.e. indicative of hypersensitivity /anaphy laxis or cytokine -
release syndrome) identified 3 (2.7 %) patients treated with crizanlizumab 5 mg/kg in the pooled 
data set. The event reported for all 3 patients was “infusion-related reaction”, none of which 
was severe (all Grade 1 or 2, all non-serious), none required hospitalization or treatment 
discontinuation, and all events resolved without sequelae or complications on the same day . 

Novartis Confidential Page 42
Amended Protocol Version 03 (clean ) Protocol No. CSEG101AUS05
However, severe IRRs including cases requiring hospitalization have been described in ongoing 
clinical trials and the post-marketing setting. Refer to Investigator’s Brochure for additional 
details regarding these IRRs.
Additionally , a broad search for IRRs using an extensive list of potential signs and symptoms 
related to infusion reactions, and occurring within 24 hours of the infusion, identified 37 pa tients 
(33.3 %)in the safety  pool with at least one event. Most of these events were reported in 1 or 2 
patients only, except for nausea (9.0%), headache (9 %), arthralgia (6.3% ), back pain (4.5%), 
and fatigue , hypertension, dizziness, and myalgia (2.7%). None of the events were Grade 3 or 
4 in severit y. In the SUSTAIN stud y, IRRs using this broader search were more frequent in the 
5 mg/kg arm (34.8%) compared to the placebo arm (21.0%). However, except for nausea, none 
of the events were reported with an a bsolute difference of more than 5% in the crizanlizumab 5 
mg/kg vs. the placebo armand none were severe. Based on post marketing reports, IRRs may 
present as pain, refer to Investigator’s Brochure for additional details . 
In summary , current data suggest that administration of crizanlizumab can be commonl y 
associated with infusion related reactions, some of which can be severe and/or require 
hospitalization. Patients should be monitored for potential signs and symptoms of IRRs, and 
subject s instructed to contact the investigator/site when experiencing such events. In case of 
severe IRRs (eg. hypersensitivity /anaph ylactic reaction), study  treatment should be 
discontinued. 
Immunogenicity 
Administration of mAb can be associated with immunogenicit y, including development of anti-
drug antibodies (ADA) or hypersensitivity  following treatment with crizanlizumab (see above). 
In clinical studies, treatment -emergent ADAs were transiently  detected in 1 patient among the 
111 patients who received crizanlizumab 5 mg/k g (0.9%). There was no evidence of an altered 
PK/PD or safet y profile with ADA development. 
Infections 
Based on the mechanism of action and physiological role of P-selectin, crizanlizumab could 
potentially  be associated with an increased infection risk. 
Infection-related AEs (based on all preferred terms included in the system organ class 
“Infections”) were reported in 55 (49.5 %)patients in the safety  pool. The most frequentl y 
reported infections were urinary  tract infection (13 patients, 11.7%), upper respiratory  tract 
infections (
11 patients, 9.9%), pneumonia (5 patients, 4.5%) and sinusitis (4 patients, 3.6%). 
Most infections were low in severity  (Grade 1 or 2). In the randomized SUSTAI N study , 
infection -related AEs were similar across the arms: 53.0% in the crizanlizumab 5 mg/kg and 
53.2% in the placebo arm. In addition, there was no difference between the arms in the incidence 
of neutropenia or white blood cell counts. 
In summary , no increased frequency  or severit y of infections has been observed in clinical 
studies with crizanlizumab so far, suggesting that crizanlizumab has no clinically relevant effect 
to induce or complicate infections in SCD patients. However, investigators are advised to 
monitor patients for signs/sy mptoms of infections .

Novartis Confidential Page 43
Amended Protocol Version 03 (clean ) Protocol No. CSEG101AUS05
Effect on hemostasis 
Considering the mode of action of crizanlizumab and physiological role of P-selectin, a 
potential effect on the hemostatic system was evaluated by searching for AEs related to 
hemorrhage, abnormal laboratory  parameters. In the safet y pool, a search for hemorrhagic 
events identified 16(14.4%) patients. Except for prolonged prothrombin time, decreased 
hemoglobin, and epistaxis reported in 3 (2.7%) patients each, these events were reported in 1 
or 2 patients only. None were Grade 4 or led to study  withdrawal, and none were considered 
treatment related as per investigator assessment. The only Grade 3 event was decreased 
hemoglobin (2 patients) , consistent with hemoly sis and the underl ying disease.  
In Study  A2201, hemorrhagic events were reported in 11 (16.7%) patients in the 5 mg/kg and 
8 (12.9%) patients in the placebo arm, mostl y related to laboratory  abnormalities. Of note, 1 
event (intracranial hemorrhage) reported in the 2.5 mg/kg arm was considered serious (Grade 
4, hospitalization) and led to study  drug discontinuation. Cerebrovascular accidents, including 
hemorrhagic stroke, are known complication and leading cause of death in patients with SCD. 
In summary , bleeding events were rare, with the majority  of the observed AEs being abnormal 
laboratory  parameters on single occasions. The available data do not suggest an adverse effect 
of crizanlizumab on hemostasis. Nevertheless, subject s should be monitored for 
signs/sy mptoms of bleeding; additionally , hematolog y and coagulation parameters will be 
regularl y assessed during the study.
A separate search for potential AEs related to thrombosis did further not identify any patients 
with AEs related to thrombosis in the 5 mg/kg pooled data, suggesting that crizanlizum ab does 
not have relevant a pro -aggregant or pro- thrombotic effect. 
Laboratory test interference with automated platelet counts 
Interference with automated platelet counts (platelet clumping) has been observed in patients 
treated with crizanlizumab in clinical studies, in particular when tubes containing EDTA were 
used. This may lead to unevaluable or falsel y decreased platelet counts. Current clinical and 
pre-clinical data suggest this is an ex vivo effect that is EDTA -and time-dependent, without 
indication of platelet clumping, true reduction in circulating platelets or pro -aggregant effect in 
vivo. 
QT prolongation and hepatic safety 
Based on the data generated to date, crizanlizumab does not have a clinically relevant effect on 
QT interval, and the re is no evidence for severe or drug- induced hepatotoxicity . 
Monoclonal antibodies and male fertility
Regarding male fertility , IgG monoclonal antibodies can distribute to seminal fluid, however to 
an extent approximately one log lower than what could maximally  be observed for a small 
molecule (Scialli et 
al 2015 ,Banholzer et al 2016). A clinical trial of denosumab, an IgG2 
monoclonal antibody  in healthy  male volunteers showed that denosumab was measurable at 
low concentrations in seminal fluid (approximately  2% of serum concentrations, (Sohn et al 
2015). Data indicate that male -mediated mAb drug transfer via the semen provides negligible 
exposure of the mother to the mAb and that the mAb is not bioavailable to the fetus. Based on 
the pharmacokinetic features of IgG monoclonal antibodies includ ing low distribution to the 
semen and very low absorption in the vagina, the expected mAb dose to the fetus via seminal 

Novartis Confidential Page 44
Amended Protocol Version 03 (clean ) Protocol No. CSEG101AUS05
drug delivery  to the vagina would be approximately  10,000 to 30,000 fold lower than by 
intravenous dosing. Thus the potential of fetal harm from semen delivery  of a monoclonal 
antibody  is currentl y considered to be biologicall y implausible ( Breslin et al 2014 ).
Appropriate eligibility  criteria and stopping rules are included in this protocol. Recom mended 
guidelines for proph ylactic or supportive management of study -drug induced adverse events are 
provided in Section 6.5. The risk to subject s in this trial may  be minimized by compliance with 
the eligibility  criteria and study  procedures and close clinical monitoring. If deemed clinicall y 
necessary , subject s optionally  could be kept in-the hospital for 24 hours following an 
investigational treatment dose.  
There may  be unforeseen risks with crizanl izumab, which could be serious.
In summary , the sponsor considers that the benefit -
risk ratio for conducting this study  is 
favorable.
COVID -19 pandemic
No substantial additional risk for patients due to the SARS -CoV -2 
virus and the COVID -19 
pandemic has been identified at this time and therefore the benefit risk remains unchanged. In 
case of active COVID- 19 infection, please refer to Section 6.5. The risk/benefit balance will be 
re-evaluated as and when required whilst the COVID -19 pandemic continues.
5 Population
A total ofapproximately 36 male patients with SCD -related priapism aged ≥ 12years will be 
recruited across the United States .To be considered for this study , subjects must have had≥
4 
priapic events during the 14week sprior to screening and having atleast 3priapic events during
the 12week screening period with at least 1event occurring within 4 weeks prior to the first 
treatment.
The investigator or designee must ensure that only subject s who meet all the following inclusion 
and none of the exclusion criteria are enrolled in the study .
5.1 Inclusion criteria
Subjects eligible for inclusion in this study  must meet allof the following criteria:
1. Signed informed consent and applicable adolescent assent and /orparental consent for 
adolescent subjects, must be obtained prio r to participation in the study
2.Male patients aged 12years and above
3.Confirmed diagnosis of SCD by  hemoglobin electrophoresis or high performance liquid 
chromatograph y. All SCD genoty pes are eligible (HbSS, HbSβ0, HbSC, HbSβ+, and 
others)
4.Patients who have experienced ≥ 4 priapic events (unwanted erection lasting at least 
60minutes) over 14week pre -screening
5.Patients who have experienced at least 3priapic events (unwanted erection lasting at least 
60minutes) during the 
12week screening period with at least 1event occurring within 
4weeks prior to the first treatment.

Novartis Confidential Page 45
Amended Protocol Version 03 (clean ) Protocol No. CSEG101AUS05
6.If receiving HU/HC or L-glutamine or erythropoietin stimulating agent or voxelotor , must 
have been receiving the drug for at least 14 weeks prior to screening and plan to continue 
taking the drug at the same dos e and schedule during the trial
7.If receiving proph ylactic treatment for p riapism , must have been receiving the drug for at 
least 14 weeks prior to screening and plan to continue taking the drug at the same dose and 
schedule during the trial
8.Adequate renal and hepatic function as defined prior to Week 1 Day  1:
Glomerular filtration rat e
≥45 mL /min/1.73 m2calculated by CKD -EPI
Alanine a minotransferase ( ALT) ≤ 3 × ULN
Direct (conjugated) bilirubin ≤ 2 × ULN
9.Patient must meet the following laboratory  values prior to Week 1 Day  1:
Absolute Neutrophil Count 
≥ 1.0 × 109/L 
Hemoglobin > 4.0g/dL
Platelets ≥
75 × 109/L
5.2 Exclusion criteria
Subjects meeting an y of the following criteria are not eligible for inclusion in this study .
1.
Patients who have penile prosthetic implants . Shunts or any other surgical procedure on 
the penis performed within 12 months prior to consenting are not allowed.
2.Patients who have taken drugs/medications that may  induce priapism (as per Appendix 5)
over the 14 weeks pre
-screening period
3. Patients who have received leuprolide a cetate (Lupron) or an y other gonadotropin -
releasing hormone receptor (GnRHR) agonist agents within 3 months before pre-
screening.
4.Patients who had an erection lasting more than 12 hours over the 14 week pre -screening 
period
5.Patients who had an 
erection lasting more than 12 hours during the 12weeks of the 
screening period
6.History  of severe hy persensitivity  reaction to other monoclonal antibodies, which in the 
opinion of the investigator may  pose an increased risk of serious inf usion reaction
7.Contraindication or hy persensitivity  to any  drug or metabolites from similar class as study  
drug or to an y excipient s of the study  drug formulation
8.Received crizanlizumab
9.Received a monoclonal antibody  or immunomodulatory  agent within 1 y ear of screening , 
or has documented immunogenicity  to a prior biologic
10.Received other selectin inhibitor or plans to receive it during the duration of the study
11.Patients should not be receiving another investigational trial within 30 days (or 5 half- lives 
of that agent, whichever is greater) prior to Screening or plans to participate in another 
investigational drug trial
12.History  of familial long QT sy ndrome or know family  history  of Torsades de Pointes
13.History  or current diagnosis of ECG abnormalities indicating signifi cant risk of safet y 
such as:

Novartis Confidential Page 46
Amended Protocol Version 03 (clean ) Protocol No. CSEG101AUS05
Concomitant clinically  significant cardiac arrh ythmias (e.g ventricular tachy cardia), 
and clinically  significant second or third degree AV block without a pacemaker
14. Subjects with evidence of current alcohol/drug abuse:
15.Any docu mented history  of a clinical stroke or intracranial hemorrhage, or an 
uninvestigated neurologic finding within the past 12 months before screening .Silent 
infarct onl y pre sent on imaging is not excluded
16.Clinically  significant bleeding disorder
17.Planning to undergo a major surgical procedure during the duration of the study
18.Patient with active HIV infection (detectable viral load)
19. Patients with active Hepatitis B infection (HBsAg positive) 
Note: Patients with antecedent but no active Hepatitis B ( i.e. anti -HBc positive, HBsAg 
and HBV -DNA negative) are eligible
20.Patients with positive test for hepatitis C ribonucleic acid (HCV RNA)
Note: Patients in whom HCV infection resolved spontaneously  (positive HCV antibodies 
without detectable HCV -RNA) or those that achi eved a sustained virological response 
after antiviral treatment and show absence of detectable HCV RNA ≥ 6 months (with the 
use of IFN -free regimes) or ≥ 12 months (with the use of IFN- based regimes) after 
cessation of antiviral treatment are eligible
21.Significant active infection or immune deficiency (including chronic use of 
immunosuppressive drugs)
22. Malignant disease. Exceptions to this exclusion include the following: malignancies that 
were treated curativel y and have not recurred within 3years prior to study treatment; 
completely  resected basal cell and squamous cell skin cancers and any  completely  
resected carcinoma in situ
23.Not able to understand orcomply  with study  instructions and requirements
24.Any condition which, in the opinion of the investigator, is likel y to interfere with the 
successful collection of the measurements required for the study
6 Treatment
6.1 Stud y treatment
Novartis will supply crizanlizumab (SEG101) as an open -label medication. The investigational 
drug will be acrizanlizumab solution provided every  4weeks with an additional loading dose 
2weeks after the first dosing (i.e.dosing on first day of Week1, W eek3, W eek7, and then 
every  4 weeks until Week 51).
6.1.1 Investigational and control drugs
Crizanlizumab will besupplied in single use vials containing 10mL at a concentration of 
10mg/mL for administration by IV infusion. Each study  site will be supplied with study  drug 
in packaging as described under investigational drugs section.
A unique medication number is printed on the study  medication label.

Novartis Confidential Page 47
Amended Protocol Version 03 (clean ) Protocol No. CSEG101AUS05
On infusion day, the pharmacist or designated personnel will prepare individual doses of 
crizanlizumab for subjects on a milligram per kilogram basis in a 100 mL infusion bag in 
accordance with the Pharmacy Manual. S tudy drug will be administered over 30 minutes by IV 
infusion. Please refer to Table 6-1 for dose and treatment schedule.
Table 6-1 Dose and treatment schedule
Study treatments Pharmaceutical form 
and route of 
administrationDose Frequency and/or 
Regimen
Crizanlizumab Intravenous infusion 5.0 mg/kg Week 1 Day 1, Week 3 
Day 1, W eek 7 Day 1 
and Day 1 of ever y 
4-week cy cleuntil 
Week51
6.1.2 Additional study treatments
No additional treatments bey ond investigational drug are included in this trial.
6.1.3 Treatment arm/group
This is single arm study, all the subject s enrolled in this study  will receive crizanlizumab 
(5.0mg/kg).
6.1.4 Treatment duration
The total duration of treatment in the study  for each subject is planned to be up to 52weeks.
Subjects may  be permanently  discontinued due to unacceptable toxicity , death, lost to - follow -
upor discontinued from the investigational treatment for any  other reasons at the discretion of 
the investigator or the subject ,prior to 52 weeks.
6.2 Other treatments
6.2.1 Concomitant therapy
6.2.1.1 Permitted concomitant therapy  for the management of SCD
In general, the use of any concomitant medication/therapies deemed necessary  for the care of 
the subject is permitted, except prohibited treatments ( Section 6.2.2) . The subject must be told 
to notify  the investigational site about any new medications he/she takes within 30days prior 
to initial dosing until the completion of thesafet y follow -
up or EOT visit as applicable ). All 
medications (including prescription drugs, herbal medications/supplements, over the counter 
(OTC) medication, dietary  and vitamin supplements) and significant non-drug therapies 
(including ph ysical therapy  and blood transfusions) taken or administered within the timeframe 
defined in the entry  criteria until completion of the safet y follow-up or EOT 
visit as applicable 
must be listed on the Prior and Concomitant medications, Surgical and Medical Procedures ,or 
Transfusion page of the Case Report/Record Form (CRF ). Each concomitant drug must be 
individually  assessed against all exclusion criteria/prohibited medication. If in doubt, the 
investigator should contact the Novartis medical monitor before allowing a new medication to 

Novartis Confidential Page 48
Amended Protocol Version 03 (clean ) Protocol No. CSEG101AUS05
be started. If the subject is alread y enroll ed, contact Novartis/sponsor to determine if the subject 
should continue participation in the study . Concomitant sickle cell therapy  with HU/HC , L-
glutamine or voxelotor ispermitted, provided the subject has been prescribed HU/HC , L-
glutamine or voxelotor consistently  over at least the 14 weeks prior to screening, as stated in 
the Inclusion criteria. The dosing should not be altered or terminated, other than for safet y 
reasons until the subject has completed 1-year of investigational treatment. In subjects not on 
HU/HC ,
L-glutamine or voxelotor , treatment should not be initiated during the first year of 
investigational treatment. If a physician deems it is medicall y necessary  to terminate or alter 
HU/HC treatment , L-glutamine or voxelotor during the first year of crizanlizumab treatment, 
changes should not lead by default to discontinuation of the trial; however, the medical monitor 
must be notified. Erythropoietin -stimulating agents are also permitted to manage chronic 
symptomatic anemia with the same requirement for 6 months prior therap y. Aspirin, 
nonsteroidal -anti-inflammatory  drug (NSAIDs ) and prophy lactic doses (as per local 
guidelines) of anticoagulants are permitted, while other anti-platelets agents or anticoagulants 
at doses targeting therapeu tic levels should be used with caution (refer to Section 6.2.1.3 ). All 
approved forms of analgesia for pain are permitted per standard of care. Other approved 
medications for supportive care (antiemetics, anxioly tics, hypnotics, antihistamines) are 
permitted, including marinol (dronabinol) .
6.2.1.2 Permitted concomitant therapy  for the management of SCD -related 
priapism
Concomitant prophy lactic treatment for SCD -related priapism is permitted provided the subject 
has been prescribed the same medication consistently  for at least 14 weeks prior to screenin g 
as per inclusion criteri on 7. Dosing should not be altered or terminated other than for safet y 
during the duration of the study . In subjects not on prophy lactic medications, treatment should 
not be initiated during the study . If a physician deems it necessary  to terminate or alter treatment 
during the study , the monitor must be notified immediately  to determine whether the subject
may continue the study .
6.2.1.3 Permitted concomitant therapy  requiring caution and/or action
Although transfusion of cellular blood products is permitted, it is unclear how such transfusions 
will impact crizanlizumab. It should also be considered that the admin
istration of products 
containing immunoglobulins (plasma, IVIG, anti-globulins) may also impact the efficacy  of 
crizanlizumab.
Although EndariTM, the FDA -approved version of L -glutamine, is permitted as outline dabove , 
other over-the counter forms of L-glutamine are discouraged, as are other natural and herbal 
remedies (e.g.EvenFlo and/or products containing dang gui, Ligustrum root, ginseng root, 
white peon y, corydalis, salvia, copodonosis, poria, jujube, angelica sinensis , lovage) due the 
unproven effic acy and variable quality  and composition of these products. If other forms of L -
glutamine not approved by the FDA are used, the treatment information will be collected in the 
eCRF.  Vitamin and mineral supplements 
(e.g.fish oil, folic acid, L-arginine, L-citrulline, 
magnesium, riboflavin, vitamin C, vitamin D, vitamin E, and zinc) are also permitted, though 
caution is advised when taking amounts exceeding 100% of the recommended daily allowance .
It is recommended to avoid any  live vaccines within 4 weeks prior to the first dose of 
investigational treatment and during study duration. However, the decision to administer or 

Novartis Confidential Page 49
Amended Protocol Version 03 (clean ) Protocol No. CSEG101AUS05
withhold a vaccine should be done on case-by-case basis considering the poten tial 
benefits/risks such as developing severe infection, adverse effects from the vaccination, or 
vaccination failure.
Anti- platelets agents or anticoagulants at therapeutic doses should be used with caution due to
a potential effect of P -selectin on hem ostasis.
Infusion related reactions have been observed with crizanlizumab administration. Prophy lactic 
pre-medication with analgesics (e.g. paracetamol/acetaminophen or NSAID) and anti-
histamines (e.g. diphenhydramine or alternative, or in combination with H2 blocker) should be 
considered as per institutional standard of care, and at the discretion of the investigator. Steroids 
should be used with caution, and when clinically  indicated (e.g. to manage 
hypersensi tivity /anaph ylactic reactions).
There is no ex isting clinical data on concomitant use of crizanlizumab and corticosteroids. For 
patients presenting for acute pain related to sickle cell disease, the 2020 guideline from 
American Society  of Hematology  suggests against corticosteroids for acute pain mana
gement 
(Brandow et al, 2020 ).
Further guideline on management of crizanlizumab infusion related reactions is provided in 
Table 6-2. If a subject experiences a Grade 3 or 4 infusion related reaction, the study  treatment 
will be discontinued.
In the event that a major surgery  becomes necessary , it is recommended to hold crizanlizumab 
for at least 4 weeks prior to t he procedure, and then restart once the patient has fully recovered, 
at the investigator discretion.
6.2.2 Prohibited medication
The use of other investigational drugs is prohibited during the stud y. In addition, the 
administration of monoclonal antibodies other than the investigational treatment is prohibited, 
due to the theoretical potential for cross -
reactivity and/or overlapping toxicities with other 
monoclonal antibodies. If investigational agents have been used in the past, they  must have 
been discontinued at least 30 days or 5 half -lives of that agent, ( whichever is greater )prior to 
the screening visit. Patients who have received a monoclonal antibody  or immunomodulatory  
agent within 1 y ear of screening, or h avedocumented immunogenicit y to a prior biologic are 
not allowed to part icipate. Patients that have received prior treatment with crizanlizumab are 
not allowed to enroll in this study . Use of approved crizanlizumab or other selectin targeting 
agents is prohibited during the entire stud y duration.  
6.2.3 Rescue medication
Any standard medications that are used for management of VOC and acute priapic events are 
allowed.

Novartis Confidential Page 50
Amended Protocol Version 03 (clean ) Protocol No. CSEG101AUS05
6.3 Subject nu mbering, treatment assignment, randomization
6.3.1 Subject numbering
Each subject is identified in the study b y a Subject Number (Subject No.) that is assigned when 
the subject is first enrolled for screening and is retained as the primary identifier for the subject
throughout his entire participation in the trial. The Subject No. consists of the Center Number 
(as assigned by N ovartis to the investigative site) with a sequential subject number suffixed to 
it, so that each subject is numbered uniquel y across the entire database. Upon signing the 
informed consent form, the subject is assigned to the next sequential Subject No. available to 
the investigator through the Clinical Data Management Sy stem interface.
6.3.2 Treatment assignment, randomization
This is a single ar m study . Therefore, no randomization will be performed in this study .
6.4 Treatment blinding
This is an open -label study. Investigators, subject s and sponsor will have full knowledge of the 
treatment allocation. In order to minimize the potential impact of thetreatment knowledge, until 
the primary  analysis 
is conducted, no aggregated statistical analyses (efficacy  or safety  across 
the study ) shall be performed by treatment (other than analyses as specified in the study 
protocol).
6.5 Dose modification
If a subject does not tolerate the protocol -specified dosing schedule, dose interruptions are either 
recommended or mandated in order to allow subject s to continue the study  treatment until the 
next scheduled dose. Dose reductions are not allowed.
If a subject experi
ences drug-induced toxicity ,the subject should be closely  monitored and a 
decision to continue or discontinue the subject from the study  should be done at the next 
scheduled dose.
These dose interruptions are summarized in Table 6-2. Deviations to mandatory  dose 
interruptions are not allowed. 
Permanent treatment discontinuation is mandatory  for specific 
events indicated as such in Table 6-2.
Dose interruptions must be recorded in the Dosage Administration Record CRF. Every  effort 
should be made to maintain the subject on the protocol -defined dosing schedule. In case of dose 
delay  for any  reason, the dose should be given as soon as possible. If tha t infusion visit occurs 
within ±
7 days of a protocol -scheduled visit, then the dose and all required assessments will be 
assigned to the nearest protocol -scheduled visit. However, if that infusion visit does not fall 
within ± 7 days of a protocol -schedule d visit, the dose and corresponding assessments will be 
documented as an unscheduled visit. At that point, every  effort should be made to bring the 
subject's infusions back onto the protocol -defined schedule (within the ± 7 day window).. If a 
subject misse s two consecutive do ses of crizanlizumab due to ADR ( i.e., an AE attributable to 
study  drug), the subject should be discontinued from crizanlizumab. A subject with Grade 3 or 
4 IRR will be permanently  discontinued from crizanlizumab .A subject with a Grade 4 ADR
will be permanentl y discontinued from the study.

Novartis Confidential Page 51
Amended Protocol Version 03 (clean ) Protocol No. CSEG101AUS05
It is recommended that trial subjects with confirmed active COVID -19 or presenting with 
symptoms indicative of COVID -19 such as fever, cough, difficulty  breathing, sore throat or 
feeling unwell should interrupt crizanlizumab until the trial subject has fully recovered; in case 
of suspected COVID-19, testing for COVID -19 is recommended as per local guidance/practice. 
For confirmed patients, re-testing is advised before re-initiating study  treatment to ensure 
adequate recovery . Patients with suspected infection tested negative may continue study
treatment. In case of trial subjects who have been exposed to someone infected by  COVI D-19 
and is in self-quarantine, it is recommended that administration of crizanlizumab be delay ed 
until the trial subject completes the quarantine and remains asymptomat ic and/or COVID -19 
has been ruled out.

Novartis Confidential Page 52
Amended Protocol Version 03 (clean) Protocol No. CSEG101AUS05
Table 6-2 Criteria for dose interruption and re-initiation of crizanlizumab treatment for adverse drug reactions.
Dose modifications for crizanlizumab
Worst toxicity
CTCAEaGrade (CTCAE version 5) during a cycle of therapy
Investigations (Hematologic)
Neutropenia (ANC)
Grade 1 (ANC < LLN - 1.5 x 109/L) Recommendation: Maintain dose 
Grade 2 (ANC < 1.5 x 109/L-1.0 x 109/L ) Recommendation: Maintain dose 
Grade 3 (ANC < 1.5 x 109/L-0.5 x 109/L ) Mandatory: Interrupt dose until resolved to ≤ Grade 2 or next dose scheduled. If 
abnormality persists, permanently discontinue the subject from the study.
Grade 4 (ANC < 0.5 x 109/L) Mandatory : Permanently discontinue the subject from the study.
Febrile neutropenia (ANC < 1.0 x 109/L, fever ≥ 38.3°C) Mandatory : Interrupt dose until resolved or next dose schedule. If abnormality persists,
permanently discontinue the subject from the study.
Trombocytopenia
Grade 1 (PLT < LLN - 75 x 109/L) Recommendation: Maintain dose 
Grade 2 (PLT < 75 - 50 x 109/L) Recommendation: Maintain dose
Grade 3 (PLT < 50 - 25 x 109/L) Recommendation: Interrupt dose until resolved to ≤ Grade 2 or next dose scheduled. If 
abnormality persists, permanently discontinue the subject from the study. 
Grade 4 (PLT < 25 x 109/L) Mandatory : Permanently discontinue the subject from the study.
Investigations (Hepatic)
Isolated Direct Bilirubin
Grade 1
(>ULN - 1.5 x ULN if baseline was normal; > 1.0 - 1.5 x
baseline if baseline was abnormal)Recommendation: Continue study treatment 
PI
Novartis Confidential Page 53
Amended Protocol Version 03 (clean ) Protocol No. CSEG101AUS05
Grade 2 and 3
(>1.5 - 10.0 x ULN if baseline was normal; >1.5 - 10.0
x baseline if baseline was abnormal)Recommendation: Interrupt study treatment . Monitor Iiver function tests ( LFTs)bweekly, or 
more frequently if clinically indicated, until resolved to ≤ 1.5 x ULN or baseline. If resolved
to ≤Grade 1 or baseline , then continue study  treatment .
Grade 4 (>10.0 x ULN if baseline was normal; >10.0
x baseline if baseline was abnormal)Mandatory : Permanently discontinue from study treatment . 
Isolated A LT elevation 
Grade 1 (> ULN -3.0 x ULN) Recommendation: Maintain dose 
Grade 2 (> 3.0 -5.0 x ULN) Recommendation: Maintain dose. Repeat LFTsbas soon as possible, preferably within 
48-72 hours from awareness of the abnormal results ; if abnormal lab values are confirmed 
upon the repeat test, then monitor LFTsbweekly, or more frequently if clinically indicated, 
until re solved to ≤ 3.0 x ULN . If resolved, then continue with next dose scheduled.
Grade 3 (> 5.0 -20.0 x ULN) Recommendation: Interrupt dose. Repeat LFTsbas soon as possible, preferably within 
48-72 hours from awareness of the abnormal results; monitor LFTsbweekly, or more 
frequently if clinically indicated, until resolved to ≤ 3.0 x ULN . If resolved, t hencontinue with 
next dose scheduled
Grade 4 (> 20.0 x ULN) Mandatory: Permanently discontinue the subject from thestudy .
Combined celevations of A LT and bilirubin (direct [conjugated])
For subject s with normal baseline ALT and direct 
bilirubin value:
ALT > 3.0xULN combined with direct bilirubin 
>2.0 x ULN without evidence of cholestasisc
OR 
For subject s with elevated baseline A LT or direct 
bilirubin value:
 ALT > 2x baseline AND direct bilirubin >2.0 x 
baseline Mandatory: In the absence of cholestasisc(ALP < ULN), subject should be immediately 
discontinued from study  treatment. Repeat LFTsbas soon as possible , preferably within 
48hours from awareness of the abnormal results, then with weekly monitoring of LFTsb), or 
more frequently if clinically indicated, until ALT, or bilirubin have resolved to baseline or 
stabilization over 4 weeks.
Refer to Section 6.5.1.1 for additional follow -up evaluations as applicable.
Infections

Novartis Confidential Page 54
Amended Protocol Version 03 (clean ) Protocol No. CSEG101AUS05
Grade 1 Recommendation: M aintain dose level
Grade 2 Recommendation: Maintain dose level
Grade 3 Mandatory : Interrupt dose until resolved. If resolved, then continue with next dose 
scheduled.
Grade 4 Mandatory : Permanently discontinue the subject from the study.
Infusion -related reactions
Grade 1
Mild transient reaction; infusion interruption not 
indicated; intervention not indicatedRecommendation: 
Continue study treatment and increase monitoring of vital signs as medically 
indicated until the subject is deemed medically stable in the opinion of the 
investigator. 
Consider slowing infusion rate.
Grade 2
Therapy or infusion interruption indicated but responds 
promptly to s ymptomatic treatment (e.g., antihistamines, 
NSAIDS, narcotics, IV fluids); prophylactic medications 
indicated for <=24 hrsRecommendation:
Temporarily i nterrupt infusion and increase moni toring of vital signs as medically 
indicated until the subject is deemed medically stable in the opinion of the 
investigator. 
Administer appropriate medical therapy (e.g. analgesics such as paracetamol 
/acetaminophen or NSAIDs and anti -histamines), as per local institutional 
guidel ines and clinical presentation.
oSteroids should be used with caution unless clinically indicated (e.g. 
managem ent of hypersensitivity/anaphylaxis).
If symptoms resolve, restart infusion per investigator discretion at a slower rat e 
under continuous observation. Ensure a minimum of 1 hour observation period 
prior to restarting the infusion.
oBefore restarting, administer premedication (e.g. analgesics such as 
paracetamol/acetaminophen or NSAIDs and anti -histamines within 1 hour 
prior to dosing) as per local institutional guidelines for prophylaxis of 
infusion related reactions, including subsequent infusions.
In case of recurring infusion reactions despite premedication and prolonged 
infusion, consider discontinuation of study treatme nt. 

Novartis Confidential Page 55
Amended Protocol Version 03 (clean ) Protocol No. CSEG101AUS05
Grade 3 and 4
Prolonged (e.g., not rapidly responsive to sy mptomatic 
medication and/or brief interruption of infusion); 
recurrence of sy mptoms following initial improvement; 
hospitalization indicated for clinical sequelae
Life-threatening consequences; urgent intervention 
indicatedMandatory :
Permanent ly discontinue study treatment.
General Note: Decision for dosing is made on prior lab results, no tthose from labs performed on the day of infusion. If lab results are found to be abnormal, repeat 
(unscheduled) labs should be performed at least 1 week prior to scheduled dose in order to have results showing resolution of the abnormality before the scheduled 
dose is given. 
aCommon Terminology Criteria for Adverse Events (CTCAE Version 5.0)
bCore LFTs consist of ALT, AST, GGT, total bilirubin (fractionated [direct and indirect], and alkaline phosphatase 
c“Cholestasis” defined as ALP elevation (> 2.0 x ULN and R value < 2 ).Note: The R value is calculated by dividing the ALT by the ALP, us ing multiples of the ULN for 
both values. It denotes whether the relative pattern of ALT and/or ALP elevation is due to cholesta tic(R ≤ 2), hepatocellular (R ≥ 5), or mixed (R > 2 and < 5) liver injury

Novartis Confidential Page 56
Amended Protocol Version 03 (clean ) Protocol No. CSEG101AUS05
6.5.1 Follow -up for toxicities
Subjects whose study  drug treatment is interrupted or permanentl y discontinued due to an AE
must be followed up at least once a week (or more frequentl y if required by institutional 
practices, or if clinicall y indicated) for 4 weeks, and subsequentl y at approximately  4-week 
intervals, until resol ution or stabilization of the event, whichever comes first. Appropriate 
clinical experts (e.g.ophthalmologist, endocrinologist, dermatologist, ps ychiatrists etc.)should 
be consulted as deemed necessary . All subjects must be followed up for AEs and SAEs for 
105days as applicable following the last dose of study  of treatment .
6.5.1.1 Follow up on potential drug -induced liver injury  (DILI) cases
Subjects with an elevation of transaminases in combination with an increase of total bilirubin 
(TBIL) and a normal ALP may be indicative of potential DILI, and should be considered as 
clinically important events .
NOTE: Subject s with SCD tend to have elevat ed transaminases, especially  AST and indirect 
bilirubin ,due to the hemoly tic nature of their condition. Hence, ONLY ALT and direct bilirubin 
will be required in this criteria. 
Subjects meeting an y of t he following criteria will require further follow -up as outlined below:
For subject swith normal ALT and direct bilirubin value at baseline:
ALT
> 3.0 × ULN combined with direct bilirubin > 2.0 × ULN without evidence of 
cholestasis
For subject swith elevated ALT or 
direct bilirubin value at baseline:
ALT > 2 × baseline AND direct bilirubin > 2 × baseline 
For subjects with normal ALT at baseline: ALT > 5.0 × ULN for more than 2 weeks
For subjects with elevated ALT at baseline: ALT > 3.0 × baseline for more than 
2weeks
For these subjects , repeat LFTs as soon as possible, preferabl y within 48-72 hours. Subjects
should be closely  monitored and workup for competing etiologies initiated, including hemol ysis 
or cholestasis, defined as AL P elevation > 2.0 × ULN with R value < 2.
Note: (The R value is ca lculated by  dividing the ALT by  the ALP, using multiples of the ULN 
for both values. It denotes whether the relative pattern of ALT and/or ALP elevation is due to 
cholestatic (R ≤ 2), hepatocellular (R ≥ 5), or mixed (R > 2 and < 5) liver injury ).
In the absence of cholestasis or an alternative explanation , these subjects should be immediatel y 
discontinued from study treatment. The evaluation 
should include laboratory  tests, detailed 
history , physical assessment and the possibility  of new liver lesions, obstructions/compressions
as described below.
1.Laboratory tests should include ALT, AST, albumin, creatine kinase, total bilirubin, direct 
and indirect bilirubin, gamma -glutam yl transferase (GGT ) ,prothrombin time (PT)/INR ,
and ALP.
2.A detailed history , including relevant information, such as review of ethanol, concomitant 
medications, herbal remedies, supplement consumption, history  of any  pre-
existing liver 
conditions or risk factors, should be collected.

Novartis Confidential Page 57
Amended Protocol Version 03 (clean ) Protocol No. CSEG101AUS05
3.Further central testing for acute hepatitis A, B, C or E infection and liver imaging ( e.g.
biliary  tract) may  be warranted.
4. Additional central testing for other hepatotropic viral infection (CMV, EBV or HSV), 
autoimmune hepatitis or liver biopsy  may  be considered as clinically  indicated or after 
consultation with specialist/hepatologist.
All cases confirmed on repeat testing and meet s the laboratory  criteria defined above, with no 
other alternative cause for LFT abnormalities identified ,should be considered as “medicall y 
significant”, thus, meet the definition of SAE and should be reported as a SAE using the term 
“potential drug-induced liver injury ”. All events should be followed up with the outcome clearl y 
documented.
6.6 Additional treatment guidance
6.6.1 Treatment compliance
Compliance will be assessed by administration of the investigational treatment under the 
supervision of the investigator or his/her designee. This information must be captured in the 
source document and in the Drug Accountability  Form .
6.6.2 Recommended treatment of adverse events
Treatment for AEs will be determined by  the study  investigator. Medication used to treat AEs 
must be recorded on the appropriate CRF Preparation and dispensation.
6.7 Handling of study  treatment and additional treatment
6.7.1 Handling of study  treatment
Investigational treatment must be received by the pharmacist or delegate at the study  site, 
handled and stored safely  and properly  and kept in a secured location. Upon receipt, all 
investigational treatment must be stored according to the instructions specified on the labels
and in the Investigator’s Brochure . Clinical supplies are to be dispensed only in accordance 
with the protocol and Pharmacy  Manual . Technical complaints are to be reported to the 
respective Novartis CPO Quality  Assurance.
The pharmacist or delegate will inventory  and acknowledge receipt of all shipments of 
investigational treatment. The pharmacist will also keep accurate records of the quantities of 
study  drug dispensed and used by each subject. Monitoring of drug accountability  will be 
performed b y field monitors during onsite or remote monitoring visits, and at the completion of 
the trial .
Medication labels will be in the local language and comply with the legal requirements of each 
country . They  will include storage conditions for the investigational treatment but no 
information about the subject except for the medication number .
Crizanlizumab solution will be prepared by a pharmacist or study  personnel appropriatel y 
trained in the preparation of solutions for parenteral administration in accordance with the 
Pharmacy  Manual.

Novartis Confidential Page 58
Amended Protocol Version 03 (clean ) Protocol No. CSEG101AUS05
At the conclusion of the study , and as appropriate during the course of the study , the investigator 
or delegate will destroy all unused crizanlizumab, packaging, drug labels as appropriate in 
compliance with site processes, monitoring processes, and as per local regulation/guidelines.   
Otherwise, the investigator or delegate will return all unused study  treatment, packaging, drug 
labels, and a copy of the completed drug accountability  log to the Novartis monitor or to the 
Novartis address provided in the investigator folder at each site.
6.7.2 Instruction for prescribing and taking study treatment
All the instructions will be provided in the pharmacy  manual.
7 Informed consent procedures
Eligible subjects may  only  be included in the study  after providing (witnessed, where required 
by law or regulation), I RB-approved informed consent.
If applicable, in cases where the subject's representative(s) gives consent (if allowed according 
to local requirements), the subject must be informed about the study to the extent possible given 
his/her understanding. If the subject is capable of doing so, he/she must indicate agreement by 
personall y signing and dating the written informed consent document.
Informed consent must be obtained before conducting any study-specific procedures (e.g.all of 
the procedures described in the protocol). The process of obtaining informed consent must be 
documented in the subject source documents.
Novartis will provide to investigators in a separate document a proposed informed consent form 
that complies with the ICH GCP guidelines and regulatory  requirements and is considered 
appropriate for this study . Any changes to the proposed consent form suggested by the 
investigator must be agreed by  Novartis before submission to the I RB.
Information about common side effects alread y known about the investigational drug can be 
found in the Investigator’s Brochure .This information will be included in the subject informed 
consent and should be discussed with the subject during the study  as needed. Any new 
information regarding the safet y profile of the 
investigational drug that is identified between 
Investigator’s Brochure updates will be communicated as appropriate, for example, via an 
investigator notification or an aggregate safet y finding . New information might require an 
update to the informed consent and then must be discussed with the subject.
Male subjects must be informed that if a female partner becomes pregnant while he is enrolled 
in the study , contact with the female partner will be attempted to request her consent to collect 
pregnancy  outcome information.
The study includes an optional biomarker component which requires a separate signature if the 
subject agrees to participate. It is required as part of this protocol that the investigator presents 
this option to the subjects, as permitted by local governing regulations. The process for 
obtaining consent should be exactly  the same as described above for the main informed consent.
Declining to participate in these optional biomarker assessments will in no way affect the 
subject’s ability to participate in the main research study .

Novartis Confidential Page 59
Amended Protocol Version 03 (clean ) Protocol No. CSEG101AUS05
A copy of the approved version of all consent forms must be provided to Novartis/sponsor after 
IRB/IEC approval.
Subjects might be asked to complete an optio nal questionnaire to provide feedback on their 
clinical trial experience.
8 Visit schedule and assessments
Table 8-1lists all of the assessments and indicates with an “X”, the visits when they are 
performed. All data obtained from these assessments must be sup
ported in the subject ’s source 
documentation.
Subject s should be seen for all visits/assessments as outlined inthe assessment schedule 
(Table 8-1) or as close to the designated day/time as possible. Missed or rescheduled visits 
should not lead to automatic discontinuation. Subject s who prematurel y discontinue the study  
for any reason should be scheduled for a visit as soon as possible, at which time all of the 
assessments listed for the final visit will be performed. At this final visit, all dispensed 
investigational product should be reconciled, 
and the AEand concomitant medications recorded 
on the CRF.
If the subject cannot or is unwilling to attend any  visit(s), the site staff should maintain regular 
telephone contact with the subject, or with a person pre-designated by the subject. This 
telephone contact shou ld preferabl y be done according to the study visit schedule .
The table indicates which assessments produce data to be entered into the clinical database (D) 
or remain in source documents only (S) (“Category ” column).
Allowed visit windows are specified as follows:
Screening assessments 
must occur within 84 days (12weeks) ± 7 daysprior to the 
enrol lment as per Table 8-1.
For all screening 
visits a general ± 7day visit window is allowed
A ± 7 dayvisit window is allowed at Week 1 Day 1 (calculated from day  of consent)
A ±
3day visit window is permitted on assessments at Week 3 Day  1.
For all other 
dosing visits a general ± 7dayvisit window is permitted on assessments 
A ±7 day visit window for the end of treatment phase (last infusion + 2 weeks ) is allowed.
A +7 day visit window for the end of the safet y follow -up phase (last infusion + 105 
days) is allowed.
Every  effort should be made to follow the schedule outlined in Table 8-1.

Novartis Confidential Page 60
Amended Protocol Version 03 (clean ) Protocol No. CSEG101AUS 05
Table 8-1 Assessment Schedule
Reference 
to protocol 
sectionScreening phase Treatment phaseEnd of 
treatment 
(EOT)Follow up 
phase
(as applicable)f
Visit Number 1 2 3 1 01 102In every 
4thCycle108In every 
4thCycle114
Visit on Day1 of the 
week (unless otherwise 
specified)aScreening
(-Day 84 to Day -1)Wk1 Wk3Wk7, 11, 
4qWkWk27Wk31, 
35, 4qWkWk 51: last 
infusionWk 53Last infusion + 
105d
Day -84 
to 
Day -57Day -56 
to 
Day -29Day-28 
to 
Day -1
Screening
Obtain Study Informed 
Consent8.1 X
Priapism medical 
history questionnaire8.1 X
Obtain optional 
Informed Consent for 
future biomarker 
studies8.1 X
Disposition assessment
End of phase 
disposition8 X X X
Subject history
Demography 8.1.3 X
Inclusion/exclusion 
criteria5.1/5.2 X
Medical History 8.1.3 X
Sickle Cell –VOC
history8.1 X
Priapism Historye8.1 X
Alcohol history 8.1 X

Novartis Confidential Page 61
Amended Protocol Version 03 (clean ) Protocol No. CSEG101AUS 05
Reference 
to protocol 
sectionScreening phase Treatment phaseEnd of 
treatment 
(EOT)Follow up 
phase
(as applicable)f
Visit Number 1 2 3 1 01 102In every 
4thCycle108In every 
4thCycle114
Visit on Day1 of the 
week (unless otherwise 
specified)aScreening
(-Day 84 to Day -1)Wk1 Wk3Wk7, 11, 
4qWkWk27Wk31, 
35, 4qWkWk 51: last 
infusionWk 53Last infusion + 
105d
Day -84 
to 
Day -57Day -56 
to 
Day -29Day-28 
to 
Day -1
Smoking history 8.1 X
Drug history 8.1.3 X
Physical rxamination
Physical examination 8.3.1 X X
Abbreviated physical 
exam8.3.1 X X X X X X
Vital signs 8.3.1 X X X X X X X X
Height 8.3.1 X
Weight 8.3.1 X X X X X X X
Laboratory assessments
Hematology 8.3.2 X X X X X X X X X
Platelets (Local)d8.3.2 X X X X X X X X X
Chemistry 8.3.2 X X X X X X X X X
Coagulation 8.3.4 X X X X X X X X X
Urinalysis 8.3.3 X X X X X X X X X
Hepatitis testing 8.3.6 X
HIV test 8.3.8 X
Optional blood sample 
for future biomarker8.5 X X
Efficacy assessments
Priapic Events8.2.2.1 and 
8.2.2.2X X X Continuous
.

Novartis Confidential Page 62
Amended Protocol Version 03 (clean ) Protocol No. CSEG101AUS 05
Reference 
to protocol 
sectionScreening phase Treatment phaseEnd of 
treatment 
(EOT)Follow up 
phase
(as applicable)f
Visit Number 1 2 3 1 01 102In every 
4thCycle108In every 
4thCycle114
Visit on Day1 of the 
week (unless otherwise 
specified)aScreening
(-Day 84 to Day -1)Wk1 Wk3Wk7, 11, 
4qWkWk27Wk31, 
35, 4qWkWk 51: last 
infusionWk 53Last infusion + 
105d
Day -84 
to 
Day -57Day -56 
to 
Day -29Day-28 
to 
Day -1
Sickle Cell –VOC
Event8.2.2 Continuous
Chest x -rayb8.2.2 X As clinically indicated
Hospitalization 8.2.2 X X X Continuous
Prior/concomitant 
medications –
Analgesic8.2.2 X X X Continuous
Prior/concomitant 
medications -
Hydroxyurea8.2.2 Continuous
Transfusion 8.2.2 Continuous
Employment status and 
sick time8.2.2 X X X X
Safety assessments
ECG 8.3.5.1 - X X
Cardiac imaging 8.3.5.2 X X
Urine protein/creatinine 
ratio8.3.7 - X X

Novartis Confidential Page 63
Amended Protocol Version 03 (clean ) Protocol No. CSEG101AUS 05
Reference 
to protocol 
sectionScreening phase Treatment phaseEnd of 
treatment 
(EOT)Follow up 
phase
(as applicable)f
Visit Number 1 2 3 1 01 102In every 
4thCycle108In every 
4thCycle114
Visit on Day1 of the 
week (unless otherwise 
specified)aScreening
(-Day 84 to Day -1)Wk1 Wk3Wk7, 11, 
4qWkWk27Wk31, 
35, 4qWkWk 51: last 
infusionWk 53Last infusion + 
105d
Day -84 
to 
Day -57Day -56 
to 
Day -29Day-28 
to 
Day -1
Adverse Event/ Serious 
Adverse Event10 Continuous
IRRc4.5 Continuous
Prior/concomitant 
medications6.2.1 Continuous
Study Drug administration
Crizanlizumab IV 6.1.1 X X X X X X
aIn case the study drug is interrupted, the dose should be resumed as soon as possible. If the dose is delayed for more than 7 days, every effort should be made to bring the 
subject's infusions back onto the protocol -defined schedule ( Section 6.5 ).
bChest X -ray must be conducted during the screening period and must be repeated in case of suspected acute chest syndrome, during the during the treatment or follow -up.
c Certain adverse events reported in the AE/SAE eCRF as Infusion Related Reactions will require the IRR eCRF to be completed .
d Local sampling for platelet assessment will be performed throughout the trial for all subjects .
eThe date, number, and duration of the priapic events in the 14 -week period prior to consenting will be captured in a separate CRF .
fSubjects who will receive commercially approved crizanlizumab approximately 4 weeks after their last dose of study treatment, do not need to complete the 105 -day follow -up.

Novartis Confidential Page 64
Amended Protocol Version 03 (clean ) Protocol No. CSEG101AUS05
8.1 Screening
After signing the study  informed consent form (ICF), the screening assessments will bedone 
within the screening window prior to Week 1 Day 1 (see Table 8-1for list of assessments to be 
performed). During this screening period, the prospective subject s will need to come to clinic 
for 3 visits:at Day 
-84, at Day  -56, and at Day -28. At the first screening visit after signing the 
ICF (at Day 
-84), subject s will be briefed about the study  requirements, including the instruction 
on how to record the priapic event (s)information as described in Section 8.2.4. At the first 
screening visit, the prospective subject s will also be asked about their prior medical history 
related to priapi sm. This information will be collected via a priapism medical history
questionnaire. The investigator will obtain consent/assent of subject s and/or paren ts according 
to local procedures
.The additional details of the procedure of informed consent has been 
provided in Section 7.
For laboratory  evaluations used to determine eligibility , a repeated 
evaluation within the 
screening window is permitted for screening results out of the defined range before screen 
failing the subject . If the results from the central laborator y are partial or unavailable before the 
first infusion, local sampling is allowed. In addition, local re -sampling for platelet count test is 
allowed at any  time in case of clumping or other issues reported from the central laboratory . If 
therepeated laboratory  result meets the criteria, that result may be used to determine eligibility . 
If the repeated laboratory  result does not meet the criteria , the subject will be considered a 
screening failure. For details of ass essments, see Table 8-1. Assessments of subject reported 
outcomes should be collected prior to any clinical assessments, drug dosing or diagnostic testing .
Re-screening of subjects is allowed if the subj ect has not been treated and was screened failed . 
In case of re-screening, site should enter this patient as a new subject with a new ID. A new 
infor med consent form must also be signed. AEs and medical history  will be assessed relative 
to the new informed consent date.
The study includes an optional biomarker component which requires a separate signature if the 
subject agrees to participate. For details, see Section 7 .
8.1.1 Eligibility  screening
The investigator is responsible to ensure onl y subject s who meet all inclusion and do not meet 
any exclusion criteria are included in the study .
Subject eligibility  will be checked b y the sponsor once all screening procedures are completed. 
The eligibility check form will be sent from the site to the sponsor via email for evaluation. 
Upon confirmation of eligibility , the sponsor will return the signed eligibility  check form via 
email to the site. The investigator site will then be allowed to start treatment to the subject . 
Please refer and compl y with detailed guidelines in the eligibility  check user guidelines for the 
manual process .
8.1.2 Information to be collected on screening failures
Subject s who sign an informed consent 
but fail to be enrolled (subject who does not enter in the 
treatment phase) for any reason will be considered a screen failure. The reason for not being 
started on treatment will be entered on the screening phase disposition page . The demographic 

Novartis Confidential Page 65
Amended Protocol Version 03 (clean ) Protocol No. CSEG101AUS05
information, informed consent, Inclusion/ Exclusion pages and, if applicable, withdrawal of 
informed consent must also be completed for screen failure subject s. No other data will be 
entered into the clinical database for subject s who are screen failures, unless the subject
experienced an SAE during the screening Phase ( see Section 10 for SAE reporting details).
If a screen failure subject experiences an AE which does not meet the SAE criteria, details about 
the AE will berecorded only in the investigator’s source documents. In case of an SAE after 
signing of main study  informed consent, data must be recorded on both the AE and SAE forms.
If the subject fails to be enrolled, the sponsor must be notified within 2 days of the screen fail 
via email that the subject was not enrolled.
8.1.3 Subject demographics/other baseline characteristics
Subject demographic characteristics, which include age, gender, self-identified race and 
ethnicity , will be collected.
Following are the example s of the procedures that will be performed at the baseline: 
Background medical information including sickle cell and VOC history , priapism history , 
blood transfusion history, leg ulcer, ECG , cardiac imaging and urine protein/creatinine 
ratio
. 
Relevant and current medical history ; SCD genoty pes (HbSS, HbSβ0, HbSC, HbSβ+, and 
others).
Concomitant medication use; history  of analgesic and hy droxy urea use.
Complete phy sical examination .
Vital signs (blood pressure pulse measurement, respiratory  rate, oxy gen saturation ,and 
body  temperature), weight and height
.
Clinical laboratory  evaluations
Chest X -ray, if none has been performed within 3 months of Day  1
Drug, alcohol and smoking history  will also be collected. The details of other baseline 
characteristics and assessments that will beperformed at thescreening for eligibility  are detailed 
in Table 8-1.
8.2 Efficacy
8.2.1 Primary  efficacy  endpoint
Priapism is defined as an unwanted or painful penile erection lasting at least 60minutes. The 
end of the priapi cevent will be the duration when the unwanted erection has resolved. This 
event will be self-reported, and this data should be collected throug hout the study  period. In 
order to be treated as independent priapic events, two events will have to be separated by at 
least 2 hours, and the event would have to return to baseline during those 2 hours . Primary 
efficacy  endpoint will be assessed by evalua ting the percent reduction in priapic event sby26 
weeks .

Novartis Confidential Page 66
Amended Protocol Version 03 (clean ) Protocol No. CSEG101AUS05
8.2.2 Secondary  efficacy  endpoints
For purposes of this study , the following detailed definitions will be used to identify  each 
sub-type of VOC event:
8.2.2.1 Priapic event s
Priapism, as defined in the primary  efficacy  endpoint (Section 8.2.1), will also be assessed by 
evaluating the rate of priapi c events byweeks 26 and 52.
8.2.2.2 Acute priapic events
Acute priapic events are defined as unwanted orpainful erection sthat last at least 4hours and 
need a visit to the emergency  room. Management of ischemic priapism require saggressive and 
stepwise 
procedure sto achieve prompt resolution. Aspiration /irrigation , in combination with 
intracavernous injections of α-agonist is usuall y the first- line therapy . Penile blood aspiration 
involves using a transglanular intracorporal angiocatheter insertion or a proximal penile shaft 
needle access. The percent reduction in acute priapic events from baseline by  26 and 52 weeks 
of tre atment will be assessed.
8.2.2.3 Uncomplicated VOC
An u ncomplicated pain crisis is defined as an acute event of pain with no known cause for pain 
other than a vaso-occlusive event; and requiring treatment with a parenteral or oral opioids or 
other parenteral analgesic ; but is NOT classified as an acute chest syndrome, hepatic 
sequestration, splenic sequestration, or priapism. The end of an uncomplicated pain crisis will 
be considered the resolution of acute pain, such that residual pain (or absence of any pain) is
considered to be chronic, and the current pain medication regimen is considered to be for this 
chronic pain.
8.2.2.4 Complicated VOC
8.2.2.4.1 Acute Chest Syndrome
Acute Chest Syndrome is defined on the basis of the finding of a new pulmonary  infiltrate 
involving at least 1complete lung segment that was consistent with alveolar consolidation, but 
excluding atelectasis (as indicated by  chest X -ray). At least 1of the following additiona l signs 
or symptoms needs to be present as well: chest pain, a temperature of more than 38.5°C, 
tachypnea, wheezing ,or cough. Acute chest syndrome will be considered resolved when the 
subject is no longer hospitalized (unless for reason other than the acute chest sy ndrome event ) 
and none of the additional signs or s ymptoms above are present.
8.2.2.4.2 Hepatic sequestration
Hepatic sequestration is defined on the basis of findings of right upper quadrant pain, an 
enlarged liver, and an acute decrease in hemoglobin concentration (e.g. a decrease in 
hemoglobin of ~ 2 g/dL). Acute hepatic sequestration will be considered resolved when right 
upper quadrant pain has returned to baseline (pre -event) levels and hemoglobin has been stable 
for 24 hrs.

Novartis Confidential Page 67
Amended Protocol Version 03 (clean ) Protocol No. CSEG101AUS05
8.2.2.4.3 Splenic sequestration
Splenic sequestration if defined on the basis of findings of left upper quadrant pain, an enlarged 
spleen, and an acute decrease in hemoglobin concentration (e.g.a decrease in hemoglobin of 
~ 2 g/dL). Acute splenic sequestration will be considered resolved when left upper quadrant 
pain has returned to baseline (pre -event) levels and hemoglobin has been stable for 24 hrs.
General considerations for VOC assessments
Associated conditions in SCD ( e.g.intermittent or chronic pain due to ankle/leg ulcers, aseptic 
necrosis of bone or gout) should not be considered VOC event s. Similarly , complications such 
as pulmonary , cardiac, or renal failure are not themselves to be considered. If such events 
precipitates VOC, the VOC event will be documented separatel y.
For each visit to a medical facility  for a pain event thought to be a VOC, the following 
information must be documented in the eCRF ;diagnostic evaluation for the event , subject
treatment and management, course, duration of the crisis, and outcome. For subject s who are 
treated at medical facilities other than the study  site, summary  documents (e.g.ER or hospital 
discharge summaries) will need to be obtained. 
Subject s should be encouraged to contact the investigator (or surrogate from the site) when they 
believe they are experiencing a VOC , which they believe they can manage at home, both for 
treatment guidance and for accurate information which may be obtained for the VOC eCRF 
page. VOCs and other acute pain crisis manag edat home will be reconciled at regular study 
visits and captured in the corresponding VOC eCRF.
If a subject experiences a VOC surrounding a protocol -scheduled visit day, and the subject
presents for this visit, it will be counted as a VOC that led to a healthcare visit (provided the 
event meets the criteria for VOC discussed above). VOC is not a known contra -indication, but 
dosing during a crisis should be at investigator’s discretion.
General considerations for Chest X -Rays and transfusions
Chest X -Ray must be conducted during the screening period . Chest X -Ray must be repeated in 
case of suspected acute chest sy ndrome .
Transfusion data should be collected during thescreening period until the subject end of 
treatment ( EOT ). Episodic transfusion in response to worsened anemia or VOC is permitted.

Novartis Confidential Page 68
Amended Protocol Version 03 (clean ) Protocol No. CSEG101AUS05
Table 8-2 Vaso- Occlusive Crisis A ssessment Collection Plan 
Procedure / A ssessment 
collection planScreening/Baseline During Treatment/Fo llow-up
Chest X -Ray Mandated If clinically indicated
Vaso- Occlusi veCrisis 
information Mandated Mandated, when VOC crisis 
occurs
Concomitant medication -
AnalgesicIf clinically indicated Mandated, when VOC crisis 
occurs
Hospitalization details If clinically indicated Mandated, when VOC crisis 
occurs and hospitalization is 
done
Transfusion If clinically indicated If clinically indicated
Employment status and sick 
time If clinically indicated If clinically indicated
 
8.2.4 Collection of priapic event info rmation
Electronic reporting toolshave been shown in adolescents to have additional advantages over 
the paper format foraccuracy  as well as compliance in recording PROs (McGrath et al 2008 ). 
In SCA subject s, daily  reporting tool have 
been shown a more sensitive means of capturing 
reported pain frequency  than through retrospective interviews ( Porter et al 1998 ).

Novartis Confidential Page 69
Amended Protocol Version 03 (clean ) Protocol No. CSEG101AUS05
In this study, an electronic event repor ting system , paper s ystemor a call center will be used to 
collect information on the event by answering a few simple questions. The questionnaire will 
include information on what triggered the event, the event duration, and how the event was 
managed.. Subjects will receive daily reminders to record whether or not they have experienced 
a priapic event. Reconciliation of the events will be conducted by the site personnel at each 
scheduled stud y visit.
8.2.5 Appropriateness of efficacy  assessments
The primary  objective of this study  is to evaluate the clinical efficacy  of crizanlizumab in 
SCD -related priapism . A very significant proportion of male patients, ranging from 35% to 89%, 
with SCD have a history  of priapism (Ho ward andTelfer 2015). Scientific evidences suggested 
arole of P
-selectin for the priapic events. In this study , thehypothesis is that crizanlizumab 
treatment will reduce priapic events by  at least 25% in SCD patients with priapism. Therefore , 
the current efficacy  assessment plan of quantify ing the reduction in priapic event is considered 
appropriate.
Sickle cell–related pain crises were defined as acute events of pain, with no medically 
determined cause other than a vaso -occlusive event that resulted in a medical facilit y visit and 
treatment with oral or parenteral narcotic agents or with a parenteral nonsteroidal 
anti-inflammatory  drugs
. The acute chest syndrome, hepatic sequestration, splenic 
sequestration, and priapism were also considered to be crisis events. Therefore, the planned 
assessment could be considered appropriate for this indication.
8.3 Safet y assessments
Safety  will be monitored by assessing physical examinations, vital signs, ECG, laboratory 
assessments including hematology , chemistry , coagul ation, urinal ysis and as well as collecting 
of the AEs at every  visit. For details on AE collection and reporting, refer to Section 10.
8.3.1 Physical assessments
The phy sical assessments must be performed b ythe investigator as scheduled in Table 8-3.

Novartis Confidential Page 70
Amended Protocol Version 03 (clean ) Protocol No. CSEG101AUS05
Table 8-3 Physical assessments
Assessment Specification
Physical 
examinationA complete physical examination will include the examination of general 
appearance, skin, neck (including thyroid), eyes, ears, nose, throat, lungs, heart, 
abdom en, back, ly mph nodes, extremities, vascular, and neurological. If indicated 
based on medical histor y and/or sy mptoms, rectal, external genitalia, breast, and 
pelvic exams will be performed. A com plete physical examination will be 
performed at screening and within 7 days following last infusion.
An abbreviated (short) physical exam will include the examination of general 
appearance and vital signs (blood pressure [BP] and pulse), as well as additional 
components of the physical exam, as needed based on observed signs or reported 
symptoms. A short phy sical exam will be performed at all vis its for which there is a 
scheduled study drug infusion.
Significant findings that were present prior to the signing of informed consent must 
be included in the Medical History page on the subject ’s CRF. Significant new 
findings that begin or worsen after i nformed consent must be recorded on the 
Adverse Event page of the subject ’s CRF.
Vital signVital signs include blood pressure (supine position preferred when ECG is 
collected), pulse measurement, respirator y rate , oxygen saturation ,and body 
temperature will be measured as specified in Table 8-1.
Height and 
weightHeight in centimeters (cm) will be measured at screening.
Body weight (to the nearest 0.1 kilogram (kg) in indoor clothing, but without shoe s) 
will be measured at screening and all visits for which there is a scheduled study 
drug infusion (for dosing), as specified in Table 8-1.
8.3.2 Laboratory  evaluations
Clinical laboratory  anal yses (hematology , chemistry , urinal ysis, coagulation, hepatitis and HIV 
markers ) are to be performed centrall y according to the schedule of assessments and collection 
plan outlined in Table 8-1. Details on the collection, shipment of samples and reporting of 
results by the central laboratory  are provided to investigators in the Central Laboratory Manual/. 
Visit windows are allowed for all visits ( see Section 8).
Novartis must be provided with a copy  of the central laboratory ’s certification (if applicable), 
and a tabulation of the normal ranges and units of each parameter collected in the eCRF. Any 
changes regarding normal ranges and units for laboratory  valu
es assessed during the study  must 
be reported via an updated tabulation indicating the new effective date. Additionally , if at any 
time a subject has laboratory  parameters obtained from a different (outside) laboratory , Novartis 
must be provided with a copy of the certification and a tabulation of the normal ranges and units 
for this laboratory  as well. The investigator is responsible for reviewing all laboratory  reports 
for subject s in the study  and evaluating an y abnormalities for clinical significance.
For assessment of subject s’ eligibility to the study, only laboratory results from the central 
laboratory will be used (except in the event that the results from the central laboratory are not 
available at time of the first infusion, then eligibility may be based on the results from the local 
laboratory . In such a case,the results of the local laboratory  will need to be recorded in the 
eCRF unscheduled pages and copy  of the local lab normal ran ges must be provided).
Unscheduled local laboratory  assessments may be performed if medically  indicated to 
document a (potential) AE if central laboratory  results are unevaluable or inconclusive , or when 
the treating physician cannot wait for central labor atory  results for decision making. In this 

Novartis Confidential Page 71
Amended Protocol Version 03 (clean ) Protocol No. CSEG101AUS05
particular situation, if possible, the blood sample obtained at the same time point should be 
submitted to the central laboratory  for analy sis in parallel with local anal ysis.
The results of the local laboratory  will be recorded in the eCRF if any  the following criteria are 
met:
A treatment decision was made based on the local results, or
There are no concomitant central results available, or
Local lab results document an AE not reported b y the central lab, or
Loca l lab results document an AE where the severity  is worse than the one reported b y the 
central lab, or
Eligibility  had to be based on the local lab results due to pending/missing central lab 
results.
Laboratory assessments can be repeated during the screeni ng period as deemed appropriate by 
the investigator. 
At any time during the study up to safet y follow -up, abnormal laboratory parameters which are 
clinically  relevant and require an action to be taken with study  treatment (e.g.require dose 
interruption of study  treatment, lead to clinical symptoms or signs, or require therapeutic 
intervention), whether specificall y requested in the protocol or not, will be recorded on the AE 
eCRF page. 
The severit y of laboratory  data will be graded using the Common Terminology 
Criteria for Adverse events (CTCAE) version 5.0or later. Additional analy ses are left to the 
discretion of the investigator.  
Specificall y, for platelet count, local sampling will also be performed throughout the trial. To 
mitigate the potential fo r unevaluable or false low platelet counts ( LPTs), it is recommended to 
run blood samples as soon as possible. Based on in vitro data, platelet clumping was observed 
in some donor samples as early as 4hours following the addition of crizanlizumab. When 
needed, manual platelet estimation via blood smear to assess adequacy  of the platelet count may 
be considered. Additional details on the measures to be used will be provided in the laboratory 
manual.

Novartis Confidential Page 72
Amended Protocol Version 03 (clean ) Protocol No. CSEG101AUS05
Table 8-4 Laboratory  Assessments
Test Category Test Name
HematologyHematocrit, Hemoglobin, MCH, MCHC, MCV, reticulocytes (%), Platelets *, Red 
blood cells, W hite blood cells, RBC Morphology, Differential (Basophils, 
Eosinophils, Ly mphocytes, Monoc ytes, Neutrophils, Bands, Other (absolute value 
preferred, %s are acceptable)
Chemistry, Alkaline phosphatase, ALT, AST, Gamma -glutam yl-transferase (GGT), Lactate 
dehy drogenase (LDH), Bicarbonate, Calcium, Magnesium, Phosphorus, Chloride, 
Sodium, Potassium, Creatinine, Creatine kinase, Direct Bilirubin, Indirect Bilirubin, 
Total Bilirubin, Total Cholesterol, LDL, HDL, Total Protein, Triglycerides, Blood 
Urea Nitrogen (BUN) or Urea, Uric Acid, Am ylase, Lipase, Glucose ( non-fasting), 
estimated glomerular filtration rate (eGFR) .
UrinalysisMacroscopic Panel (Dipstick) will be done locally: Color, Bilirubin, Blood, 
Glucose, Ketones, Leukocytes esterase, Nitrite, pH, Protein, , Specific Gravity, 
Urobilinogen
Microscopic Pa nelwill be performed if dipstick is positive: Red Blood Cells, 
White Blood Cells, Casts, Cry stals, Bacteria, Epithelial cells
Urine creatinine/protein ratio, Microalbumin
CoagulationProthrombin time (PT) , International normalized ratio [INR]), Activate d partial 
thromboplastin time (APTT)
Hepatitis 
markersHBV-DNA, HbsAg, HbsAb, HbcAb, HCV RNA -PCR, HCV Ab (at screening only)
Additional 
testsHIV Ab (at screening only)
Glomerular filtration rate (using CKD-EPI formula):
Glomerular filtration rate = 141 × min(Scr/κ,1)α× max(Scr/κ,1)-1.209 × 0.993Age×1.159 [if 
black]
κ = 0.9 if male.
α = -0.411 if male
min = the minimum of Scr/κ or 1
max = the maximum of Scr/κ or 1
Scr: Serum creatinine (mg/dL)
8.3.3 Urinaly sis
Macroscopic urinalysis dipstick analysis (blood, protein and glucose) will be performed locally
according to the schedule of assessments and collection plan outlined in Table 8-1. Detailed 
urinaly sis panel is described on Table 8-4.Microscopic panel will be performed centrall yif 
dipstick is positive .

Novartis Confidential Page 73
Amended Protocol Version 03 (clean ) Protocol No. CSEG101AUS05
8.3.4 Coagulation
Prothrombin time (PT), international normalized ratio (INR), activated partial thromboplastin 
time (APTT) will be assessed centrally according to the schedule of assessments and collection 
plan outlined in Table 8-1.
8.3.5 Cardiac assessments
8.3.5.1 Electrocardiogram (ECG)
Standard 12-lead ECG will be performed (in the supine position) after the subject has been 
resting for 5
-10 min prior to ECG assessments. 
A standard 12 lead ECG will be performed
at screening 
at the end of treatment
Additional, unscheduled, safety  ECGs may be repeated at the discretion of the investigator at 
any time during the study as clinically  indicated. Unscheduled ECGs with clinically  significant 
findings should be collected in triplicate. Local cardiologist ECG assessment may also be 
performed at an y time during the study  at the discretion of the investigator.
Interpretation of the tracing must be made by a qualified physician and documented on the ECG 
CRF page. Each ECG tracing should be labeled with the study  number, subject initials (where 
regulations permit), subject number, date, and kept in the source documents at the study site.
Clinically  significant ECG abnormalities present at screening should be reported on the Medical 
History  CRF page. New or worsened clinicall y significant findings occurring after informed 
consent must be recorded on the Adverse Events CRF page.
8.3.5.2 Cardiac imaging 
Cardiac imaging will be performed by Echocardiogram (ECHO) in order to assess the left 
ventricular ejection fraction (LVEF) and mean pulmonary arterial pressure (mPAP), as 
estimated from the tricuspid regurgitation jet velocity  (TRV) if assessable, or otherwise by other 
formula (per institutional preference). This assessment will be performed locally , interpreted 
by site personnel as per Table 8-1, and documented on the CRF page. Each echocardiograph y 
must be kept in the source documents at the study  site. Clinically  significant echocardiograph y 
abnormalities present at screening when the subject signed informed consent should be reported 
on the Medical History CRF page. Clinicall y significant findings must be discussed with 
Novartis prior to enrolling the subject .
New or worsened clinically  significant findings occurring after informed consent must be 
recorded on the Adverse Events CRF page.
8.3.6 Hepatitis markers
Hepatitis testing will be performed centrally  as per Table 8-1.

Novartis Confidential Page 74
Amended Protocol Version 03 (clean ) Protocol No. CSEG101AUS05
8.3.7 Urine protein/creatinine ratio
At screening a urine sample (at least 15 ml) will be collected and sent to the central laborator y 
for urinary  protein/creatinine ratio to assess the eligibility  of the subject . The assessment will 
be repeated at the EOT . First morning void samples must not be used for this analy sis.
8.3.8 Additional test
HIV screening will be performed centrall y as per Table 8-1.
8.3.9 Appropriateness of safety  measurements
The safet y assessments selected are standard for this indication/subject 
population.
8.4 Additional assessments

Novartis Confidential Page 75
Amended Protocol Version 03 (clean ) Protocol No. CSEG101AUS05
8.4.2
VOCs as defined above, can be managed at home or by  a healthcare visit.
 
 
 
 
 
 
 
8.5 Optional u se of biological samples
If the subject agrees, additional blood sample will be collected at screening visit and EOT for 
future biomarker analysisoutside of this study . The sample may be stored up to 15 years for 
future biomarker analysisandadditional studies related to crizanlizumab or SCD . This may
includ e research to help develop ways to detect, monitor or treat SCD . A decision to perform 
such exploratory  biomarker research studies would be based on outcome data from this study 
or from new scientific findings related to the drug class or disease, as well as assay availabilit y.
The biological sample collection is optional and necessitates the consenting of the subject as 
described in S ection 7 .

Novartis Confidential Page 76
Amended Protocol Version 03 (clean ) Protocol No. CSEG101AUS05
9 Study  discontinuation and completion
9.1 Discontinuation
9.1.1 Discontinuation of study treatment
Discontinuation of study  treatment for a subject occurs when stu dy treatment is stopped earlier 
than the protocol planned duration and can be initiated b y either the subject or the investigator.
The investigator must discontinue study  treatment for a given subject if, he/she believes that 
continuation would negatively  impact the subject's well -being.
Study  treatment must be discontinued under the following circumstances 
Subject/guardian decision
Death
Use of prohibited treatment as per recommendations in the prohibited treatment section
(Section
6.2.2)
Any situation in which study  participation might result in a safet y risk to the subject
Discontinuation to study  treatment due to toxicity  that result in treatment discontinuation 
(see Section 6.5)
Any laboratory  abnormalities that in the judgment of the investigator, taking into 
consideration the subject’s overall status, prevents the subject from continuing 
participation in the study
If discontinuation of study  treatm ent occurs, the investigator should make a reasonable effort 
to understand the primary reason for the subject’s premature discontinuation of study treatment 
and record this information.
Subjects who discontinue study  treatment or who decide they do not wish to participate in the 
study  further should NOT be considered withdrawn from the study  UNLESS 
they withdraw 
their consent (see withdraw alof informed consent section,). Where possible, they should 
return for the assessments indicated in the assessment schedule. If they fail to return for these 
assessments for unknown reasons, every  effort (e.g.telephone, e -mail, and letter) should be 
made to contact the subject/pre -designated contact as specified in the lost to follow -up section. 
This contact should pr eferably  be done according to the study  visit schedule.
If the subject cannot or is unwilling to attend any visits, the site staff should maintain regular 
telephone contact with the subject, or with a person pre-designated by the subject. This 
telephone contact should preferabl y be done according to the study visit schedule.
After study  treatment discontinuation, at a minimum, in abbreviated visits, the following data 
should be collected at clinic visits or via telephone/email contact:
new/concomitant treatments
AE/SAE
Subject s who discontinue study  treatment should undergo an EOT visit within 14days of the 
last dose of the discontinued study  treatment, followed by a 105 day safety follow -upas 
applicable . At EOT visit, all the assessments as listed in Table 8-1will be performed. If the 

Novartis Confidential Page 77
Amended Protocol Version 03 (clean ) Protocol No. CSEG101AUS05
decision to discontinue the subject occurs at a regularly  scheduled visit, that visit may  serve as 
the EOT visit rather than having the subject return for an additional visit.
9.1.2 Withdrawal of informed consent
Subjects may voluntarily  withdraw consent to participate in the study  for any reason at any time. 
Withdrawal of consent occurs onl y when a subject:
Does not want to participate in the study  anymore
and
Does not want a ny further visits or assessments
and
Does not want an y further study related contacts
In this situation, the investigator should make a reasonable effort ( e.g.telephone, e-mail, letter) 
to understand the primary reason for the subject’s decision to withdr aw his/her consent and 
record this information.
Study  treatment must be discontinued, and no further assessments conducted, and the data that 
would have been collected at subsequent visits will be considered missing.
Further attempts to contact the subject are not allowed unless safety  findings require 
communication or follow -up.
All efforts should be made to complete the assessments prior to study  withdrawal. A final 
evaluation at the time of the subject’s study  withdrawal should be made ,as detailed in the 
assessment table.
Novartis will continue to retain and use all research results (data) that have alread y been 
collected for the study  evaluation.
All biological samples that have alread y been collected may  be retained and analy zed at a later 
date (or as required b y local regulations).
9.1.3 Lost to follow -up
For subjects whose status is unclear because they  fail to appear for study  visits without stating 
an intention to discontinue or withdraw, the investigator must show "due diligence" by 
documenting in the source documents steps taken to contact the subject, e.g.dates of telephone 
calls, registered letters, etc. A subject should not be considered as lost to follow -up until due 
diligence has been completed .Subject s lost to follow up should be recorded as such on the 
appropriate CRF.
9.1.4 Early  study termination by the sponsor
The study  can be terminated by  Novartis at any  time for any  reason. This may  include reasons 
related to the benefit/risk assessment of participating in the study , practical reasons (including 
slow enrollment), or for regulatory  or medical reasons. In taking the decision to terminate, 
Novartis will alway s consider the subject welfare and safet y. Should early  termination be 
necessary , subjects must be seen as soon as possible (provide instruction for contacting the 
subject, when the subject should stop taking drug, when the subject should come for a final 

Novartis Confidential Page 78
Amended Protocol Version 03 (clean ) Protocol No. CSEG101AUS05
visit) and treated as a prematurel y withdrawn subject. The investigator may be informed of 
additional procedures to be followed in order to ensure that adequate consideration is given to 
the protection of the subject’s interests. The investigator or sponsor depending on the local 
regulation will be responsible for informing IRBs of the early  termination of the trial.
9.2 Stud y completion and post -study  treatment
Study  completion is defined as when the last subject finishes their Study  Completion visit
(defined as last patient last visit), and any repeat assessments associated with this visit have 
been documented and followed -up appropriately  by the investigator , or in the event of an earl y 
study  termination decision, the date of that decision. Subjects who will receive commerciall y 
approved crizanlizumab approximately  4 weeks after their last dose of study  treatment, do not 
need to complete the 105-day follow -up. All other subjects are required to complete the 105-
day follow -
up.
10 Safety  monitoring and reporting
10.1 Definition of adverse events and reporting requirements
10.1.1 Adverse events
An AE is any untoward medical occurrence (e.g. any unfavorable and unintended sign 
[including abnormal laboratory  findings] , symptom or disease) in a subject or clinical 
investigation subject after providing written informed consent for participation in the study . 
Therefore, an AE may or may not be temporally  or causall y associated with the use of a 
medicinal (investigational) product.
The investigator has the responsibility  for managing the safet y of individual subject and 
identify ing AEs.
Novartis qualified medical personnel will be readily  available to advise on trial related medical 
questions or problems.
The occurrence of AEs must be sought b y non -directive questioning of the subject at each visit 
during the study . Adverse events also may be detected when they are volunteered by the subject 
during or between visits or through physical examination findings, laboratory  test findings, or 
other assessments.
Adverse events must be recorded under the signs, symptoms or diagnosis associated with them, 
accompanied by the following information (as far as possible) (if the event is serious refer to
Section 10.1.3):
1.The Common T erminology Criteria (CTC) AE grade (version 
5.0 or higher ).If CTCAE 
grading does not exist for an AE, the severity  of mild, moderate, severe, and 
life-threatening, death related to the AE corresponding respectivel y to Grades 1 - 5, will 
be used. Information about any deaths (related to an AE or not) will also be collected 
though a Death form.
2.Itsrelationship to the study  treatment .If the event is due to lack of efficacy or progr ession 
of underl ying illness ( i.e.progression of the stud y indication) the assessment of causalit y 
will usually  be ‘Not suspected’. The rationale for this guidance is that the sy mptoms of a 

Novartis Confidential Page 79
Amended Protocol Version 03 (clean ) Protocol No. CSEG101AUS05
lack of efficacy or progression of underly ing illness are not caused by  the trial drug, they  
happen in spite of its administration and/or both lack of efficacy  and progression of 
underly ing disease can only  be evaluated meaningfull y by an anal ysis of cohorts, not on a 
single subject .
3.Itsduration (start and end dates) or if the event is ongoing, an outcome of not 
recovered/not resolved must be reported.
4. W hether it constitutes a SAE (see Section 10.1.3 for definition of S AE) and which 
seriousness criteria have been met
5.Action taken regar ding with study  treatment.
All adverse events must be treated appropriately . Treatment may include one or more of the 
following:
Dose not changed
Drug interrupted/withdrawn
Itsoutcome (notrecovered/not resolved, recovered/resolved, recovering/resolving, 
recovered/resolved with sequalae , fatal, unknown).
If the event worsens ,the event should be reported a second time in the CRF noting the start date 
when the event worsens in toxicity . For Grade 3 and 4 AEs only, if improvement to a lower 
grade is determined a new entry  for this event should be reported in the CRF noting the start 
date when the event improved from having been Grade 3 or Grade 4.
Conditions that were alread y present at the time of informed consent should be recorded in 
medical history  of the subject.
Adverse events (including lab abnormalities that constitute AEs) should be described using a 
diagnosis whenever possible, rather than individual underly ing signs and s ymptoms.
Adverse event monitoring should be continued for at least 105days following the last dose of 
study  treatment as applicable
Once an AEis detected, it must be followed until its resolution or until it is judged to be 
permanent (i.e.continuing at the end of t he study ), and assessment must be made at each visit 
(or more frequentl y, if necessary ) of any changes in severity , the suspected relationship to the 
interventions required to treat it, and the outcome.
Information about adverse drug reactions for the investigational drug can be found in the 
Investigator’s Brochure .
Abnormal laboratory  values or test results constitute AEs only  if they  fulfill at least one of the 
following criteria:
they induce clinical signs or sy mptoms
they are considered clinically  signi ficant
they require therapy
Clinically  significant abnormal laboratory  values or test results must be identified through a 
review of values outside of normal ranges/clinically  notable ranges, significant changes from 
baseline or the previous visit, or values which are considered to be non -typical in subjects with 
the underl ying disease.

Novartis Confidential Page 80
Amended Protocol Version 03 (clean ) Protocol No. CSEG101AUS05
10.1.2 Protocol exempt A Es & SA Es
Protocol Exempt AEs & SAEs are implemented in the crizanlizumab program. VOCs must be 
reported on the VOC page in the eCRF. As VOCs are considered secondary  endpoints for the 
purpose of evaluation of efficacy , AEs and SAEs involving VOCs SHOULD NOT be reported 
as AEs or SAEs for the purpose of this study . These events will not be considered as SAEs in 
regard toreporting requirements. Procedures which are directl y related to the VOC, e.g.
ventilation of a patient with acute chest sy ndrome are considered part of the VOC and will not 
be reported as AE/SAEs but entered inthe CRF -page "concomitant non-drug 
therapies/procedures". Additional events or complications 
which are not VOCs itself will be 
reported as AE/SAEs. Details will be given in the CRF -completion guidance .In case that new 
information arises which changes thediagnosis of a VOC, i.e.gives another medicall y 
determined explanation than vaso -occlusion in the opinion of the investigator, the event has to 
be reported according to the rules of Section 10.1 and must be reported to Novartis within 
24hours of learning of the new information.
The events in Table 10 -1will not be reported as AEs/SAEs.
Table 10-1 List of Events Not Requiring A E/SA E Reporting
VOC Event s
Uncomplicated sickle cell -related pain crisis (SCPC) or vaso -occlusive crisis (VOC)*
Acute chest syndrome
Hepatic sequestration
Splenic sequestration
Acute p riapism requiring a visit to a medical facility
*VOC is defined as pain crises (defined as an acute onset of pain for which there is no other medically 
determined explanation other than vaso- occlusion and which requires therapy with oral or parenteral 
opioids or parenteral NSAIDs) as well as other complicated crises , such as acute chest syndrome , 
acute priapism, and hepatic or splenic sequestration.
10.1.3 Serious adverse events
An SAE is defined as any AE[appearance of (or worsening of any pre-existing)] undesirable 
sign(s), s ymptom(s) or medical conditions(s)) which meets an y one of the following criteria:
fatal
life-threatening
Life-threatening in the context of a SAE refers to a reaction in which the subject was at risk of 
death at the time of the reaction; it does not refer to a reaction that hypothetically  might have 
caused death if it were more severe (please refer to the I CH-E2D Guidelines).
results in persistent or significant disability /incapacity
constitutes a congenital anomaly /birth defect
requires inpatient hospitalization or prolongation of existing hospitalization, unless 
hospitalization is for: 
routine treatment or monitoring of the studied indication, not associated with any  
deterioration in condition . 

Novartis Confidential Page 81
Amended Protocol Version 03 (clean ) Protocol No. CSEG101AUS05
elective or pre -planned t reatment for a pre-existing condition that is unrelated to the 
indication under study  and has not worsened since signing the informed consent
social reasons and respite care in the absence of any  deterioration in the subject’s 
general condition
treatment o n an emergency  outpatient basis for an event not fulfilling any  of the 
definitions of a SAE given above and not resulting in hospital admission
is medically  significant, e.g.defined as an event that jeopardizes the subject or may  
require medical or surgic al intervention to prevent one of the outcomes listed above
Medical and scientific judgment should be exercised in deciding whether other situations should 
be considered serious reactions, such as important medical events that might not be immediately 
lifethreatening or result in death or hospitalization but might jeopardize the subject or might 
require intervention to prevent one of the other outcomes listed above. Such events should be 
considered as “medicall y significant”. Examples of such events are intensive treatment in an 
emergency  room or at home for allergic bronchospasm, blood dyscrasias or convulsions that do 
not result in hospitalization ,or development of dependency  or abuse.
All malignant neoplasms will be assessed as serious under “medically  significant” if other 
seriousness criteria are not met.
Any suspected transmission via a medicinal product of an infectious agent is also considered a 
serious adverse reaction.
All reports of intentional misuse and abuse of the product are also considered SAE irrespective 
if a clinical event has occurred. 
10.1.4 SAE reporting
To ensure subject safet y, every  SAE, regardless of causalit y, occurring after the subject has 
provided informed consent and until up to105days after the subject has stopped study  treatment 
must be reported to Novartis within 24 hours of learning of its occurrence. Detailed instructions 
regarding the submission process and requirements are to be found in the investigator folder 
provided to each site.
All follow -up information for the SAE incl uding information on complications, progression of 
the initial SAE and recurrent events must be reported as follow -up to the original event within 
24 hours of the investigator receiving the follow -up information. An SAE occurring at a 
different time interval or otherwise considered completely  unrelated to a previously  reported 
one must be reported separatel y as a new event.
Any SAEs experienced after the end of thesafet y evaluation follow -up period should only  be 
reported to Novartis if the investigator s uspects a causal relationship to the study treatment.
Each re-occurrence, complication, or progression of the original event should be reported as a 
follow -up to that event regardless of when it occurs. The follow -up information should describe 
whether theevent has resolved or continues, if and how it was treated, whether the blind was 
broken or not, and whether the subject continued or withdrew from study  participation.

Novartis Confidential Page 82
Amended Protocol Version 03 (clean ) Protocol No. CSEG101AUS05
Follow -up information is submitted in the same way as the original SAE Report and should 
describe whether the event has resolved or continues, if and how it was treated, and whether the 
patient continued or withdrew from study  participation.
If the SAE is not previously documented in the Investigator’s Brochure or Package Insert (new 
occurr ence) and is thought to be related to the study treatment, a Novartis Chief Medical Office 
and Patient Safet y (CMO & PS) Department associate may urgentl y require further information 
from the investigator for health authorit y reporting. Novartis may need t o issue an Investigator 
Notification (IN) to inform all investigators involved in any study  with the same study  treatment 
that this SAE has been reported.
Suspected Unexpected Serious Adverse Reactions (SUSARs) will be collected and reported to 
the compete nt authorities and relevant ethics committees in accordance with EU Guidance 
2011/C 172/01 or as per national regulatory requirements in participating countries.
10.1.5 Pregnancy  reporting
Pregnancy  outcomes should be collected for the female partners of any males who took study 
treatment in this study . Consent to report information regarding these pregnancy  outcomes 
should be obtained from the mother. To ensure subject safet y, each pregnancy  occurring after 
signing the informed consent must be reported to Novartis within 24 hours of learning of its 
occurrence. The pregnancy  should be followed up to determine outcome, including spontaneous 
or voluntary  termination, details of the birth, and the presence or absence of any  birth defects, 
congenital abnormalities, or maternal and/or newborn complications.
Pregnancy  should be recorded and reported by the investigator to the CMO&PS. Pregnancy 
follow -up should be recorded on the same form and should include an assessment of the 
possible relationship to the study  treatment any pregnancy  outcome. Any SAE experienced 
during pregnancy  must be reported.
10.1.6 Reporting of study treatment errors including misuse/abuse
Medication errors are unintentional errors in the prescribing, dispensing, administration or 
monitoring of a medicine while under the control of a healthcare professional, subject or 
consumer (EMA definition).
Misuse refers to situations where the medicina l product is intentionally  and inappropriatel y used 
not in accordance with the protocol.
Abuse corresponds to the persistent or sporadic, intentional excessive use of a medicinal product, 
which is accompanied b y harmful ph ysical or ps ychological effects.
Study treatment errors and uses outside of what is foreseen in the protocol will be recorded on 
the appropriate CRF irrespective of whether or not associated with an AE/SAE and reported to 
Safety  only if associated with an SAE. Misuse or abuse will be colle cted and reported in the 
safet y database irrespective of it being associated with an AE/SAE within 24 hours of 
investigator’s awareness.

Novartis Confidential Page 83
Amended Protocol Version 03 (clean ) Protocol No. CSEG101AUS05
Table 10-2 Guidance for capturing th e study  treatment errors including 
misuse/abuse
Treatment error typeDocument in Dosing 
CRF (Yes/No)Document in A E 
eCRFComplete SA E form
Unintentional study 
treatment errorYesOnly if associated 
with an AEOnly if associated with 
an SAE
Misuse/Abuse Yes YesYes, even if not 
associated with a SAE
For more information on AE and SAE definition and reporting requirements, please see the
respective sections.
10.2 Additional safety  monitoring 
10.2.1 Steering committee
The steering committee will be established and comprised of SCD and priapism medical experts 
as well as Novartis representatives from the Clinical Trial Team.
The steering committee will ensure transparent management of the study  according to the 
protocol through recommending and approving modifications as circumstances require. The SC 
will review protocol amendments as appropriate. Together with the clinical trial team, the SC 
will also develop recommendations for publications of study results including authorship rules. 
The details of the role of the steering committee will be defined in the steering committee 
charter.
11 Data Collection and Database Management
11.1 Data collection
Designated investigator staff will enter the data required by the protocol into the Electronic 
Case Report Forms (eCRF). The eCRFs have been built using fully  validated secure 
web -enabled software that conforms to 21 CFR Part 11 requirements, investigator site staff 
will not be given access to the EDC sy stem until they  have been trained. Automatic validation 
programs check for data discrepancies in the eCRFs, allow modification and/or verification of 
the entered data b y the investigator staff.
The investigator/de signee is responsible for assuring that the data (recorded on CRFs) (entered 
into eCRF) is complete, accurate, and that entry  and updates are performed in a timely  manner. 
The investigator must certify  that the data entered iscomplete and accurate .
After final database lock, the investigator will receive copies of the subject data for archiving 
at the investigational site.
All data should be recorded, handled and stored in a way that allows its accurate reporting, 
interpretation and verification.

Novartis Confidential Page 84
Amended Protocol Version 03 (clean ) Protocol No. CSEG101AUS05
11.2 Database management and quality  control
Novartis personnel (or designated CRO) will review the data entered by investigational staff 
for completeness and accuracy . Electronic data queries stating the nature of the problem and 
requesting clarification will be create d for discrepancies and missing values and sent to the 
investigational site via the EDC system. Designated investigator site staff are required to 
respond promptly  to queries and to make any  necessary  changes to the data.
Concomitant treatments and prior medications entered into the database will be coded using the 
WHO Drug Reference List, which employ s the Anatomical Therapeutic Chemical classification 
system. Medical history /current medical conditions and AEs will be coded using the Medical 
dictionary  for regulatory  activities (MedDRA) terminology .
At the conclusion of a non-IRT study , the occurrence of any emergency  code breaks will be 
determined after return of all code break reports and unused supplies to Novartis.
Once all the necessary  actions have been completed and the database has been declared to be 
complete and accurate, it will be locked and made available for data analy sis/moved to restricted 
area to be accessed by independent programmer and statistician. Any changes to the database 
after that time can only be made after a written agreement by Novartis development 
management.
11.3 Site monitoring
Before study  initiation, at a site initiation visit or at an investigator’s meeting, a Novartis 
representative will review the protocol and data capture requirements ( i.e.eSource DDE or 
eCRFs) with the investigators and their staff. During the study , Novartis employ s several 
methods of ensuring protocol and GCP compliance and the quality /integrity  of the sites’ data. 
The field monitor will visit the site to check the completeness of subject records, the accuracy 
of data capture / data entry , the adherence to the protocol and to Good Clinical Practice, the 
progress of enrollment, and to ensure that study treatment is being stored, dispensed, and 
accounted for according to specifications. Key study personnel must be available to assist the 
field monitor during these visits. Continuous remote monitoring of each site’s data may be 
performed by a centralized Novartis -affiliated Clinical Research Associate (CRA) organization . 
Additionally , a central analy tics organization may analyze data & identify  risks & trends for 
site operational parameters andprovide reports to Novartis/ sponsor clinical teams to assist with 
trial oversight.
The investigator must maintain source documents for each subject in the study , consisting of 
case and visit notes (hospital or clinic medical records) containing demographic and medical 
information, laboratory  data, ECG s, and the results of any other tests or assessments. All 
information on CRFs must be traceable to these source documents in the subject’s file. The 
investigator must also keep the original informed consent form signed by  the subject (a signed 
copy  is given to the subject).
The investigator must give the monitor access to al l relevant source documents to confirm their 
consistency  with the data capture and/or data entry . Novartis monitoring standards require full 
verification for the presence of informed consent, adherence to the inclusion/exclusion criteria, 
documentation of SAEs, and of data that will be used for all primary  variables. Additional 
checks of the consistency  of the source data with the CRFs are performed according to the 

Novartis Confidential Page 85
Amended Protocol Version 03 (clean ) Protocol No. CSEG101AUS05
study -specific monitoring plan. No information in source documents about the identity  of the
subjects will be disclosed.
12 Data analy sis and statistical methods
Summary  statistics for continuous variables will generall y include the number of subject s, mean, 
standard deviation (SD), lower quartile (Q1), median, upper quartile (Q3), minimum, and 
maxi mum . For categorical or binary  variables, the number and percent of subject s in each 
category  will be presented.
The primary anal ysis of study  data for the primary clinical study report (CSR) will be based on 
all subject data up to the Week 26 (up to assessments taken on Week 27 Day 1 before infusion) . 
The additional data for any subject s continuing to receive study drug after this time, as allowed 
by the protocol, will be further summarized in a final study  report once these subject s have 
completed or disc ontinued the study .
Baseline period is defined as the 12weeks screening period prior to the first infusion of 
crizanlizumab 5 mg/kg at Week 1 Day  1.
12.1 Analysis sets
Full Analysis Set(FAS) :The FAS include all enrolled subjects to whom the study  treatment 
has been assigned regardless of whether or not they have received at least 1 dose of study 
treatment or have at least 1 post- baseline assessment .
Safety  Anal ysis Set(SAF) :The SAF will consist of all subject s who received at least 1dose of 
study  treatmen t.
Allefficacy  analy seswill be performed on subjects in 
FAS who have completed treatment .
12.2 Subject demographics and other baseline characteristics
Demographic and other baseline disease characteristics will be listed and summarized 
descriptiv ely forall subject s in the FAS as well as for those subjects in FAS who have 
completed the treatment .
Categorical data will be presented as frequencies and percentages. For continuous data, mean, 
standard deviation (SD) , lower quartile (Q1), median, upper quartile (Q3) , minimum and 
maximum will be presented.
Relevant medical histories and current medical conditions at baseline will be summarized 
separately , by system organ class and preferred term.
Prior disease information will also be summarized.
12.3 Treatments
The Safety set will be used for the analy ses below. Categorical data will be summarized as 
frequencies and percentages. For continuous data, mean, standard deviation (SD) , lower quartile 
(Q1), median, upper quartile (Q3) , minimum and maximum will be presented.

Novartis Confidential Page 86
Amended Protocol Version 03 (clean ) Protocol No. CSEG101AUS05
The duration of exposure in weeks to study  drug as well as the dose intensity (computed as the 
ratio of actual cumulative dose received and actual duration of exposure) and the relative dose 
intensity  (computed as the ratio of dose intensity  and planned dose intensity ) will be 
summarized by  means of descriptive s tatistics using the S
afety set.
The number of subject s with dose interruption or permanent discontinuation and the reasons 
will be summarized for all subject s and all dosing data will be listed.
Concomitant medications and significant non-drug therapies prior to and after the start of the 
study  treatment will be listed and summarized according to the Anatomical Therapeutic 
Chemical (ATC) classification sy stem for all subject s.
12.4 Analysis of the prim ary endpoin t
The primary  objective of this study  is to evaluate clinical efficacy  of crizanlizumab 5 mg/kg, 
over 26 weeks compared to baseline in sickle cell subject s with a history  of priapism.
12.4.1 Definition of primary  endpoint
The primary  endpoint of the study is percent reduction from baseline in priapism events by 
26weeks (i.e.up to pre-infusion Week27, 
Day 1). Priapism event is defined as unwanted, or 
painful erection lasting at least 60minutes, self -reported.
12.4.2 Statistical model, hypothesis, and metho dof analy sis
It is expected that crizanlizumab treatment reduces priapic events by at least 25% in SCD 
subject s with priapism .Demonstration of significant percent reduction from baseli ne in priapic 
events will be evaluated using the following hy pothesis:
H0: p <0.25, where p is the percent reduction in priapic events b y 26 weeks.
H1: p ≥0.25, where p is the percent reduction in priapic events b y 26 weeks.
If the above null hypothesis is rejected, significant reduction in priapic events willbe
demonstr ated statistically.
Assuming uniformity  in the occurrence of priapic events before exposure to crizanlizumab 
treatment , baseline will be adjusted for 26 weeks for anal ysis purpose.
Percent reduction from baseline in priapic events will be tested using a no nparametric test (i.e.
Wilcoxon’s Sign Rank test). Hodges -Lehmann estimate of median percent reduction in priapic 
events will also be reported, along with corresponding 95% confidence intervals
.The 
significance of the efficacy endpoints will be assessed at α = 0.05 level.
The primary  analysis will be performed on all FAS subjects who have com pleted 26 weeks on 
treatment.
Number of priapic events will be summarized at baseline (adjusted for 26 we eks) and b yWeek 
26, and percent reduction from adjusted baseline byWeek 26 will be summarized by mean, 
standard deviation (SD) , lower quartile (Q1), median, upper quartile (Q3) , minimum and 
maximum. Inaddition, subgroup anal ysis of the primary endpoint willalsobe performed based 
on the number of priapic events categories (i.e.<7, 7 – 13, 14 – 21, ≥ 22)at baseline .Thepriapic 
events categories may be re-grouped to ensure that there is adequate number of subject sin each 

Novartis Confidential Page 87
Amended Protocol Version 03 (clean ) Protocol No. CSEG101AUS05
category for anal ysis.Additional analy ses will also be performed for the subgroups of subject s 
with acute priapism and subjects who have experienced priapic episodes lasting less than one 
hour.
Further details will be provided in the SAP.
The imputation of missing data caused by intercurrent events will be handled by defining the 
estimand framework. The primary  estimand is described by  the following four attributes:
1. The target population comprises Sickle Cell Disease Patients with Priapism
2.The primary  variable is percent reduction from baseline period in priapic events (priapism 
defined as unwanted, or painful erection lasting at least 60 min self -reported) by  26 weeks.
3.Treatment of interest: investigational drug will be a crizanlizumab solution provided every 
4 weeks with an additional loading dose 2 weeks after the first dosing. Further details about 
the investigational treatment are provided in Section 6 .  
4.The intercurrent events are the events occurring after enrollment that may  impact the 
treatment effect. The intercurrent events of interest are listed below :
a.Treatment discontinuation 
b.Initiation or discontinuation of HU/HC or L -Glutamine (or other therapies to treat 
SCD and or to prevent/reduce VOCs such as voxelotor and ery thropoietin) or of 
prophy lactic treatment for priapism
c.Intake of analgesic (including opioids) or ad hoc transfusions administered 
temporaril y
5.The summary  measure is the 
median percent agechange from baseline period in priapic 
events (priapism defined as unwanted, or painful erection lasting at least 60 min self -
reported) b y 26 weeks .
Handling of the intercurrent events:
The approach of accounting for intercurrent events is as follows:
For the intercurrent events 4a:Only  data before study  treatment discontinuation will be 
included. The data between treatment discontinuation and week 26 will be imputed using 
Poisson distribution (primary  method to handle missing dat a).
For the intercurre nt events 4b:Only  data before initiation or discontinuation of HU/HC 
or L-Glutamine (or other therapies to treat SCD and or to prevent/reduce VOCs such as 
voxelotor and erythropoietin) or of proph ylactic treatment for priapism will be included. 
The data between initiation or discontinuation of therapies to treat SCD or of prophy lactic 
treatment for priapism and week 26 will be imputed using Poisson distributi on (primary 
method to handle missing dat a).
For the intercurrent events 4c:Data after intake of analgesic (including opioids) or ad hoc 
transfusions administered temporaril y will be included (treatment policy strategy). 
12.4.3 Handling of missing values/censori ng/discontinuations
The missing values will be imputed for the primary  analysis. Missing values will be imputed 
using Poisson distribution, assuming the same effect as observed data. Imputed datasets 

Novartis Confidential Page 88
Amended Protocol Version 03 (clean ) Protocol No. CSEG101AUS05
(approximately  1,000) will be created, and each dataset will be analy zed using the method 
described for primary  endpoint. The results will be combined using Rubin’s rule (Barnard J and 
Rubin DB 1999) Further details will be outlined in the SAP. 
As stated in Section 12.4.4 , the volume of missing data generated due to COVID -19 crisis will 
also be assessed and sensitivity  anal yses will be performed. 
12.4.4 Sensitivity and supportive analy ses
Sensitivity analy ses
To explore the robustness of analysis, sensitivity analysisas a'tipping point approach
will be performed for the primary  endpoint to evaluate the impact of a deviation from 
the MAR assumption. The basic idea is to first impute the missing values using the 
multiple imputation (MI ) method based on the missing at random (MAR) assumption
,
then adjusted by a delta 
value. The delta adjusting approach described in Ratitch et al 
(2013) will be used to find the tipping poi nt, in a spectrum of conservative missing not 
at random (MNAR) assumptions, at which conclusions change from being favorable to 
being unfavorable. After such a tipping point is determined, clinical judgment can be 
applied as to the plausibility  of the assumptions underly ing this tipping point. A 
detailed description of the anal ysis will be provided in SAP.
As part of the sensitivity  anal ysis, treatment policy  strategy (that is, data after the 
intercurrent events will be included) will also be applied for the intercurrent events 4a 
and 4b, described in Section 12.4.2 .
As part of the sensitivity  anal ysis, the primary  analy sis will be anal yzed on all subjects 
in FAS without missing data.
Additionally , as the study  is ongoing during COVID 19 pandemic, the impact of 
COVID -19 (if any) on the primary  endpoint will be assessed in accordance to FDA’s 
guideline entitled “Statistical Considerations for Clinical Trials During the COVID -19 
Public Health Emergency ”. The analy sis (as stated below) will be repeated on the FAS 
excluding the subjects with missing data due to COVID -19. 
oPercent reduction f rom baseline in priapic events will be tested using a 
nonparametric test (i.e., Wilcoxon’s Sign Rank test). Hodges -Lehmann 
estimate of median percent reduction in priapic events will also be reported, 
along with corresponding 95% confidence intervals. The significance of the 
efficacy  endpoints will be assessed at α = 0.05 level.
Further details will be provided in the SAP , as needed .
Supportive analy ses
The supportive analy ses described below will be performed on all FAS subjects who 
have completed 26 weeks on treatment.  Missing values will be imputed as stated in
Section 12.4.3 .Annualized priapic Events Rate : The annualized rate of priap icevents is 
defined as the total number of priapi cevents for a subject occurring from the date of 
initial infusion to the last contact date of the Treatment Phase of the study ×
365.25
divided by the number of day s during that same time period. This calculation accounts 
for early  dropouts or lost to follow -
up by extrapolating the priapism events rate of every 
subject to 1year.

Novartis Confidential Page 89
Amended Protocol Version 03 (clean ) Protocol No. CSEG101AUS05
Percent reduction from baseline in priapic events will also be assessed b y Week 52.
The total number of priapic episodes in the screening period (12 weeks baseline) will 
be compared to the total number of priapic episodes occurring in the first 12 weeks on 
treatment (0-12 weeks) using a nonparametric test (i.e. Wilcoxon’s Sign Rank test). 
Additionally ,a similar analy sis will be performed to compare to the total number of 
priapic episodes occurri ng in the last 12 weeks on treatment (15 -26 weeks).
Number of priapic events will be summarized in the screening period (12 weeks 
baseline) , in first 12 weeks on treatment (0-12 weeks), andin the last 12 weeks on 
treatment (15- 26 weeks) and percent reduc tion from baseline will also be summarized.
12.5 Analysis of secondary  endpoints
The secondary  objectives in this study  are to assess efficacy , safet y and tolerability  of 
crizanlizumab 5.0 mg/kg in SCD subject s. 
12.5.1 Efficacy  endpoint s
The following secondary endpoints will be analy zed on all FAS subjects who have completed 
52 weeks on treatment to evaluate clinical efficacy of crizanlizumab 5 mg/kg:
a.The rate of priapic events by 26 and 52 weeks of treatment.
b. The percent reduction from baseline in acute priapic events by 26 and 52 weeks of 
treatment. 
c.The rate of uncomplicated VOC events (defined as an acute event of pain with no known 
cause for pain other than a vaso- occlusive event; and requiring treatment wi th a parenteral 
or oral opioids or other parenteral analgesic; but is NOT classified as an acute chest 
syndrome, hepatic sequestration, splenic sequestration or priapism and these events will 
not be adjudicated ) by 26 and 52 weeks of treatment. Events incl ude both healthcare and 
self-reported events.
d.The rate of complicated VOCs (defined as acute chest sy ndrome, hepatic sequestration, 
splenic sequestration, and acute priapism) recorded by  healthcare visit, by  26 and 
52weeks of treatment.
The efficacy  endpo ints will be assessed by 26 weeks and by 52 weeks .
12.5.2 Methods of analy ses
Similar analy seson percent reduction in acute priapic events forsubject s from full anal ysis set 
will be conducted, as done for primary  endpoint .
Descriptive summary  statistics including n, mean, standard deviation (SD)
, lower quartile (Q1), , 
median, upper quartile (Q3), minimum and maximum will be presented for the rate of events 
and number of priapic events at Baseline, byWeek 26 and by Week 52. The change from 
baseline in Rates of Events at Week 26 (i.e.evaluation at Week 27, Day 1) and Week 52 (i.e.
evaluation at Week 53, Day 1) will be summarized by n, mean, standard deviation (SD) , lower 
quartile (Q1), median, upper quartile (Q3), minimum and maximum.
As appropriate, the estimated median change from Baseline at 26weeks (i.e. evaluation at
Week27, D ay 1) and 52 (i.e. evaluation at Week 53, D ay 1) weeks in events or events with 

Novartis Confidential Page 90
Amended Protocol Version 03 (clean ) Protocol No. CSEG101AUS05
associated 95% CI using a non-parametric approach will be reported . The median percent 
reduction will also be presented by Week 26 and Week 52 .
12.6 Safet y endpoints
Allthe 
safet y analyses will be based on the safety  set.
The overall observation period will be divided into 3 mutually  exclusive segments:
1. P re-treatment period: from day  of subject’s informed consent to the day  before first dose 
of study  medication
2. On- treatment period: from day  of fi rst dose of study  medication to 105 days after last dose 
of study  medication (or until EOT date for subjects continuing crizanlizumab after their 
EOT via commercial supply )
3.
Post-treatment period: starting at Day 106 after last dose of study medication (or after 
EOT date for subjects continuing crizanlizumab after their EOT via commercial suppl y or 
a post -
trial a ccess program).
Summary  tables for AEs will include only AEs that started or worsened during the on-treatment 
period, the treatmen t
-emergent AEs.
The incidence of TEAEs (new or worsening from baseline) will be summarized by system organ 
class and or prefer red term, severity  (based on CTCAE grades), type of AE, relation to study 
treatment .
Serious adverse events will be tabulated.
All deaths (on
-treatment death and post-treatment death ) will be summarized.
All AEs, deaths and SAEs (including those from the pre-and post-treatment periods) will be 
listed and those collected during the pre -treatment and post -treatment period will be flagged.
Separate summaries will be provided for other significant AEs leading to discontinuation and 
AEs leading to dose adjustment .
12.6.1 Clinical laboratory  evaluations
For results reported by the central laboratory , continuous hematology  and chemistry  results will 
be summarized descriptively  in SI units at each scheduled time point. Visits summaries will 
include baseline and post baseline visits, including early  termination and Follow -Up. Changes 
from baseline will also be summarized at each time point.
In addition, shift tables will be provided for all parameters to compare a subject ’s baseline 
laboratory  evaluation relative tothe visit’s observed value. For the shift tables, the normal 
laboratory  ranges will be used to evaluate whether a particular laboratory  test value was normal, 
low or high for each visit value relative to whether 
the baseline value was normal, low or high.
These summaries will be presented b y laboratory  test.
Coagulation parameters (as described in Section 8.3.4) willbesummarized descriptivel y at each 
time-point. Changes from baseline will also be summarized.
Urinalysis 
results will be listed in individual subject data listings onl y. In addition, a listing 
containing individual subject hematology , chemistry , and coagulation values outside the 

Novartis Confidential Page 91
Amended Protocol Version 03 (clean ) Protocol No. CSEG101AUS05
reference ranges will be provided. This listing will include data from scheduled and 
unscheduled time points.
Hepatitis markers and additional tests results will be summarized descriptively  at screening only.
12.6.2 Other safety  evaluations
Vital signs
Data on vital signs , including sy stolic and diastolic blood pressure, pulse rate, r espiratory  rate, 
oxygen saturation ,and body  temperature) will be tabulated and listed for each visit, notable 
values will be flagged.
12-Lead ECG
12-lead ECGs including PR, QRS, QT, QTcF and HR intervals will be obtained for each subject
during the stud y. ECG data will be read and interpreted locall y
.
The number and percentage of subject s with notable ECG values will be presented. In addition, 
a listing of these subject s will be produced.
Notable/abnormal values for safety  data will be further specified in the RAP.
Echocardiogram
The assessments for Cardiac I maging using ECHO will be summarized at screening and end of 
treatment visit.
Urine protein/creatinine ratio
The assessments for urine protein/creatinine ratio will be summarized descr iptively at screening 
and end of treatment visit
.

Novartis Confidential Page 92
Amended Protocol Version 03 (clean ) Protocol No. CSEG101AUS05
12.8 Interim analy ses
No formal interim anal ysis will be performed for this study .As required, interim anal yses will 
be performed for publication purpose s only. No decision onstudy  continuation will be based 
on these descriptive reports, and as such, no alpha adjustment will be needed.
12.9 Sample size calculation
A total of 34evaluable subject s is required for the study  to have approximately 80% power to 
detect at least 25% reduction in rates of priapic events (defined as an unwanted erection lasting 
at least 60 min reported via daily diary  tool) with a mean baseline priapism event rate of 10.0 
and standard deviation of the difference of 5.0, b y 26 weeks.
The calculations were based on simulation with 5,000 repetitions (from Poisson distribution) 
using one -sample Wilcoxon’s Signed -Rank Test and 2 -sided α=0.05.
Retaining the same above assumptions, robustness of the estimated sample size was also 
validated using a one -sampl e t test.
Assuming a 5% dropout rate, approximately  36 subjects will be enrolled in the study .
Recruitment of the required number of subject s with priapism will be challenging as the 
incidence of priapic events are sporadic andvaries over time intervals. Also, in the absence of 
relevant clinical data on priapism, the expected reduction and higher variability  in events rates 
have been conservativel y assumed. The above expected 25% reduction in rates of priapic events 
from baseline is based on medical expert opinion and feedback. L-glutamine (Endari ™) was 
approved by the US FDA in July 2017 for the reduction of vaso-occlusive crises (VOCs), based 
on a 25% reduction. Since priapism is also considered to be a complicated VOC, the assumption 
was that the relativ
e risk reduction of 25% (approved for VOC events), would be similar for 
priapism.

Novartis Confidential Page 93
Amended Protocol Version 03 (clean ) Protocol No. CSEG101AUS05
13 Ethical considerations and administrative procedures
13.1 Regulatory  and ethical compliance
This clinical study  was designed and shall be implemented, executed and reported in accordance 
with the ICH Harmonized Tripartite Guidelines for Good Clinical Practice, with applicable 
local regulations (including European Directive 2001/20/EC, US CFR 21), and with the ethical 
principles laid down in the Declaration of Helsinki.
13.2 Responsibi lities of the investigator and IRB
Before initiating a trial, the investigator/institution must obtain approval/favorable opinion from 
the Institutional Review Board (IRB) for the trial protocol, written informed consent form, 
consent form updates, subject recruitment procedures (e.g. advertisements) and any other 
written information to be provided to subjects. Prior to study  start, the investigator is required 
to sign a protocol signature page confirming his/her agreement to conduct the study  in 
accordance with these documents and all of the instructions and procedures found in this 
protocol and to give access to all relevant data and records to Novartis monitors, auditors, 
Novartis Qualit y Assurance representatives, designated agents of Novartis, IRBs, and
regulatory  authorities as required. If an inspection of the clinical site is requested by a regulatory 
authority , the investigator must inform Novartis immediately  that this request has been made.
13.3 Publication of study  protocol and results
The protocol will be registered in a publicly  accessible database such as clinicaltrials.gov and 
as required in EudraCT. In addition, after study  completion (defined as last patient last visit) 
and finalization of the study report the results of this trial will be submitt ed for publication and 
posted in a publicly  accessible database of clinical trial results, such as the Novartis clinical trial 
results website and all required Health Authority  websites (e.g.Clinicaltrials.gov, EudraCT 
etc.).
For details on the Novartis publication policy  including authorship criteria, please refer to the 
Novartis publication policy training materials that were provided to you at the trial investigator 
meetings .
13.4 Qualit y c
ontrol and qualit y assurance
Novartis maintains a robust Quality  Management System (QMS) that includes all activities 
involved in quality  assurance and qualit y control, to ensure compliance with written Standard 
Operating Procedures as well as applicable global/local GCP regulations and I CH Guidelines.
Audits of investi gator sites, vendors, and Novartis systems are performed by auditors, 
independent from those involved in conducting, monitoring or performing quality  control of the 
clinical trial. The clinical audit process uses a knowledge/risk -based approach.
Audits are conducted to assess GCP compliance with global and local regulatory requirements, 
protocols and internal SOPs, and are performed according to written Novartis processes .

Novartis Confidential Page 94
Amended Protocol Version 03 (clean ) Protocol No. CSEG101AUS05
14 Protocol adherence
This protocol defines the study  objectives, the study procedures a nd the data to be collected on 
study  subject s. Additional assessments required to ensure safet y of subjects should be 
administered as deemed necessary  on a case-by-case basis. Under no circumstances including 
incidental collection is an investigator allowe d to collect additional data or conduct any 
additional procedures for any purpose involving any investigational drugs under the protocol, 
other than the purpose of the study . If despite this interdiction prohibition, data, information, 
observation would beincidentally  collected, the investigator shall immediately  disclose it to 
Novartis and not use it for any purpose other than the study , except for the appropriate 
monitoring on study  subject s .
Investigators ascertain they will apply due diligence to avoid protocol deviations. If an 
investigator feels a protocol deviation would improve the conduct of the study  this must be 
considered a protocol amendment, and unless such an amendment is agreed upon by Novartis 
and approved b y the IRB and health authorities, where required, it cannot be implemented.
14.1 Protocol amendments
Any change or addition to the protocol can onl y be made in a written protocol amendment that 
must be approved by Novartis, health authorities where required, and the IRB/IEC prior to 
implementa tion.
Only  amendments that are required for subject safet y may be implemented immediately 
provided the health authorities are subsequently  notified by protocol amendment and the 
reviewing IRB is notified.
Notwithstanding the need for approval of formal protocol amendments, the investigator is 
expected to take any immediate action required for the safety  of any subject included in this 
study , even if this action represents a deviation from the protocol. In such cases, Novartis should 
be notified of this action and the IRB at the study  site should be informed according to local 
regulations.

Novartis Confidential Page 95
Amended Protocol Version 03 (clean ) Protocol No. CSEG101AUS05
15 References
References are available upon request
Adey oju AB, Olujohungbe AB, Morris J, et al (2002) Priapism in sickle -cell disease; 
incidence, risk factors and complicati ons - an international multicenter study . BJU I nt.; 
90(9):898-902.
Ataga KI, A. Kutlar, J. Kanter, et al (2017) Crizanlizumab for the Prevention of Pain Crises in 
Sickle Cell Disease. N Engl J Med; 376(5):429–439.
Ballas SK, Bauserman RL, McCarth y WF, et a l (2010) Hy droxyurea and acute painful crises 
in sickle cell anemia: effects on hospital length of stay
 and opioid utilization during 
hospitalization, outpatient acute care contacts, and at home. J Pain Sy mptom Manage; 
40(6): 870-82.
Banholzer M, Wandel C, 
Barrow P, et al (2016). Clinical trial considerations on male 
contraception and collection of pregnancy  information from female partner:update. Clin Trans 
Med ; 5(23).
Barnard J and Rubin DB (1999). Small- sample degrees of freedom with multiple imputation.
Biometrika. Volume 86, Issue 4, 948 -955.
Bender MA (2003) Sickle Cell Disease. GeneReviews®. Seattle (WA): University  of 
Washington, Seattle; 1993-2019.
Brandow AM, Carroll CP, Creary S, et al. (2020), American Societ y of Hematology  2020 
guidelines for sickle cell disease: management of acute and chronic pain, Blood Advances; 4 
(12): 2656
-2701.
Brousseau DC, Owens PL, Mosso AL, et al (2010) Acute care utilization and 
rehospitalizations for sickle cell disease. JAMA; 303(13): 1288-94.
Burnett AL, Anele UA, Trueheart IN, et al (2014) Randomized controlled trial of sildenafil 
for preventing recurrent ischemic priapism in sickle cell disease. Am J Med; 127(7):664
-8.
Charache S, Terrin ML, Moore RD, et al (1995) Effect of hy droxyurea on the frequency of 
painful crises in sickle cell anemia. Investigators of the Multicenter Study  of Hy droxyurea in 
Sickle Cell Anemia. N Engl J Med; 332(20): 1317-22.
Droxia US Prescribing Information (201
7) Available at: 
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/016295s049s050lbl.pdf (last 
accessed 28- Dec-2018 ).
El-
Bahnasawy  MS, Dawood A, Farouk A (2002) Low-flow priapism: risk factors for erectile 
dysfunction. BJU I nt.;89(3):285-290.
Embury  SH, Matsui NM, Ramanujam S, et al (2004) The contribution of endothelial cell 
P-selectin to the microvascular flow of mouse sickle ery throcy tes in vivo. Blood; 
104(10):3378-85.
Emond AM, BChir MB, et al (1980) Priapism and I mpotence in Homozy gous Sickle Cell
Disease. Archives of Internal Medicine, Volume 140, I ssue 11, 1434-1437.
Fowler JE Jr, Koshy  M, Strub M, et al (1991) Priapism associated with the sickle cell 
hemoglob inopathies: prevalence, natural history  and sequelae. J Urol; 145(1):65 -8. 

Novartis Confidential Page 96
Amended Protocol Version 03 (clean ) Protocol No. CSEG101AUS05
Frenette PS (2004) Sickle Cell Vasoocclusion: heterotypic, multicellular aggregations driven 
by leukocy te adhesion. Microcirculation; 11(2):167-77.
Furtado PS, Costa MP, Ribeiro do Prado, et al (2012) The prevalence of priapism in children 
and adolescents with sickle cell disease in Brazil. Int J Hematol ; 95(6):648-51.
Geng J G, Bevilacqua MP, Moore KL, et al (1990) Rapid neutrophil adhesion to activated 
endothelium mediated by GMP -140. Nature; 343(6260):757 -60.
Gill FM, Sleeper LA, Weiner SJ, et al (1995) Clinical events in the first decade in a cohort of 
infants with sickle cell disease. Cooperative Study of Sickle Cell Disease. Blood; 
86(2):776-83.
Gutsaeva DR, Parkerson JB, Y erigenahally  SD, et al (2011) Inhibition of cell adhesion by  
anti-P-selectin aptamer: a new potential therapeutic agent for sickle cell disease. Blood ; 
117(2):727-35.
Hamre MR, Harmon EP, Kirkpatrick DV, et al (1991) Priapism as a complication of sickle 
cell disease. J Urol; 145:1-5.
Hamburger SA, McEver RP (1990) GMP -140 mediates adhesion of stimulated platelets to 
neutrophils. Blood, 75(3):550-4.
Hebbel RP, Boogaerts MA, Eaton JW, et al (1980) Ery throcy te adherence to endothelium in 
sickle -cell anemia. A possible determinant of disease severity . N Engl J Med; 302(18):992-5.
Hydrea US Prescribing Information (2016) Available at: 
https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/016295Orig1s047,s048L bl.pdf
(last accessed 2 8-Dec-2018).
ICH E9(R1) Har
monized Guideline: addendum on estimands and sensitivity analysis in clinical 
trials to the guideline on statistical principles for clinical trials. Final version adopted on 20 
November 2019.
Inwald DP, Kirkham FJ, Peters MJ, et al(2000) Platelet and leuco cyte activation in childhood 
sickle cell disease: association with nocturnal hypoxaemia. Br J Haematol ;111(2):474-81.
Howard J,Telfer P. Sickle Cell Disease in Clinical Practice. 1st ed. Springer -Verlag London 
2015.
Jones D A,Abbassi O, McIntire LV,et al ( 1993) P -selectin mediates neutrophil rolling on 
histamine -stimulated endothelial cells. Bioph ys J; 65(4):1560-9.
Kanter J, Kruse -Jarres R (2013) Management of sickle cell disease from childhood through 
adulthood. Blood Rev; 27(6):279-87.
Kato GJ, Steinberg MH, Gladwin MT (2017) Intravascular hemol ysis and the 
pathophy siology  of sickle cell disease. J Clin I nvest; 127(3):750-60.
Kauf TL, Coates TD, Huazhi L , et al (2009) The cost of health care for children and adults 
with sickle cell disease. Am. J . Hematol; 84(6):323 -7.
Kaul DK and Hebbel RP (2000) Hypoxia/reoxy genation causes inflammatory  response in 
transgenic sickle mice but not in normal mice. J Clin Invest; 106(3) :411-20.

Novartis Confidential Page 97
Amended Protocol Version 03 (clean ) Protocol No. CSEG101AUS05
Lawrence MB, Springer TA (1991) Leukocy tes roll on a selectin at phy siologic flow rates: 
Distinction from and prerequisite for adhesio n through integrins; 65(5): 859-73.
LeeSP, Ataga KI, Zay ed M ,et al 
(2007) Phase I study of eptifibatide in patients with sickle 
cell anaemia. Br J Haematol ;139(4): 612-20.
Liu Z, Miner JJ, Yago T, et al (2010) Differential regulation of human and murine P- selectin 
expression and function in vivo. J Exp Med; 207(13):2975 -87.
Mantadakis E, Cavender JD, Rogers ZR, et al (1999 ) Prevalence of priapism in children and 
adolescents with sickle cell anemia. J Pediatr Hematol Oncol; 21 (6):518–22.
Matsui NM, Borsig L, Rosen SD, et al (2 001) P -selectin mediates the adhesion of sickle 
erythrocy tes to the endothelium. Blood; 98(6):1955 -
62.
Matsui NM, Varki A, Embury  SH (2002) Heparin inhibits the flow adhesion of sickle red 
blood cells to P -selectin. Blood; 100(10):3790 -6.
McGrath PJ, Walco GA, Turk DC, et al (2008) Core outcomes domains and measures for 
pediatric acute and chronic/recurrent pain clinical trials: PedI MMPACT recommendations. 
JPain; 9 (9):771-783.
Montague DK, Jarow J, Broderick GA, et al (2003) American Urological Association 
guideline on the management of priapism. J Urol ; 170(4 Pt 1):1318-24.
Nietert PJ, Silverstein MD, Abboud MR (2002) Sickle cell anaemia: epidemiology  and cost of 
illness. Pharmacoeconomics; 20(6): 357-66.
Niihara Y, Smith WR, Stark CW (2018) A Phase 3 Trial of l- Glutamine in Sickle Cell 
Disease. N Engl J Med; 379(19):1880
Olujohungbe AB, Adey oju A, Yardumian A, et al (2011) A prospective diary  study  of 
stuttering priapism in adolescents and young men with sickle cell anemia: report of an 
international randomized control trial –the priapism in sickle cell 
study . JAndrol ;32(4):375-82.
Pászty  C, Brion CM, Manci E, et al (1997) Transgenic knockout mice wi th exclusively  human 
sickle hemoglobin and sickle cell disease. Science; 278(5339):876-8.
Piel FB, Steinberg MH, Rees DC (2017) Sickle Cell Disease. N Engl J Med; 
376(16): 1561-73.
Porter L S, Gil KM, Sedway  JA, et al (1998) Pain and stress in sickle cell di sease: an anal ysis 
of daily  pain records. Int J Behav Med ; 5(3): 185-203.
Powars DR, Chan L S, Hiti A, et al (2005) Outcome of sickle cell anemia: a 4
-decade 
observational study  of 1056 patients. Medicine (Baltimore); 84(6):363-76.
Ratitch, Bohdana ; O'Kelly , Michael ; Tosiello, Robert (2013) Missing data in clinical trials: 
from clinical assumptions to statistical analy sis using pattern mixture models. Pharmaceutical 
statistics : the journal of the pharmaceutical industry , 2013, Vol.12 (6), p.337 -347.

Novartis Confidential Page 98
Amended Protocol Version 03 (clean ) Protocol No. CSEG101AUS05
Rees DC, Williams TN, Gladwin MT (2010) Sickle-cell disease. Lancet; 376(9757): 2018-31.
Rogers Z R (2005) 
Priapism in Sickle Cell Disease . Hematol Oncol Clin N Am 19 : 917–928 .
Scialli A, Bailey  G, Bey er B, et al (2015). Potential seminal transport of pharmaceuticals to 
the conceptus. Reproductive Toxicology 58: 213- 221.
Stuart J, Johnson CS (1987) Rheology  of the sickle cell disorders. Baillieres Clin Haematol; 
1(3): 747-75.
Turhan A, Weiss LA, Mohandas N, et al (2012) Primary  role for adherent leukocy tes in sickle 
cell vascular occlus ion: a new paradigm. Proc Natl Acad Sci U S A.; 99(5):3047 -51.
Vichinski E, Hoppe C, Ataga K, et al (2019) A Phase 3 Randomized Trial of Voxelotor in 
Sickle Cell Disease. N Engl J Med; 381(6):509- 519.
Wagner MC, Eckman JR, Wick TM (2006) Histamine increase s sickle erythrocy te adherence 
to endothelium. Br J Haematol, 132(4):512-22.
Ware RE, de Montalembert M, Tshilolo L , et al (2017) Sickle cell disease. Lancet ;
390(10091):311-23.
Wood K, Russell J, Hebbel RP, et al (2004) Differential Expression of E- and P-Selectin in 
the Microvasculature of Sickle Cell Transgenic Mice. Microcirculation; 11(4):377 -85.

Novartis Confidential Page 99
Amended Protocol Version 03 (clean ) Protocol No. CSEG101AUS05
16 Appendices

Novartis Confidential Page 100
Amended Protocol Version 03 (clean ) Protocol No. CSEG101AUS05

Novartis Confidential Page 101
Amended Protocol Version 03 (clean ) Protocol No. CSEG101AUS05

Novartis Confidential Page 102
Amended Protocol Version 03 (clean ) Protocol No. CSEG101AUS05

Novartis Confidential Page 103
Amended Protocol Version 03 (clean ) Protocol No. CSEG101AUS05

Novartis Confidential Page 104
Amended Protocol Version 03 (clean ) Protocol No. CSEG101AUS05

Novartis Confidential Page 105
Amended Protocol Version 03 (clean ) Protocol No. CSEG101AUS05

Novartis Confidential Page 106
Amended Protocol Version 03 (clean ) Protocol No. CSEG101AUS05
Appendix 3: Priapism medical history  questionnaire

Novartis Confidential Page 107
Amended Protocol Version 03 (clean ) Protocol No. CSEG101AUS05

Novartis Confidential Page 108
Amended Protocol Version 03 (clean ) Protocol No. CSEG101AUS05

Novartis Confidential Page 109
Amended Protocol Version 03 (clean ) Protocol No. CSEG101AUS05

Novartis Confidential Page 110
Amended Protocol Version 03 (clean ) Protocol No. CSEG101AUS05

Novartis Confidential Page 111
Amended Protocol Version 03 (clean ) Protocol No. CSEG101AUS05

Novartis Confidential Page 112
Amended Protocol Version 03 (clean ) Protocol No. CSEG101AUS05
Appendix 5: List of drugs that may  induce priapism
Table 16-1 List of non-antipsy chotic and non -antidepressant drugs that may 
Induce Priapism
Category Substances
Medicines associated with increas edrisk of priapism *
Vasoactive erectile agents** alprostadil, papaverine, phentolamine
α-adrenergic receptor antagonists doxazosin, tamsulosin, terazosin, prazosin
Antihypertensives hydrala zine, propranolol, guanethidine
Anticoagulants heparin, warfarin
Hormones testosterone, gonadotropin -releasing hormone
Medicines that have been reported to cause priapism *
Phosphodiesterase type 5 inhibitors sildenafil, tadalafil
Anti-anxiety agents (including ADHD drugs) methylphenidate, atomoxetine , hydroxyzine
Recreational Drug Cocaine, crack cocaine
Herbal Supplement Any herbal supplement to treat ED:including (but not 
limited to) the following products containing Tribulus 
terrestris, Saw palmetto extract , Panax ginseng, 
Dehydroepiandrosterone (DHEA) , L-arginine, 
Rhodiola rosea, Yohimbe, Propionyl-L- carnitine, 
Horny goat weed (epimedium)
* PO drugs unless specified; ** I njectable solutions
References
Salonia A, Eardley  I, Giuliano F, et al. 2014. European Association of Urology  Guidelines on 
Priapism. 
European Urology 65: 480-489
Broderick GA, Kadioglu A, Bivalacqua TJ, et al. 2010. Priapism: Pathogenesis, 
epidemiology , and management. The Journal of Sexual Medicine 7: 476 -500.
Food and Drug Administration. 2013. FDA warns of rare risk of long -lasting erections in 
male s taking meth ylphenidate ADHD medications and has approved label changes. Drug 
Safety Communication 17 December 2013. URL: 
www.fda.gov/Drugs/DrugSafety /ucm375796.htm
https://potency up.com/what- is-priapism -definition -types-causes- symptoms -diagnosis -and-
treatment/
https://www.may oclinic.org/diseases- conditions/erectile -dysfunction/in -depth/erectile -
dysfunction -herbs/art -20044394
https://www.webmd.com/erectile -dysfunction/features/natural- remedies -for-erectile -
dysfunction#1

Novartis Confidential Page 113
Amended Protocol Version 03 (clean ) Protocol No. CSEG101AUS05
Table 16-2 List of A ntidepressants and A ntipsy chotics that may  induce priapism
USA N Trade Names* Type of Medication Reference*
Buproprion Wellbutrin, Zyban Antidepressant Am J Psychiatry. 1995;152(5):813
Trazodone Desyrel Antidepressant Prim Care Companion J Clin Psychiatry. 2010; 
12(2): PCC.09l00816.
Risperidone Risperdal Antipsychotic Prim Care Companion J Clin Psychiatry. 2009; 
11(4): 174 –175. J Clin Psychiatry 2010- 12(5) -
e1–e2
Olanzapine Zyprexa Antipsychotic J Clin Psychopharmacol. 1998 Aug;18(4):351-
3; Am J Psychiatry. 2000;157(4):659; J Clin 
Psychiatry 2010 -12(5) -e1–e2
Clozapine Clozaril Antipsychotic Am J Psychiatry. 2000;157(4):659; J Clin 
Psychiatry 2010 -12(5) -e1–e2
Choropromazine Thorazine and Largactil Antipsychotic Int J Clin Pract. 1999 Mar;53(2):152 -3.
Quetiapine Seroquel Antipsychotic West J Emerg Med. 2014 Feb; 15(1): 114 –
116.
Sertraline Zoloft Antidepressant J Am Acad Child Adolesc Psychiatry 46:7 -July 
2007
Citalopram Celexa Antidepressant Pharmacotherapy 2002;22(4):538 –541
Escitalopram Lexapro Antidepressant Fed Pract. 2019 Feb 36(2), 92 -96; J Inst Med. 
2014;36(1):118 –120.
Fluoxetine Prozac, Sarafem Antidepressant J Pak Med Assoc 1996; 46: 45 –6
Trifluoperazine Stelazine Antipsychotic
Pericyazine Neulactil Antipsychotic Postgrad Med J. 1974 Aug; 50(586): 523 –
524. 
Paroxetine Paxil, Seroxat Antidepressant Int J Psychiatry Med. 2015;50(3):326 -34
Fluvoxamine Faverin, Luvox Antidepressant Same MoA as citalopram, paroxetine and 
fluoxetine
Aripiprazole Abilify Antipsychotic Ind Psychiatry J. 2016 Jan -Jun; 25(1): 119 –
121.
Haloperidol Haldol Antipsychotic Encephale. 2014 Dec;40(6):518 -21.
Amisulpride Solian Antipsychotic Bulletin of Clinical Psychopharmacology 
2016;26(1):85 -6
Duloxetine Cymbalta Antidepressant Ment Health Clin [Internet]. 2016;6(4):197 -
200.
Ziprasidone Geodon Antipsychotic Pharmacotherapy 2002;22(8):1070 –1073
Venlafaxine Effexor Antidepressant J Am Acad Child Adolesc Psychiatry. 2000 
Jan; 39(1):16 -7.
Desvenlafaxine Pristiq Antidepressant Same MoA as duloxetine and venlafaxine
Mirtazapine Remeron Antidepressant Klinik Psikofarmakoloji Bulteni, suppl. S1; 
Istanbul Vol. 28, ( 2018): 233 -234
*Other tradenames may  exist for the same USAN. ** References are quoted as examples only 
and are non -exhaustive.
